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Abstract 
Low back pain is the single highest contributor of disease burden worldwide. It is a condition 
for which prescription medicines, over-the-counter (OTC) medicines and advice are 
commonly sought. Opioid analgesics and muscle relaxants are commonly prescribed for low 
back pain however there is limited evidence of their clinical effectiveness and tolerability. 
There is also uncertainty around the effectiveness of OTC interventions and advice that can 
be delivered for acute LBP. 
Chapter two evaluated the efficacy and tolerability of opioid analgesics, muscle relaxants 
and benzodiazepines in the management of LBP. Online databases: AMED, CENTRAL and 
PsycINFO (inception to end July 2014) were searched and citation tracking was performed 
for eligible randomised controlled trials (RCTs). Two reviewers (CAS and CGM) 
independently extracted data and assessed risk of bias. Data were pooled using a random 
effects model with strength of evidence assessed using the GRADE criteria. Pain and 
disability outcomes were converted to a common 0-100 scale. 
There is moderate quality evidence that opioid analgesics provide pain relief in the short 
term for chronic LBP; mean difference (MD) -10·6 [95% CI -13·5, -7·7] and high quality 
evidence of pain relief in the intermediate term -9·2 [95% CI -11·7, -6·7]. Meta-regression 
showed a significant relationship between effect size and morphine equivalent dose with a 
14.5 point increase in pain relief for every one log unit increase in morphine equivalent 
dose. There is high quality evidence that muscle relaxants provide pain relief in the short 
term for acute LBP -21·3, [95 % CI -29·0, -13·5]. The median (interquartile range) rate of 
adverse events for placebo controlled trials of opioids was 69% (55.0% to 85%) and for 
muscle relaxants was 19·6% (5·5% to 37·5%). No eligible RCTs of benzodiazepines were 
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identified. There is a paucity of evidence on long term use, and effects on disability for these 
three classes of medicines. 
Chapter three is a systematic review evaluating evidence from randomised controlled trials 
(RCTs) investigating interventions available OTC and advice that could be provided to people 
with acute LBP. Searches were conducted on MEDLINE, EMBASE, Cochrane Database of 
Systematic Reviews, AMED, CENTRAL and PsycINFO for eligible RCTs. The primary outcome 
measure was pain. Eligible controls included placebo, no treatment or usual care.  
Two reviewers (CAS and CGM) extracted data and rated study quality. A random effects 
model was used to pool trial effects with the overall strength of evidence described using 
the GRADE criteria.  
Thirteen RCTs (2847 participants) evaluating advice, bed rest, simple analgesics 
(paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs)), heat application and a 
topical rubefacient were included. There was low quality evidence that bed rest is 
ineffective and very low quality evidence that advice is ineffective in the short, intermediate 
and long term. There was very low quality evidence that NSAIDs (ibuprofen and diclofenac 
‘when required’ dosing) provide an immediate analgesic effect; MD (mean difference) -10.9 
[95% CI -17.6, -4.2] and -11.3 [95% CI -17.8, -4.9] respectively. There is very low quality 
evidence that heat wrap and a capsicum-based rubefacient provide an immediate analgesic 
effect MD -13.5 [95%CI -21.3, -5.7] and 17.5, p<0.001 respectively but there was no 
information on longer term outcomes.  
Chapter four explored the experiences of pharmacists who collaborated on a LBP clinical 
trial conducted in Australia, the challenges they faced and screening and management of 
people with acute LBP. A convenience sample of 15 pharmacists who successfully recruited 
people to the clinical trial and 15 pharmacists who collaborated on the trial but did not 
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recruit any participant were invited to complete an open-ended questionnaire. The 
questionnaire consisted of six items framed to evaluate pharmacists' views on participation 
in the LBP clinical trial, ideas for addressing the challenges they faced and screening and 
management of people with LBP who present to the pharmacy. 
A total of 30 pharmacists completed the questionnaire. Pharmacists identified lack of time 
and patient reluctance to participate as the major challenges to recruiting participants to 
the LBP clinical trial. Greater patient incentives and a more efficient paperwork system have 
been recommended as strategies to overcome these challenges. The recruiters and non-
recruiters held similar views on pharmacological management of acute LBP and these 
complied with guideline recommended care; although their views on the non-
pharmacological management of acute LBP were less consistent with the guidelines.  
Chapter five investigated pharmacists’ knowledge, attitudes and beliefs towards LBP 
from participation in a LBP clinical trial or educational workshop.  
Knowledge, attitudes and beliefs was measured using the “Pharmacists’ Back Beliefs 
Questionnaire”, with items from two previously reported questionnaires on back 
beliefs. Responses from pharmacists attending a two-hour educational workshop on 
LBP (n=204) and pharmacists recruiting participants for a LBP clinical trial (n=66) were 
compared to responses from a control group of pharmacists (n=65) to allow an 
evaluation of the two interventions. Responses from workshop participants were also 
evaluated before and after the session. Participants indicated their agreement with 
statements about LBP on a 5-point Likert scale. Preferred responses were based on 
guidelines for the evidence-based management of LBP. The primary analysis evaluated 
total score on the 9-inevitability items of the Back Beliefs Questionnaire (“inevitability 
score”). 
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There was no significant difference in inevitability score between LBP clinical trial 
pharmacists and the control group MD 0.47 [95% CI -1.35 to 2.29; p=0.61]. The educational 
workshop led to a significant and favourable change in inevitability score MD 7.23 (p<0.001) 
and notable changes in responses to misconceptions regarding bed rest and the need for 
imaging (p<0.001) among participating pharmacists. 
Chapter six investigated the knowledge and satisfaction of pharmacists who attended the 
same two-hour educational workshop referred to above. Case-based learning, underpinned 
by key adult learning principles was one teaching method used to deliver important 
educational messages.  
Knowledge was assessed using a questionnaire consisting of multiple-choice, true/false 
questions and a written vignette based on a real-life clinical case scenario. Written feedback 
from pharmacists was used to gauge the success and limitations of the intervention.  
One hundred and ninety-three pharmacists completed the in-house assessment. 
Pharmacists demonstrated an accurate understanding of evidence-based pharmacological 
management of LBP with all identifying paracetamol as first-line drug choice for non-specific 
LBP. Ninety-nine per cent of pharmacists identified the symptoms presented in the vignette 
as a syndrome representing a significant clinical red flag requiring urgent referral. 
Chapter seven evaluated the management recommendations for LBP provided in 
community pharmacies using a cross-sectional observational design involving a simulated 
patient approach.  
Simulated patient visits were conducted between August and September 2013 across 534 
community pharmacies in Australia. During the visit, the trained actor requested an OTC 
medicine or asked for management advice for one of two simulated patient scenarios; a 
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case of non-specific LBP or a vertebral compression fracture. Visits were audio-recorded to 
allow data capture, validation and review.  
Primary outcome measures included recommendations for pharmacological and non-
pharmacological management, referral to a health care professional and advice on the need 
for imaging. Management was compared to recommendations endorsed in evidence-based 
low back pain guidelines.  
Five hundred and thirty four visits were conducted across community pharmacies in 
Australia comprising 336 non-specific scenarios and 198 fracture scenarios. 
Recommendations for pharmacological management, but not non-pharmacological 
management, were typically consistent with guidelines. For the non-specific scenario a 
simple analgesic was supplied in 88% (n=296) of visits (correct response) with NSAIDs being 
supplied most often (86% of visits). For the fracture scenario, combination medicines 
containing paracetamol and codeine were supplied in 46% of all visits ahead of single 
ingredient NSAIDs (supplied in 30% of visits). The non-pharmacological recommendations 
for non-specific LBP that were not consistent with guidelines were: infrequent provision of 
reassurance of favourable outcome (<8%) or advice to stay active (5%) or avoid bed rest 
(0%) and excessive endorsement of imaging (22.7%). For compression fracture, the concerns 
were low medical referral (46.0% prompt referrals) and low endorsement of rest (1.0%).  
Conclusion 
In chronic LBP patients who respond favourably to a trial of the medicine, opioid analgesics 
provide short/intermediate pain relief, though the effect is small and adverse events are 
common. Muscle relaxants provide short term pain relief for acute LBP. There is insufficient 
evidence to inform the prolonged use of any of these medicines for people with LBP.  
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There is limited evidence that NSAIDs, heat wrap and rubefacients provide pain relief for the 
immediate term in acute LBP and that bed rest and advice are both ineffective. Future 
research is needed to provide evidence to support rational use of OTC remedies and advice 
for people with acute LBP.  
The experiences of pharmacists evaluated in this study has broadened the understanding 
around challenges to recruitment for a placebo-controlled clinical trial of back pain and 
identified gaps which can be addressed in future training and education of pharmacists. 
Time pressure was identified as the major barrier to recruitment of participants to the LBP 
clinical trial.  
The educational interventions described in this thesis have delivered key messages on LBP 
management to pharmacists. Pharmacists attending the educational workshop provided 
the most compelling evidence that education specifically aimed at delivering evidence-
based information can be successful in changing practitioner knowledge, beliefs and 
attitudes towards LBP. There is continued need for educational interventions addressing 
common conditions. Education of pharmacists on the appropriate non-pharmacological 
management of people with LBP and screening for possible red flag conditions is required. 
In community pharmacy practice, pharmacological management is within the scope of 
guidelines, however, much of the non-pharmacological advice provided for management of 
low back pain is not consistent with evidence-based practice guidelines. These results 
reinforce the need to broaden the education of community pharmacists to include non-
pharmacological management of LBP. 
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Chapter One 
INTRODUCTION 
In recent years, low back pain (LBP) has emerged as a major health burden worldwide and 
attention has turned towards evaluating interventions, both pharmacological and non-
pharmacological, which are appropriate to treat the condition. Although LBP is an area 
which is widely published, and continues to attract interest from researchers and clinicians 
worldwide, surprisingly little is known about the causes of LBP. This has intrigued 
researchers and created an interesting discussion around how clinicians can target 
treatments toward a condition with a poorly understood aetiology. There are also few 
studies which have systematically evaluated the clinical effectiveness of pharmacological 
interventions used to treat LBP, exposing an area of research requiring closer assessment. 
This step is also pertinent to ensuring that current, evidence-based and reliable information 
is relayed to the clinicians managing this condition. As such the broad focus of this thesis 
was to examine the evidence for commonly used interventions for LBP, and to compare 
current practice to recommendations endorsed in the LBP guidelines.  
1.1 DEFINITION: LOW BACK PAIN  
Low back pain (LBP), anatomically defined as pain between the 12th rib and buttock crease, 
is a common condition affecting more than 80% of adults over their lifetime (Goubert et al., 
2004). The condition is subcategorised by duration: 
 Acute LBP < 6 weeks duration;  
 Subacute LBP > 6 weeks but < 3 months duration; and  
 Chronic LBP > 3 months duration.  
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Interestingly many cases of LBP have no identifiable physical or structural cause (Derbyshire, 
2004) – hence the term “non-specific” LBP.  
A more comprehensive definition of non-specific LBP has been described in the literature as:  
“….pain localized between the scapulas and inferior gluteal folds that may or may not 
radiate down towards the knees, for which specific aetiologies such as infections, 
neoplasms, metastases, osteoporosis, fractures, rheumatological disorders, 
neurologic disorders, and other relevant pathologic entities have been ruled out 
clinically.” (van Tulder et al., 2003a; van Tulder et al., 2003b) 
Fortunately, an estimated 90% of acute non-specific cases are likely to resolve completely 
within three months of pain onset (van Tulder et al., 2006). Fewer than 1% of LBP cases 
presenting in primary care represent significant clinical ‘red flags’ requiring urgent medical 
or surgical intervention (Henschke et al., 2009).   
Clinical red flags are potential indicators (which may include symptoms, past or current 
medical history), for serious underlying disease (Downie et al., 2013). Clinical red flags 
associated with acute onset LBP could be attributable to a range of serious underlying 
aetiologies: tumour, bone fracture, infection and nerve damage (Dan-Phuong, 2003; Downie 
et al., 2013; Henschke et al., 2009). Red flags associated with acute onset LBP are described 
in greater detail in Chapter six. 
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1.2 ECONOMIC AND HEALTH BURDEN OF LOW BACK PAIN 
Globally, LBP represents a significant social and economic health burden. It is the world’s 
leading cause of disability-adjusted life years (DALYs) (Chappandale et al., 2013, Vos et al., 
2012) (Note: one DALY = one lost year of "healthy" life (WHO, 2014). 
Acute non-specific LBP alone affects more than one quarter of the population at any given 
point in time (point prevalence) (Walker et al., 2003) and the lifetime prevalence is 
estimated to be as high as 84% (Goubert et al., 2004). Disability associated with chronic LBP 
is estimated to be 11% (Vos et al., 2012). The condition is a significant cause of personal 
distress and is associated with sleep disorders, elevated levels of anxiety and depression 
(Gore et al., 2012; Licciardone et al., 2012) and an inability to work or return to work 
(Rathmell et al., 2008). However the mechanisms linking LBP with these co-morbid 
conditions are largely unclear.  
Each year in Australia approximately $1 Billion is spent on LBP treatment (Walker et al., 
2003) with over 71% of this amount going towards the health professionals most commonly 
sought for treatment among people with LBP. These include general practitioners (GPs), 
physiotherapists, chiropractors, acupuncturists and massage therapists (Walker et al., 2003). 
The indirect costs associated with LBP exceed $8 billion annually (Walker et al., 2003). This 
figure is estimated to be as high as $50 billion in the US (Deyo et al., 1998, Katz et al., 2006). 
Furthermore, back pain is a common condition keeping the elderly out of the workforce. 
This problem reduces Australia’s GDP by $3.2 Billion per annum (Schofield et al., 2008). 
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1.3 RISK FACTORS FOR LOW BACK PAIN 
LBP affects men and women equally, with those aged between 30 and 50 years most 
commonly affected (Chou et al., 2008). People aged 60-64 have also been identified as 
being at high risk of experiencing back problems (AIHW, 2012a), suggesting a likely 
contributing role of the natural ageing process (Chou et al., 2008). Furthermore, 
complications associated with LBP such as disc disease or spinal degeneration are likely to 
increase with age (Chou et al., 2008).  
Construction workers and people whose work involves lifting heavy objects are at increased 
risk of experiencing LBP (Chou et al., 2008). Being overweight or obese has been associated 
with increased risk of LBP, particularly recurrent or persistent LBP (Chou et al., 2008; Wilk et 
al., 2010). In one survey of practice, those who had sought professional advice for recurrent 
LBP were more than twice as likely to receive advice on weight loss than first-time sufferers 
(13% vs 5.4%, respectively, p<0.05) and interestingly, over two thirds had self-reported to 
be either overweight or obese (Wilk et al., 2010). A sedentary lifestyle and little or no 
exercise is also thought to contribute to the onset of LBP (Chou et al., 2008), although a 
recent review has found that a sedentary lifestyle alone it is not a causal factor (Chen et al., 
2009). Nevertheless, this substantiates the need for regular activity and exercise as part of 
the broader management plan for people with non-specific LBP. 
Smoking is another risk factor that has been directly linked with clinic visits in acute LBP 
(Feuerstein et al., 2008). LBP is also reported in association with hormonal variations e.g. 
pre-menstrual or menstrual symptoms and the use of the oral contraceptive pill 
(Brynhildsen et al., 1997). Long term use of medications which can increase the risk of bone 
fracture such as some antiepileptics e.g. carbamazepine and phenobarbitone, oral (and to 
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lesser extent inhaled) corticosteroids, are also risk factors for LBP and are important 
considerations in the care pathway for these patients (Chou et al., 2008; Jette et al., 2011). 
Common modifiable causes of LBP include such things as lifting heavy objects and incorrect 
positioning (e.g. when sitting or standing) (Feuerstein et al., 2008). It is therefore not 
surprising that interventions designed to target ergonomic risks are being encouraged, 
particularly in the workplace environment, (Feuerstein et al., 2008) as a way of reducing the 
burden of LBP.  
Reports suggest that up to 33% of patients who have experienced an episode of acute LBP 
are likely to experience persistent pain of at least moderate intensity one year after the 
initial episode (Chou et al., 2007a). Therefore, strategies aimed at preventing onset of LBP 
are key to minimising the health burden of this condition. 
1.4 HEALTH CARE SEEKING BEHAVIOUR  
Healthcare seeking behaviour among people with LBP appears to increase with age and pain 
severity (Wilk et al., 2010). An estimated 50% of people with LBP are likely to seek medical 
care (Walker et al., 2003) with the vast majority of cases of non-specific LBP being managed 
in the primary care setting (although up to one quarter of all hospitalisations in Australia are 
due to LBP (AIHW, 2012b). General practitioners are the most commonly sought health 
provider among LBP patients (Walker et al., 2003). In the US LBP is the 5th most common 
reason for GP visits (Hart et al., 1995) and the 7th most common reason for GP visits in 
Australia (Britt et al., 2008; Williams et al., 2010a). However, many consumers will often 
seek care from a number of sources and health providers (Wilk et al., 2010), in line with a 
multimodal approach to care. Physiotherapists and pharmacists, in particular, are among 
the most commonly sought health care providers among LBP patients (Wilk et al., 2010). 
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These primary health care providers are therefore well positioned to provide quality care to 
LBP patients.  
The role of the pharmacist expands beyond medicines provider to encompass a broader 
commitment to providing quality health care for people in the community. Medication 
management, health promotion and disease-state management (DSM) services represent 
core areas of pharmacist-led initiatives. Such programs recognise that pharmacists are 
suitably positioned to provide appropriate interventions to people with a range of disease 
conditions. Pharmacy–led services have established benefits on clinical and quality of life 
outcomes for patients (Carter et al, 2008; Santschi et al, 2011). However, the current focus 
of disease state management programs in Australia is on cardiovascular conditions (Lowres 
et al, 2014) or respiratory health (Armour et al, 2013). Less is known of pharmacist-led 
interventions for common musculoskeletal condition such as non-specific LBP. 
Pharmacists are ideally positioned to educate patients on the recommended management 
for LBP. In Australia, pharmacists have been involved in recruitment for a low-back-pain 
clinical trial (Williams et al, 2010) and there is a potential role for pharmacists in offering a 
specialised pain management and counselling service for low-back-pain sufferers. 
1.5 LBP MANAGEMENT: EVIDENCE-BASED GUIDELINES VERSUS 
ACTUAL PRACTICE 
Current guidelines for the evidence-based management of non-specific LBP recommend 
staying active and avoiding prolonged periods of bed rest (Australian Acute Musculoskeletal 
Pain Guidelines Group, 2004; Chan et al., 2002; van Tulder et al., 2006). Simple analgesics 
(paracetamol or non-steroidal anti-inflammatory medications) are recommended in LBP and 
have particular benefits in helping the patient to maintain regular activity (Australian Acute 
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Musculoskeletal Pain Guidelines Group, 2004; Chan et al., 2002; van Tulder et al., 2006). 
Where paracetamol is chosen, time contingent dosing (4 g daily in divided doses) has been 
suggested for optimal pain relief (Faas et al., 1996, Royal College of General Practitioners 
UK; 1996-1999). However findings from the only large randomised placebo-controlled trial 
has surprisingly shown that time contingent or when required dosing of paracetamol is no 
more effective than placebo for acute LBP (Williams et al., 2014a). Health care providers are 
encouraged to provide reassurance of a favourable prognosis after screening for and 
excluding possible red flag conditions. Combination opioid analgesic medications are 
reserved for use for those who do not respond to this simple first-line approach (Australian 
Acute Musculoskeletal Pain Guidelines Group, 2004; Chan et al., 2002). However, surveys of 
practice in Australia (Williams et al., 2010a) and overseas (Bishop et al., 2003; Frankel et al., 
1999; Gonzalez-Urzelai et al., 2003; Schers et al., 2000; Tacci et al., 1999) reveal that these 
simple first line steps are often ignored or incompletely practised and instead care begins 
with more complex interventions such as combination opioid analgesic medicines, 
chiropractic and imaging. These findings suggest interventions are needed to help align 
actual practice with guideline-endorsed care for LBP management, (Bishop et al., 2003; 
Frankel et al., 1999; Gonzalez-Urzelai et al., 2003; Schers et al., 2000; Tacci et al., 1999; Wilk 
et al., 2010; Williams et al., 2010a) particularly as the present approach to care is more 
costly, carries greater risk of adverse effects and in some cases may even delay recovery.  
A recent survey has shown that non-steroidal anti-inflammatory drugs and opioid analgesics 
are the two most common types of medication recommended or prescribed by GPs for back 
pain (37.4% and 19.6% respectively) (Williams et al., 2010a). Among those who were 
prescribed paracetamol (17.7%), less than a third received the recommended dose of 4 g/d 
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in divided doses (i.e. 1 g four times a day) (Williams et al., 2010a). Interestingly, diazepam, 
an anxiolytic with sedative (and claimed “muscle relaxant”) properties features among the 
ten most commonly prescribed medications for back pain based on Australian health data 
(AIHW, 2012c). Such an approach is likely to encourage bed rest, which has been shown to 
delay recovery from non-specific LBP compared to staying active (Dahm et al., 2010). 
Despite activity being an important treatment recommendation for non-specific LBP, studies 
show only around 50% of patients (first-time or recurrent LBP sufferers) received advice 
from their heath provider to stay active (Wilk et al., 2010). Additionally, bed rest was a 
common initial treatment recommendation by GPs highlighting a mismatch between 
current practice and best practice care.  
1.6 HEALTH EDUCATION A POSSIBLE SOLUTION? 
Education of health care providers may serve an important role in helping to align regular 
practice with the recommendations endorsed in current evidence based guidelines. A 
paucity of appropriate education and training of health professionals has been identified as 
a barrier to providing optimal pain care (Strassels et al., 2008). Studies show that even those 
doctors with a special interest in LBP have poorer knowledge about its management than 
doctors without special interest in LBP (Buchbinder et al., 2009). The resulting gaps in 
knowledge are evidently being translated into actual practice with recent reports showing 
that over one quarter of patients with acute non-specific LBP are referred for imaging 
(Williams et al., 2010a) despite evidence this can delay recovery (Chou et al., 2009). 
However there appears to be a certain pressure on doctors to order X-rays from patients 
themselves, (Buchbinder et al., 2001; Buchbinder et al., 2009) with surveys revealing 
doctors are more likely to order X-rays for acute non-specific LBP if the patient expects them 
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to do so. This highlights a need to similarly educate patients about optimal LBP 
management, including advice about the benefits and risks of treatments and interventions.  
Exposure to ionising radiation from a standard X-ray of the lumbar spine is reported to be 65 
times that of a single chest x-ray (typical effective dose 1.30 msV versus 0.02 msV 
respectively) (Flinders Medical Centre Diagnostic Imaging Pathways, 2009). A CT scan of the 
lumbar spine exposes the patient to far greater radiation (3.3 msV, equivalent to 165 
standard chest x-rays). Unnecessary and repeated exposure to radiation of this kind poses a 
health risk to the patient (Chou et al., 2009). Clinical guidelines recommends that imaging 
should only be requested where a thorough patient history and physical examination 
indicates that there may be a medically serious cause for the lower back pain. In patients 
without clinical ‘red flags’, evidence indicates that routine imaging is not associated with 
clinically meaningful benefits but can lead to harms (Chou et al., 2009). Health care 
professionals can relay important information regarding the need for such tests in LBP. 
Indeed patient beliefs and treatment decisions with regards to LBP are influenced by the 
health providers own beliefs, knowledge and approach to care (Coudeyre et al., 2006; 
Houben et al., 2005a). Even the language health care professionals use has been suggested 
to influence health outcomes for LBP patients. Increasingly, health professionals are being 
encouraged to avoid terms that infer gradual degeneration (Sloan et al., 2010) such as 
“wear and tear”, “disc prolapse” in acute non-specific LBP as a way of challenging negative 
beliefs that may contribute to fear avoidance behaviours (e.g. limiting physical activity) or 
catastrophising. Fear avoidance beliefs and catastrophising among LBP sufferers have been 
associated with delayed recovery and in some cases progression to chronic pain and 
disability (Buer et al., 2002; Elfving et al., 2007; Pincus et al., 2002). One study has also 
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found that patients' fear-avoidance beliefs about physical activity were associated with low 
levels of education (Poiraudeau et al., 2006).  
However the mismatch between guideline recommended care and actual practice is being 
seen translated in the self-care situation on a broader scale. For example, even among 
patients who do receive advice to stay active, only 39% reported maintaining the same level 
of activity and close to one third of patients reported less activity than usual (Wilk et al., 
2010). This highlights a need to challenge misconceptions and negative beliefs regarding 
physical activity in the management of LBP. 
Furthermore, consumers will commonly seek pain relief for their LBP regardless of whether 
or not they seek professional advice from their health provider (Wilk et al., 2010). However 
the choice of analgesics does not typically follow guideline recommended care (Wilk et al., 
2010). Whilst paracetamol is often the first choice of analgesic for LBP, figures show that 
around 80% of consumers report using a sub-therapeutic dose (Wilk et al., 2010). The choice 
of analgesic also seems to be guided by pain severity, with non-steroidal anti-inflammatory 
drugs (NSAIDs) such as ibuprofen being a common first choice among those who reported at 
least moderate LBP and combination opioid analgesic medicines being first choice among 
those who reported severe LBP (WIlk et al., 2010). Evidence to support the use of ibuprofen 
in LBP is both limited and conflicting (Dreiser et al., 2003; Milgrom et al., 1993). 
Furthermore a recent study investigating the use of diclofenac, spinal manipulative therapy 
or both these interventions for the management of acute non-specific LBP has found that 
these are no more effective than standard first line care, even in moderate to severe cases 
(Hancock et al., 2007). This highlights a need to educate consumers about the appropriate 
management of LBP as a way of promoting the evidence-based self-management of this 
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condition and to challenge misconceptions that ‘stronger’ medicines are more effective 
treatments in LBP.  
The high use of OTC medicines for LBP management suggests a need for close monitoring of 
people using these medications as there is some evidence to suggest people may 
inadvertently be putting themselves at risk of adverse events and experiencing clinically 
significant drug-drug interactions. For example, one survey has shown that 8% of those who 
reported using ibuprofen for their LBP had previous history of stomach ulcer and 4% 
reported sensitivity to aspirin (Wilk et al., 2010). Furthermore 10% of elderly consumers 
were deemed at significant risk of experiencing acute renal impairment as a result of using 
an NSAID for their LBP concomitantly with a diuretic and an angiotensin converting enzyme 
inhibitor or an angiotensin II receptor antagonist (Wilk et al., 2010) - a situation commonly 
known as the triple whammy effect.   
Complementary and alternative medicines (CAM) and therapies such as acupuncture are 
commonly used to manage LBP, particularly chronic LBP (Gaul et al., 2011). This is perhaps 
an indication of current deficits in the appropriate use of conventional therapies, especially 
with regards to first line care. In one study almost 85% of patients reported using CAM for 
their LBP. The most frequently used complementary therapies in LBP were thermotherapy 
(77.4%), massage (62.7%), and acupuncture (51.4%), and 100% of patients who reported 
having previous experience with complementary therapies were using complementary 
therapies for their LBP at the time of the study (Gaul et al., 2011). There are some views 
that the growing use of complementary medicines and or therapies in LBP could also reflect 
“unfulfilled goals in conventional treatment” (Gaul et al., 2011). Whilst there is credible 
evidence from well-designed RCTs that support the use of some CAM interventions for LBP 
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e.g. heat wrap therapy and acupuncture, (Chou et al., 2007b) the evidence to support the 
vast majority of complementary therapies are either limited or lacking. This warrants the 
need for further investigations from high quality trials to substantiate recommendations for 
their use.  
An examination of the available literature in this area reveals a need for more interventions 
to help inform best practice care with regards to LBP in the community, targeting both 
health providers and patients.  
1.7 COMMON TREATMENTS FOR LOW BACK PAIN 
Survey of patients and practice show that the most commonly used treatments for the 
management of LBP include opioid analgesics (oxycodone), NSAIDs (diclofenac and 
ibuprofen), muscle relaxants and benzodiazepines (diazepam) (Wilk et al., 2010; AIHW, 
2009a; AIHW, 2012c). Simple analgesics such as paracetamol are less commonly used in the 
treatment of moderate to severe pain. Interventions such as lumbar supports, magnetic 
therapy and transcutaneous electric nerve stimulation have also shown some benefit in LBP, 
although they are less commonly utilised. 
Chapters two and three will provide a comprehensive evaluation of the clinical efficacy of 
these interventions for LBP.  
1.8 AIMS 
The primary aims of this thesis were to: 
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1. Assess evidence for the effectiveness of pharmacological and non-pharmacological 
interventions for LBP in order to inform recommendations by health care 
providers; 
2. Evaluate pharmacists’ knowledge, attitudes and beliefs towards low back pain and 
the influence of educational interventions on these parameters;  
3. Evaluate how LBP is managed by community pharmacists. 
Pharmacists are uniquely positioned to intervene at critical stages of the care pathway for 
low back pain patients. This includes counselling on the judicious use of OTC and 
prescription medicines, providing advice about non-drug management and when necessary 
referring patients to another health professional such as a GP or physiotherapist. 
The use of OTC medicines for the treatment of low back pain is common. However 
pharmacists are also well positioned to counsel patients when dispensing prescription 
medicines, including when it related to the management of LBP. Part of the pharmacists’ 
current role is also to collaborate with other health care providers to optimise patient 
management and health outcomes. There is some evidence to suggest this is not happening 
as often as it should in the context of LBP management (Strassels et al., 2008). Greater 
knowledge around the efficacy of prescrpition medicines for low back pain (expored in 
chapter three) can promote a more collaborative approach to patient care and allow 
pharmacists to identify potential gap areas in the pharmacological management of LBP 
patients. In particular, the knowledge around dose dependent effects (based on morphine 
equivalent dose) can help pharmacists and medical doctors alike, make informed 
recommendations regarding the appropriate and safe use of these medicines. 
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Chapter two presents a detailed evaluation of the clinical effectiveness of some of the most 
commonly used prescription medications for LBP: opioid analgesics, muscle relaxants and 
benzodiazepines.  
Chapter three evaluates the evidence for medication available OTC and advice that could be 
offered for people with acute LBP.  
The broad aims of chapters 2 and 3 (both of which are systematic reviews plus meta-
analyses) are to help inform the clinical decision making of both pharmacists and physicians 
in the management of this common condition. 
Chapter four is an explorative qualitative study evaluating the views of pharmacists on their 
experiences whilst collaborating on a placebo-controlled trial of LBP, and how they triage 
and manage patients with LBP in their practice. The purpose of this chapter is to explore 
how pharmacists, who participated in a low back pain clinical trial, manage low back pain in 
primary care by way of screening individuals for trial eligibility and identifying potential red 
flags. As it is not sufficient for pharmacists to simply take on an advisory role and counsel on 
medications, the need to explore pharmacists’ direct experiences with managing LBP using a 
screening and risk assessment approach is explored as part of this thesis. Screening and risk 
assessment represents a core area of pharmacist-led interventions. Furthermore, 
participation in a LBP clinical trial highlights that pharmacists are keen to be involved in LBP 
interventions. A deeper understanding on how pharmacists with previous LBP training 
(delivered by trial researchers) manage patients in primary care can provide important 
insights into the development of future training and interventions targeting these health 
providers. 
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Chapter five is an intervention study that evaluates the effects of different educational 
strategies on pharmacists’ knowledge, attitudes and beliefs towards LBP.  
Chapter six explores the knowledge and satisfaction of pharmacists attending an 
educational workshop and provides some direction for further work in the education and 
training of pharmacists.  
Chapter seven is a cross-sectional observational study utilising a simulated patient approach 
to evaluate how LBP is managed in community pharmacies across Australia.  
The concluding chapter sums up the critical findings from this dissertation and presents a 
discussion around the future direction of research in this area. 
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CHAPTER TWO 
Efficacy and tolerability of opioid analgesics and muscle relaxants 
for low back pain: Systematic Review and Meta-analysis. 
2.1 INTRODUCTION 
The prescription of opioids for the relief of LBP is common for chronic LBP (Deyo et al., 
2011; Hudson et al., 2008). Findings from the US show that more than half of the people 
regularly treated with prescription opioids have chronic LBP. Recent data from the 
Australian Institute of Health and Welfare (AIHW 2012c) has revealed that the three most 
commonly prescribed drugs for back pain are opioid analgesics or opioid analgesic 
combinations: paracetamol and high dose codeine combination (12·1%), oxycodone (11·7%) 
and tramadol (8·2%) (% of all prescribed medicines for back pain). In another Australian 
study of GP prescribing for acute LBP, approximately 20% of people were prescribed an 
opioid, commonly in combination with paracetamol, which was the second most common 
treatment offered after NSAIDs (Williams et al., 2010a). 
Muscle relaxants and benzodiazepines are more commonly prescribed for LBP (AIHW, 
2012c) than international LBP guidelines recommend. Skeletal muscle relaxants, 
carisoprodol and cyclobenzaprine, are among the most commonly prescribed drugs for LBP 
in the USA (Bernstein et al., 2004; Luo et al., 2004), whilst prescribing patterns in both the 
USA and Australia also suggest a preference for the benzodiazepine, diazepam (AIHW, 2009; 
Luo et al., 2004; NHMRC 2004; van Tulder et al., 2006). However guidelines recommend 
benzodiazepines or muscle relaxants be considered if an attempt to treat the symptoms 
using simple analgesics (e.g. paracetamol or NSAIDs) has been inadequate (See et al., 2008; 
Waddell et al., 2014). 
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Despite the widespread use of opioid analgesics and muscle relaxants for LBP, there is 
uncertainty around their clinical benefits whilst there are concerns over adverse events and 
diversion which has risen in line with the increased use of these medicines (Cerda et al., 
Compton et al., 2006; 2013; Franklin et al., 2005; Martell et al., 2007; Roxburgh et al., 2011).    
Previous systematic reviews (Chaparro et al., 2013; Chaparro et al., 2014) on opioid 
analgesics reported on patients with chronic LBP only and the last review on muscle 
relaxants for non-specific LBP (van Tulder et al., 2003b) is over a decade old warranting an 
update of the available evidence. Furthermore, there has been no systematic evaluation of 
the magnitude of the effects of opioid analgesics in LBP and how dose may influence the 
size of the treatment effect (Dworkin et al., 2008; Giraudeau et al., 2004; Ostelo et al., 
2008).  
The primary aim of this review was to evaluate the efficacy and tolerability of opioid 
analgesics and muscle relaxants and benzodiazepines in the management of LBP. 
2.2 METHODS 
2.2.1 Data sources and searches 
MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, AMED, CENTRAL and 
PsycINFO (inception to end July 2014) were searched for RCTs evaluating opioid analgesic, 
muscle relaxant and benzodiazepine medicines for non-specific LBP (search details in 
Appendix Table 1). Additionally we screened studies and reference lists from systematic 
reviews evaluating opioid analgesics, muscle relaxants or benzodiazepines in LBP to identify 
eligible RCTs.  
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We adopted the definition of non-specific LBP employed previously (van Tulder et al., 
2003b):  
“Pain localized between the scapulas and inferior gluteal folds that may or may not 
radiate down towards the knees, for which specific etiologies such as infections, 
neoplasms, metastases, osteoporosis, fractures, rheumatological disorders, 
neurologic disorders, and other relevant pathologic entities have been ruled out 
clinically.”  
One reviewer (CAS) screened titles and abstracts of retrieved studies. Two reviewers drawn 
from a pool of three reviewers (CAS, AJM and CGM) independently inspected the full 
manuscript of potentially eligible RCTs to determine eligibility, with disagreements resolved 
by consensus. 
2.2.2 Study selection 
We included studies in any language evaluating single ingredient or combination medicines 
containing an opioid analgesic, muscle relaxant or benzodiazepine for non-specific LBP. 
Studies in non-English languages which had an English abstract were screened for eligibility. 
We also contacted authors of non-English language studies for clarification on eligibility. 
These two methods revealed that most non-English language studies were ineligible. Study 
selection was not restricted by pain duration, comorbid condition(s) or concurrent 
medication use (e.g. to treat hypertension) provided participants were stabilised on these 
medications and the pattern of use was unchanged throughout the study. We included the 
Anatomical Therapeutic Chemical (ATC) (WHO collaborating centre for drugs statistics 
methodology, 2011) codes for drug classes relevant to this review in the search.  
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Placebo-controlled RCTs and RCTs comparing two drugs from the same class or different 
doses of the same drug were eligible for inclusion. Trials were included if they reported 
pain, disability, or adverse events outcomes. We considered short term pain relief as the 
primary outcome. Trials involving patients with various pain conditions were included if 
results for the subgroup of participants with LBP were presented.  
2.2.3 Data extraction and quality assessment 
Risk of bias was assessed using the Physiotherapy Evidence Database (PEDro) scale (see 
Appendix Table 2) (de Morton et al., 2009; Macedo et al., 2010; Maher et al., 2003). The 
PEDro scale is a 11-item scale that has been established as a valid and reliable method of 
rating methodological quality of individual RCTs (de Morton et al., 2009; Macedo et al., 
2010; Maher et al., 2003). Each item (excluding the item for external validity) is scored as 
either present (1) or absent (0) to give a total score out of 10. Rating of trials was carried out 
by two independent raters (CAS + AJM or CGM) with disagreements resolved by an 
independent third rater.  
Trials scoring <7/10 on PEDro scale were defined as high risk of bias; those scoring 7 or more 
were considered low risk of bias (Pinto et al., 2012a; Pinto et al., 2012b).   
Two reviewers (CAS, CGM) independently extracted outcomes data from published studies 
(Appendix Table 3). Missing data were obtained by contacting authors or estimated using 
the methods described in the Cochrane Handbook (Higgins, 2009). Analysis of data from a 
cross-over trial was performed according to recommendations in the Cochrane Handbook 
(Higgins & Green, 2009).  
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An adapted version of the GRADE criteria (Atkins et al., 2004) endorsed by the Cochrane 
Back Review Group was used to evaluate the strength of recommendations and the overall 
quality of the evidence for an intervention. This method is described elsewhere (Pinto et al., 
2012a; Pinto et al., 2012b), but briefly the quality of evidence was downgraded a level for 
each of four factors: poor study design (25% or more of trials, weighted by sample size, have 
a low PEDro score [<7/10]), inconsistency of results (25% or more of the trials, weighted by 
sample size, have results which are not in the same direction), imprecision (sample size 
<300) and publication bias (assessed using funnel plot analysis/ Egger’s regression test). 
Where the Egger’s regression two-tailed p-value was <0·10, (Egger et al., 1997) the overall 
quality of evidence was downgraded by one level. We did not assess for indirectness (when 
the trial context is not the same as the review question) as this review encompassed a 
specific population. 
Overall quality of evidence was defined (Atkins et al., 2004) as:  
 High quality – all domains satisfied, no suspected reporting bias, future research 
unlikely to change our confidence in the estimated effect; 
 Moderate quality – one domain not met, future research likely to have an important 
impact on our confidence in the estimated effect and might change the effect; 
 Low quality – two domains not met, future research likely to have a significant 
impact on our confidence in the estimated effect and is likely to change the effect; 
 Very low quality – three or more domains not met, uncertain about the estimated 
effect. 
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Single RCTs with sample sizes <300 provided “low to very low quality evidence” as these 
were deemed both inconsistent and imprecise. Effects sizes from fewer than three studies 
were downgraded for small study bias (three or more studies needed for Egger’s test).    
Note: Results from single RCTs provided “inconsistent” data as there needed to be more 
than one trial to compare results with in order to determine consistency.  
2.2.4 Data synthesis and analysis 
Pain and disability outcomes were converted to a common 0-100 scale (Bijur et al., 2003; 
Hjermstad et al., 2011; Roland & Fairbank; 2000) (0: no pain or disability to 100: worst 
possible pain or disability). The pain intensity measures used in the meta-analysis were 
visual analogue scale (VAS) scores (range, 0 to 100) and numerical rating scale (NRS) scores 
(range, 0 to 10). The NRS was converted to the same 0-100 scale as in the VAS as these two 
pain measures have been shown to be highly correlated and when transformed, can be used 
interchangeably (Bijur et al., 2003; Hjermstad et al., 2011). The disability measures used to 
calculate pooled effects were Oswestry Disability Index scores (range, 0 to 100) and Roland–
Morris Disability Questionnaire (RMDQ) scores (range, 0 to 24). The RMDQ scores were 
converted to the same 0-100 scale as in the Oswestry Disability Index as the Oswestry 
Disability Index and RMDQ are highly correlated and share similar psychometric properties 
(Roland & Fairbank; 2000).  
We present results in mean differences (MD) rather than standardised mean differences 
(SMD), as the benchmarks for clinically important difference in pain and disability are 
expressed in points on a 0-100 pain scale not proportions of a standard deviation (Dworkin 
et al., 2008; Giraudeau et al., 2004; Ostelo et al., 2008). The proposed thresholds for 
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clinically important changes in pain and disability range from 10 to 30 points on this scale of 
0 to 100 (Dworkin et al., 2008; Giraudeau et al., 2004; Ostelo et al., 2008). 
Outcomes were grouped into three time categories (with respect to follow up): short term 
(< 3 months) intermediate (≥ 3 months, < 12 months) and long term (≥ 12 months). Where 
multiple time points were available for a single category, the time closest to 6 weeks was 
chosen for short term, 6 months for the intermediate term and 12 months for the long 
term.  
As our primary analysis, pooled effects of opioid analgesics and muscle relaxants were 
evaluated over the short term and/or intermediate term. We considered mean daily 
morphine equivalent dose as the determinant of response for opioid analgesics and 
conducted meta-regression to determine the effects of the log transformed morphine 
equivalent dose on treatment effect size. Additionally we conducted sensitivity analyses to 
determine the effect of: 
a) Combination opioid analgesics containing a simple analgesic (e.g. paracetamol);  
b) Opioid agonist/antagonist combinations. 
Where there were multiple comparisons from a single study, we divided the number of 
participants in the common arm by the number of comparisons, according to 
recommendations in the Cochrane Handbook (Higgins & Green; 2009).  
Meta-analysis was carried out using RevMan 5·1 and Comprehensive Meta-Analysis 
(Comprehensive Meta-Analysis). 
Pooled effects were calculated using a random effects model.  
2.3 RESULTS 
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A total of 32 trials (19 opioid analgesics trials [6751 participants] and 14 muscle relaxant 
trials [3250 participants], 1 study overlap) were included in this review (see Table 2.1 for 
Characteristics of Included Studies and Appendix Figure 1). No eligible RCT evaluating 
benzodiazepines was identified. PEDro ratings are summarised in Appendix Table 2. Figure 
2.1 and 2.2 present pooled effects on pain for the short and intermediate term respectively. 
A funnel plot analysis for the primary time point and outcome measure is presented in 
Appendix Figure 2 for opioid analgesic trials.  
Opioid analgesic trials evaluated oral hydromorphone (Hale et al., 2010), oxymorphone 
(Katz et al., 2007; Hale et al., 2005; Hale et al., 2007), morphine (Allan et al., 2005; Chu et al., 
2012; Khoromi et al., 2007) tramadol monotherapy (Perrot et al., 2006; Schnitzer et al., 
2000; Uberall et al., 2012; Vorsanger et al., 2008) or in combination with paracetamol 
(Peloso et al., 2004; Perrot et al., 2006; Ruoff et al., 2009), tapentadol (Buynak et al., 2010), 
oxycodone monotherapy (Buynak et al., 2010; Hale et al., 2005; Steiner et al., 2011b; 
Webster et al., 2006) oxycodone in combination with naloxone (Cloutier et al., 2013), or 
naltrexone (Webster et al., 2006), transdermal buprenorphine (Steiner et al., 2011a; Gordon 
et al., 2010), and transdermal fentanyl (Allan et al., 2005).
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Table 2.1. Characteristics of included studies. 
Study  Patient population * baseline   Setting  Intervention Comparison Length of 
Treatment  
Follow Up  Eligible 
outcome 
measure(s)  
Opioid analgesic trials  
Allan, 2005 680 patients with chronic LBP 
265♂ 415♀ mean age 54·0 years 
Multicentre  Transdermal fentanyl 
25 µg/h every 3 days  
n=338 
Oral morphine 30 
mg 12 hourly  
n=342 
13 months  1 week, 13 
months 
VAS 
Buynak, 2010 965 patients with chronic LBP 
406♂ 559♀ mean age 49.9 years 
85 USA centres 
15 Canadian 
centres  
3 Australian 
centres 
Tapentadol (100 to 
250 mg twice a day) 
n=313 
or 
Oxycodone MR (20 to 
50 mg twice a day) 
n=322 
Placebo  n=313 12 weeks  1,8,12 weeks NRS (average 
NRS over 12-
hour period)   
Chu, 2012 139 patients with chronic LBP 
78♂ 61♀ mean age 41·9 years 
Clinical centres, 
Stanford  
Morphine average 
end titration dose 78 
mg/daily n=48 
Placebo n=55 1 month 1 month VAS (average 
VAS over 
preceding 2 
weeks) 
Cloutier, 2013 83 patients with chronic LBP 39♂ 
44♀ mean age 51.3 years 
Canada – 10 
centres  
Combination tablet 
containing controlled 
release oxycodone 10 
mg plus naloxone 5 
mg  (increasing to up 
to 40 mg / 20 mg) 
twice a day n=32 
Placebo n=31 8 weeks  Week 8 VAS (average 
VAS over past 
week) 
25 
 
Gordon, 2010 79 patients with chronic LBP 31♂ 
47♀ (1 unclear) mean age 50·7 
years  
13 Canadian 
centres  
Buprenorphine 
transdermal patches 
10 µg/h (up to 
maximum 40 µg/h) 
worn for 6-8 days 
n=37 
Placebo 
transdermal patch 
n=42 
8 weeks 8 weeks  VAS (average 
daily VAS) 
Hale, 2010 266 patients with chronic LBP 
132♂ 134♀ mean age 48·6 years 
66 centres in 
the USA 
≥ 12 mg and ≤ 64 mg 
hydromorphone MR 
daily n=133 
Placebo n=133 12 weeks  1,8 and 12 
weeks  
NRS  
Hale, 2005 329 patients with chronic LBP 
174♂ 155♀ mean age 45·5 years 
Clinical centres 
in the USA  
Oxymorphone MR 
79.4 mg daily n=71 
or 
Oxycodone MR 155 
mg daily n= 75 
Placebo n=67 
 
 
18 days  Days 7 and 18 VAS (measured 
4-hours after 
morning dose) 
Hale, 2007 142 opioid experienced patients 
with chronic LBP 78♂ 64♀ mean 
age 47·1 years 
30 
multidisciplinary 
pain centres 
(USA) 
Oxymorphone 20-
260 mg daily n=70 
Placebo n=72 3 months Day 10, < 3 
months 
VAS (average 
VAS over past 
24-hours)  
Katz, 2007 325 patients with chronic LBP 
216♂ 109♀ mean age 49·8 years 
Multicentre USA  Oxymorphone MR  
39.2 mg (mean 
stabilised dose) 
n=105  
Placebo n=100 12 weeks  Weeks 1 and 
8, 90 days  
VAS 
Khoromi, 2007 55 patients with chronic LBP 30♂ 
and 25♀ median age 53·0  years 
NIH clinical 
centre  
Morphine (15-90 mg) 
n=9 
Placebo n=7 28 weeks 28 weeks  NRS (average 
NRS within the 
preceding  24-
hours) 
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Peloso, 2004 336 patients with chronic LBP 
126♂ 210♀ mean age 57·5 years  
USA Combination tablet 
containing tramadol 
36.5 mg plus 
acetaminophen 325 
mg n=167 
Placebo n=169 91 days  91 days  VAS (average 
VAS within the 
preceding 48-
hours) 
Perrot, 2006 119 patients with subacute LBP 
50♂ 69♀ mean age 55·3 years 
Multicentre 
(Germany) 
Combination tablet 
containing tramadol 
37.5 mg plus 
paracetamol 325 mg; 
max 8 doses/ day 
n=51 
Tramadol 50 mg 
monotherapy; max 
8 doses/d n=48 
10 days  Day 10 VAS  
Ruoff, 2003 318 patients with chronic LBP 
117♂ 201♀ mean age 53·9 years 
minimum VAS 40 mm 
29 centres in 
the USA  
Combination tablet 
containing tramadol 
37.5 mg plus 
paracetamol 325 mg  
1-2 tablets four times 
a day n=91 
Placebo 1-2 tablets 
four times a day 
n=74 
91 days  91 days  VAS (average 
VAS over 
preceding 48-
hours) 
RMDQ 
 
Schnitzer, 
2000 
254 patients with chronic LBP 
127♂ 127♀ mean age 47·1 years 
26 centres in 
the USA 
Tramadol 200 mg to 
400 mg daily n=127 
Placebo n=127 4 weeks  49 days VAS (average 
VAS within 
preceding 24-
hours) 
RMDQ 
Steiner, 2011b 660 patients with chronic LBP 
346♂ 314♀ mean age 50·0 years 
75 centres USA  Buprenorphine 20 
µg/h once weekly 
n=176 
or 
Buprenorphine 5 
Oxycodone 40 
mg/day  
or 
Buprenorphine 20 
12 weeks  Weeks, 4, 8, 
12  
0-10 point pain 
scale (average 
pain within 
preceding 24-
hours)  
27 
 
µg/h once weekly 
n=221 
or 
Oxycodone 40 
mg/day n=219 
µg/h once weekly  
or 
Buprenorphine 5 
µg/h once weekly 
Steiner, 2011a 541 patients with chronic LBP 
242♂ 298♀ mean age 49·4 years 
86 centres in 
the USA 
Buprenorphine 
10µg/h once weekly 
n=257 
Placebo n=283 84 days  8 weeks  0-10 point pain 
scale (average 
pain within 
preceding 24-
hours)  
Uberall, 2012 355 patients with chronic LBP 
135♂ 220♀ mean age 58·5 years 
31 sites in 
Germany 
Tramadol MR 200 mg 
daily n=107 
Placebo n=110 6 weeks 4 weeks NRS (average 
NRS within 
preceding 24-
hours) 
Vorsanger, 
2008 
386 patients with chronic LBP 
192♂ 194♀ mean age 47·8 years 
minimum VAS 40 mm 
30 clinical 
centres in the 
USA  
Tramadol MR 300mg 
daily n=127 
or 
Tramadol MR 200mg 
daily n=129 
Placebo n=126 
 
 
12 weeks  1,8 and 12 
weeks  
VAS (average 
VAS) 
Webster, 2006 719 patients with chronic LBP 
277♂ 442♀ mean age 48·1 years 
45 USA sites  Oxycodone plus low 
dose naltrexone four 
times a day 
(oxycodone 34.5 
mg/d + low dose 
naltrexone) n=206  
Placebo n=101 
 
 
 
12 weeks  Weeks 1 and 
12 
VAS (current 
mean pain 
intensity) 
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or 
Oxycodone four 
times a day n=206 
(39mg/d) 
or 
Oxycodone plus low 
dose naltrexone 
twice a day n=206 
(oxycodone 34.7 
mg/d + low dose 
naltrexone) 
 
 
Muscle relaxant trials  
Aksoy, 2002 329 patients with acute/subacute 
LBP 119♂ 210♀ mean age 40·0 
years 
93 Turkish 
centres  
Standard treatment 
(NSAID) for 5-7 days  
n=155 
Standards 
treatment plus 
TCC 8 mg 
(Muscoril) for 5-7 
days  n=174 
5-7 days  Day 7 and 31 VAS 
RMDQ 
Berry, 1988 105 patients with acute LBP 58♂ 
47♀ mean age 42·5 years 
UK Tizanidine 4 mg three 
times a day plus 
ibuprofen 400 mg 
three times a day 
n=51 
Placebo plus 
ibuprofen 400 mg 
three times a day 
n=54 
1 week 1 week VAS (at rest) 
Cabitza, 2008 
 
160 patients with acute LBP 49♂ 
111♀ mean age 48·0 years 
Italy  Eperisone 100 mg 
three times daily 
n=80 
Thiocolchicoside 8 
mg twice daily 
n=80  
12 days Day 7 VAS 
(“spontaneous 
pain”) 
Chandanwale, 225 patients with acute LBP 5 tertiary care 
orthopaedic 
Eperisone 50 mg 
three times daily for 
Placebo n=113 2 weeks Day 7 VAS  
29 
 
2011 
 
106♂ 119♀ mean age 41·4 years centres across 
India  
14 days n=112 
Hindle, 1972 
 
48 patients with acute LBP 27♂ 
21♀ mean age 38·2 years 
California Carisoprodol 350 mg 
four times daily for  4 
days n=14 
Placebo n=14 4 days  Day 4 0-100 pain 
intensity scale 
(current pain) 
Ketenci, 2005 97 patients with acute LBP 47♂ 
50♀ mean age 38·0 years 
Istanbul  Thiocolchicoside 8 
mg twice a day n=38 
Tizanidine 6 mg at 
night + placebo n=32 
Placebo twice a 
day n=27  
5-7 days  Day 7 VAS (at rest) 
Pareek, 2009  197 patients with acute LBP 
120♂ 77♀ mean age 43·4 years 
 Aceclofenac (100 mg) 
tizanidine (2 mg) 
twice daily for 7-days 
n=94 
Aceclofenac (100 
mg) alone twice 
daily for 7 days 
n=91 
1 week  Day 7  VAS at rest  
Pipino, 1991 120 patients with chronic LBP 
51♂ 69♀ mean age 53·1 years 
Secondary care 
- inpatients and 
outpatients. 
Pridinol mesilate 4 
mg intramuscular 
injection twice a day 
for 3 days followed 
by orally 
administered  
pridinol 2 mg twice a 
day for 4 days n= 60 
Thiocolchicoside 4 
mg intramuscular 
injection twice a 
day for 3 days 
followed by orally 
administered 
thiocolchicoside  8 
mg twice a day for 
4 days n=60 
7 days Baseline, day 
4 and day 7 
VAS 
(“spontaneous” 
pain) 
Ralph, 2008 547 patients with acute LBP 
263♂ 284♀ mean age 40·4 years 
49 sites in the 
US  
Carisoprodol 250mg 
once daily n=269 
Placebo n=278 7 days  Day 7  RMDQ 
Rollings, 1983 58 patients with acute LBP 31♂ 
27♀ mean age 42·0  years  
USA  Carisoprodol 350 mg 
four times daily for 7 
Cyclobenzaprine 
10 mg four times 
daily for 7 days 
1 week  Day 7  VAS  
30 
 
days n=28 n=28 
Rossi, 2012 60 patients with chronic LBP 18♂ 
42♀ mean age 62·8 years  
 Tramadaol MR 100 
mg/day plus 
eperisone 100 mg 
three times daily for 
10 days then 
eperisone 100 mg 
daily for a further 20 
days n=30  
Tramadol ER 100 
mg/day plus 
tizanidine 2 mg 
three times daily 
then tizanidine 2 
mg daily for a 
further 20 days 
n=30 
30 days  Days 2, 15 and 
30 
VAS (at rest) 
Serfer, 2010  806 patients with acute 
LBP/spasm 353♂ 453♀ mean age 
40·7 years 
 Carisoprodol 250 mg 
n=264 three times 
daily and at bedtime 
or 
Carisoprodol 350 mg 
n=273 three times 
daily and at bedtime 
Placebo three 
times daily and at 
bedtime n=269 
1 week Day 3 RMDQ 
Tuzun, 2003  143 patients with acute LBP 66♂ 
77♀ mean age 40·9 years 
5 centres  Thiocolchicoside 
(intramuscular 
injection) 4 mg twice 
daily for 5 days  n=73 
Placebo n=68 5 days  Day 5 VAS 
(“spontaneous 
pain at rest”) 
Uberall, 2012 355 patients with chronic LBP 
135♂ 220♀ mean age 58·5 years 
31 sites in 
Germany 
Flupirtine MR 400 mg 
daily n=109 
Placebo n=110 6 weeks 4 weeks NRS (average 
NRS within 
preceding 24-
hours) 
VAS: Visual Analogue Scale; NRS: Numeric Rating Scale; RMDQ: Roland Morris Disability Questionnaire. MR: Modified release formulation. 
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All 19 opioid analgesic trials evaluated chronic LBP, 16 RCTs compared an opioid analgesic to 
placebo and three compared two opioid analgesics (Allan et al., 2005; Perrot et al., 2006; 
Steiner et al., 2011b). Over one third of RCTS involving opioid analgesics employed an 
enrichment design whereby only the participants who responded favourably to the study 
medication, and tolerated the medicine, in the initial trial run-in phase were eligible to 
continue in the trial proper. The total number of participants who entered the trial proper 
ranged from 52.8% to 71.2% (Appendix Table 4). Details of number of patients not 
responding in run-in phase, drop-out rates in the trial and reasons for withdrawal are 
summarised in Appendix Table 4 and Appendix Table 5.    
Muscle relaxant trials evaluated eperisone (Chandanwale et al., 2011; Cabitza et al., 2008; 
Rossi et al., 2013), carisoprodol (Hindle, 1972; Ralph et al., 2008; Rollings, 1983; Serfer et al., 
2010), thiocolchicoside (Aksoy et al., 2002; Ketenci et al., 2005; Pipino et al., 1991; Tuzun et 
al., 2003),  tizandine (Berry & Hutchinson, 1988; Pareek et al., 2009; Rossi et al., 2012) 
flupirtine (Uberall et al., 2012), pridonol (Pipino et al., 1991) and cyclobenzaprine (Rollings et 
al., 1983). Eleven muscle relaxant trials evaluated acute LBP and 3 trials evaluated people 
with chronic LBP (Pipino et al., 1991; Rossi et al., 2012; Uberall et al., 2012).  
Results from the sensitivity analyses is summarised in Figure 2.3. Results from the regression 
and funnel analysis are summarised in Appendix Figure 3 and Appendix Figure 4. 
2.3.1 Pain – Chronic LBP 
There is moderate quality evidence from 12 studies [2863 participants] of an effect of opioid 
analgesics on pain in the short term, MD -10·6 [95% CI -13·5, -7·7] (Figure 2.1) and high 
quality evidence from 9 studies [3123 participants] that opioid analgesics relieve pain in the 
intermediate term, MD -9·2 [95% CI -11·7, -6·7] (Figure 2.2). There was no information on 
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longer term outcomes. Both pooled effects were of the same magnitude as the most liberal 
threshold for clinically important pain reduction (i.e. 10 points). The meta-regression 
analysis revealed a significant effect of log dose (in morphine equivalent units) on short 
term pain relief with 14.5 point greater pain relief for every one log unit increase in dose, 
p=0·003.
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Figure 2.1: Effects of opioid analgesics on pain; short term. Mean daily morphine equivalent dose in mg. Refer to Appendix Table 6 for drug 
comparison a) b) c). Negative outcome values represent mean change from baseline. Egger’s p-value = 0·03.  
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Figure 2.2. Effects of opioid analgesics on pain; intermediate term. Control = Placebo. Mean daily morphine equivalent dose in mg. Refer to 
Appendix Table 6 for drug comparison a) b) c). Egger’s p-value = 0·50.  
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Combination opioid analgesic medicines containing an opioid antagonist or simple analgesic 
have shown moderate evidence of pain relief in the short and intermediate term, MD -11·1 
[95% CI -17·3, -4·9] and -11·9 [95% CI -19·3, -4·4], respectively (Figure 2.3). There is low 
quality evidence that opioid agonist/antagonist combinations relieve pain in the 
intermediate term, MD -9·5 [95% CI -17·2, -1·8].  The pooled effects were of the same 
magnitude as the most liberal threshold for clinically important pain relief. 
There is a paucity of evidence around the use of muscle relaxants in chronic LBP, with one 
placebo-controlled trial of flupirtine providing very low quality evidence that there is no 
clinically significant effect on pain in the short term, MD -4 [95% CI -8.6, 0.6]. 
2.3.2 Pain - Acute LBP 
There is high quality evidence from five trials (n=496 participants) that muscle relaxants 
relieve pain in the short term, MD -21·3 [95% CI -29·0, -13·5]; this pooled effect was larger 
than the 10 point threshold for clinical importance (Figure 2.4). There was no information 
on longer term outcomes. There is a paucity of evidence around opioid analgesics in acute 
LBP.  
2.3.3 Head-to-Head comparisons 
Head-to-head comparisons of opioid analgesics or muscle relaxant trials are summarised in 
Appendix Figure 5 and Appendix Figure 6.  
No clinically significant difference in effect was observed in any head-to-head opioid 
analgesic trial, however, an evaluation of morphine equivalent conversions (see Appendix 
Table 6) showed similar mean daily morphine equivalents for most comparisons, providing a 
plausible explanation for the lack of difference. 
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Figure 2.3. Sensitivity analyses. Opioid agonist/ antagonist or opioid analgesic/ simple analgesic combination; short and intermediate term 
pain relief. Control=Placebo. 
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Figure 2.4. Effects of muscle relaxants on pain; short term. Negative outcome values represent mean change from baseline. Egger’s p-value=0·50 
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2.3.4 Disability – Acute LBP 
A total of five trials (Aksoy et al., 2002; Chu et al., 2012; Ralph et al., 2008; Ruoff et al., 2003; 
Serfer et al., 2010) reported on disability (three on acute LBP and two on chronic LBP). One 
muscle relaxant trial (Aksoy et al., 2002) provided low quality evidence of clinically 
significant reduction in disability with thiocolchicoside for the short term, MD -18·8 
(p<0·001). Pooled effects from two placebo-controlled trials of carisoprodol (Ralph et al., 
2008; Serfer et al., 2010) provide moderate quality evidence that there is no clinically 
significant benefit on disability in the short term, MD -6·5 [95% CI -10·9, -2·1] and -7·2 [95% 
CI -10·3, -4·0] - see Appendix Figure 7. 
2.3.5 Disability – Chronic LBP 
There was no significant effect of the combination of tramadol/paracetamol (Ruoff et al., 
2003) on disability for the intermediate term, MD -3·7 [95% CI -11·8, 4·4], however the 
evidence is very low quality. 
A single study of morphine (Chu et al., 2012) showed no clinically significant reduction in 
disability for the short term, MD -6·3 [95% CI 0·5, 12·1], with the evidence being very low 
quality. 
2.3.6 Adverse Events 
Data on adverse events were available for 14 of 15 placebo controlled trials evaluating 
opioid analgesics (Appendix Table 7 and Appendix Table 8), however adverse events were 
reported differently across trials. Of the eight trials (Buynak et al., 2010; Hale et al., 2007; 
Hale et al., 2010; Katz et al., 2007; Ruoff et al., 2003; Steiner et al., 2011a; Uberall et al., 
2012; Vorsanger et al., 2008) providing details on the total number of participants 
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experiencing at least one adverse event in the double blind and/or run in phase, the median 
rates (interquartile range [IQR]) of adverse events in the double blind phase were 49% (44-
55%) for placebo and 69% (55-85%) for treatment groups respectively (RR 1·3, p<0·01) and 
70% (69-81%) in the run in phase (for treatment groups). Studies rarely reported the 
severity or duration of adverse events therefore it was not possible to categorise adverse 
events outcomes into levels of severity.   
Common adverse events reported in opioid analgesic trials included central nervous system 
adverse events (headache, somnolence, dizziness), gastrointestinal adverse events 
(constipation, nausea, vomiting) and autonomic adverse events such as dry mouth.  
There were 5 muscle relaxant vs placebo trials (Chandanwale et al., 2011; Ralph et al., 2008; 
Serfer et al., 2010; Tuzun et al., 2003; Uberall et al., 2012) for which adverse events 
outcomes were available, three of which (Chandanwale et al., 2011; Tuzun et al., 2003; 
Uberall et al., 2012) reported the total number of participants experiencing one or more 
adverse event. The median adverse event rate for muscle relaxants was similar to placebo 
19.6% IQR (5·5 to 37·5%) and 25·7% (6·3 to 36·7%); p=0·50 respectively.  
2.3.7 Reasons for withdrawal (Participants who discontinued the study for any reason) 
Half of all opioid analgesic trials had over 50% of participants withdraw (irrespective of 
study design) predominantly due to adverse events and lack of efficacy (Appendix Table 4). 
Muscle relaxant trials reported a much lower withdrawal rate (largest loss 26% [Rollings, 
1983]) with common reasons being loss to follow up and to a lesser extent lack of efficacy 
and adverse events (Appendix Table 5). 
Note: For grading of evidence: see Appendix Table 9.  
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2.4 DISCUSSION 
There is evidence that opioid analgesics relieve pain in the short and intermediate term for 
chronic (but not acute) LBP; however these medicines are commonly associated with 
adverse events. Muscle relaxant drugs are effective in relieving pain in the short term for 
acute (but not chronic) LBP. There is a paucity of evidence to support benzodiazepines in 
LBP. There is a paucity of evidence on long term use, and effects on disability for these 
classes of medicines. 
Strengths of this review include a comprehensive search strategy and coverage of opioid 
analgesics and muscle relaxants; medicines widely used globally to manage LBP. The PEDro 
scale was used to assess risk of bias because it has acceptably high clinimetric properties (de 
Morton, 2009; Macedo et al., 2010; Maher et al., 2003) whereas limitations have been 
reported for the Cochrane risk of bias scale (Armijo-Olivo et al., 2012; Hartling et al., 2009). 
Limitations of this study include possible publication bias, as only studies published in peer-
reviewed journals were included.  
Previous reviews in this area (Chaparro et al., 2013; Martell et al., 2007) have drawn 
conclusions based on statistically significant differences in standardised mean difference 
(SMD), whereas this review has also considered the clinical significance of such changes. 
This review presents a more detailed evaluation of the evidence in light of run-in failure, 
treatment discontinuation and loss to follow up compared with existing reviews. Over one 
third of opioid analgesic trials employed an enrichment design, therefore estimates of 
treatment effectiveness may be overly optimistic (Temple, 2013). In some opioid analgesic 
studies, nearly half of participants failed the run-in phase alone, with lack of efficacy and 
side effects being common reasons for withdrawal. Taken together, these issues suggest 
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there would be much lower treatment effects and higher adverse events rates among 
people new to these medicines.  
 
We also conducted a meta-regression to explore association between opioid analgesic dose 
and effect and found there is a 14·5 point increase in pain relief for every one log unit 
increase in dose i.e. 1 vs 10 ME mg, 10 vs 100 ME mg. However the latest review of opioid 
prescribing guidelines (Nuckols et al., 2013) cautions against exceeding 200 mg of morphine 
equivalents per day as a way of alleviating the risk of opioid-related complications such as 
life threatening respiratory depression. Higher doses of opioid analgesics have also been 
associated with physical dependence, abuse and clinically significant hormonal changes 
(Benyamin et al., 2008; Cicero et al., 2005a; Cicero et al., 2005b; Daniell, 2002; Lee et al., 
2002; Nuckols et al., 2013). Hence the findings of this review must be carefully considered 
against the risk of complications with higher doses of opioid analgesics. There is currently no 
evidence to support the long term use of opioid analgesics in LBP at any dose. Increasingly, 
evidence around back pain management supports a patient-centred approach to care within 
a multidisciplinary framework (Artner et al., 2012) because it is unlikely that complex cases 
can be adequately managed by pharmacological treatments alone, or by a single health care 
professional acting independently. 
Previous reviews excluded combination medicines containing opioid analgesics and simple 
analgesics or opioid antagonists whereas the sensitivity analyses from this review have 
identified a beneficial role in LBP therapy of these combinations. There is moderate quality 
evidence that paracetamol combined with tramadol - a weak opioid, provides clinically 
significant reduction in pain (but not disability). Whilst the evidence for paracetamol 
monotherapy in LBP is poor (Abdel Shaheed et al., 2014a; Davies et al., 2008), the addition 
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of simple analgesics to opioid analgesics is a rational approach to managing chronic pain and 
can reduce the need for higher doses of opioid analgesics (American Pain Society, 2003; 
Raffa, 2001; WHO, 1996). Ongoing monitoring for adverse events is necessary for this 
formulation as with any opioid analgesic.  
The evidence for muscle relaxants supports existing recommendations for brief treatment 
periods (< 2 weeks) for an acute episode of back pain (Waddell et al., 1999) in the absence 
of satisfactory pain relief with analgesics alone. However, there was moderate quality 
evidence that carisoprodol has no clinically significant benefit on disability in the short term. 
Furthermore, caution must be taken with some of the findings, since there are now 
restrictions around the use of some muscle relaxants such as thiocolchicoside (European 
Medical Agency, 2014) following claims that aneuploidy – a rare complication affecting 
chromosomes in the body - is linked with the drug (European Medical Agency, 2014). As 
there are no outcomes data available beyond the short term for any muscle relaxant drug, 
long term, unmonitored use of these medicines is unwarranted.  
There is a paucity of evidence to inform the use of benzodiazepines in LBP yet paradoxically, 
diazepam – a benzodiazepine with sedative properties (Chouinard, 2004) - ranked among 
the most commonly prescribed medications for back pain in Australia and the USA (AIHW, 
2009a; Luo et al., 2004). This conflicts with guideline recommendations which promote 
activity and avoiding prolonged periods of bed rest for LBP (van Tulder et al., 2006).  
Future research should focus on evaluating opioid agonist/antagonist combinations e.g. 
oxycodone + naltrexone or naloxone, particularly as the use of opioid analgesics to treat 
chronic LBP on a long term basis has risen (Chaparro et al., 2013). The addition of naltrexone 
to oxycodone has been shown to improve analgesia in osteoarthritis (Chindalore et al., 
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2005), whilst in chronic LBP the combination has been shown to reduce the incidence of 
physical dependence compared with oxycodone monotherapy (Cloutier et al., 2013). The 
therapeutic role of low dose naloxone in combination with oxycodone is to counteract 
opioid-induced constipation and may be advantageous for long term use (Cloutier et al., 
2013). This review identified preliminary evidence of pain relief with combination opioid 
agonist/antagonist, however these come from single studies. Future studies should also 
consider possible synergistic effects of non-pharmacological strategies, apart from physical 
therapy, to inform combination strategies which are efficacious for LBP.  
2.5 CONCLUSION 
In chronic LBP patients who respond favourably to a trial of the medicine; opioid analgesics 
provide short/intermediate pain relief, though the effect is small. Muscle relaxant drugs 
provide pain relief in the short term for acute LBP. There was a paucity of evidence around 
the use of benzodiazepines for LBP and effects of the three classes of medicines on 
disability. The present evidence does not substantiate prolonged use of any of these drugs 
for LBP. 
The next chapter will evaluate the effectiveness of over-the-counter interventions and 
advice that can be offered for acute LBP. 
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CHAPTER THREE 
Interventions available over-the-counter (OTC) and advice for acute 
low back pain: Systematic Review and Meta-analysis. 
A manuscript of this chapter is published in the Journal of Pain: Abdel Shaheed C., C. G. 
Maher, et al. (2014). “Interventions available over the counter and advice for acute low back 
pain: systematic review and meta-analysis.” Journal of Pain 15(1): 2-15. 
3.1 INTRODUCTION 
In Australia, it is estimated that more than $1 billion is spent annually on treatments for LBP, 
whilst a further $8 billion is spent on indirect costs (Ostelo et al., 2008). In the USA, this 
figure is estimated to be as high as $50 billion per year (Deyo, 2001). 
 
Only around half of people with acute LBP consult a health professional (Deyo 2001; Hart et 
al., 1995; Walker et al., 2003; Wilk et al., 2010), with use of remedies available over-the-
counter (OTC) widespread. Findings from a 2008 USA National Health Interview Survey 
(NHIS) (White paper on the benefits of OTC medicines in the USA, 2010) identified LBP as 
one of the most common conditions treated with OTC medicines. Many of these OTC 
interventions can be provided in a community pharmacy/drug store and include non-
prescription medicines and simple remedies such as heat or cold packs that can be provided 
to a person with LBP for self-administration. 
 
Despite the widespread use of OTC interventions and the provision of advice to those 
experiencing LBP, there are no systematic reviews summarising the clinical effectiveness of 
these interventions for acute LBP. The aim of this review was to investigate the 
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effectiveness of interventions that can be accessed over-the-counter, without the need for a 
prescription, and advice that could be delivered in a primary contact setting. 
3.2 METHODS 
3.2.1 Data sources and searches 
 
MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, AMED, CENTRAL and 
PsycINFO (inception to March 2013) were searched for randomised controlled trials (RCTs) 
evaluating OTC interventions (Appendix Table 10) and/or advice for acute LBP (full search 
details in Appendix Table 11). We also screened studies and reference lists from systematic 
reviews in the area to identify potentially eligible RCTs.  
One reviewer (CAS) screened titles and abstracts of retrieved studies. Two reviewers drawn 
from a pool of three reviewers (CAS, AJM and CGM) inspected the full manuscript of 
potentially eligible RCTs to determine eligibility, with disagreements resolved by consensus. 
3.2.2. Study selection 
Studies were restricted to English language RCTs evaluating over-the-counter remedies for 
acute (pain duration <12 weeks) non-specific LBP. We restricted interventions to those that 
could be self-administered by a person with LBP and were readily accessible from a 
community pharmacy/drug store without prescription (Appendix Table 12). Eligible controls 
included placebo, no treatment or usual care.  
 
Eligible interventions included over-the-counter medicines (e.g. paracetamol or non-
steroidal anti-inflammatory drugs), complementary/herbal remedies (e.g. comfrey) and 
topical applications (e.g. heat or cold packs). We also included advice that could be provided 
46 
 
to a person with LBP in an OTC setting. We excluded interventions that required a 
prescription (such as single ingredient opioid analgesics, analgesic adjuvants or muscle 
relaxants) and physical interventions such as spinal manipulation, acupuncture and laser 
therapy. 
Trials were included if they reported endpoints such as pain, disability, global perceived 
recovery, sickness leave or adverse events outcomes. We considered pain as the primary 
outcome.   
3.2.3 Data extraction and quality assessment 
 
Methodological quality of individual trials was assessed using the Physiotherapy Evidence 
Database scale (De Morton, 2009; Macedo et al., 2010; Maher et al., 2003). This has been 
described in detail in Chapter two. 
Given the extensive quality control procedures used by the PEDro database, we adopted 
existing ratings for 12 of the 13 RCTs with the remaining trial (Dreiser et al., 2003) allocated 
a PEDro rating by three reviewers (CAS, CGM and AJM) using a joint consensus approach. 
Trials scoring <7/10 on PEDro scale were defined as low quality; those scoring 7 or more 
were considered high quality.   
 
Two reviewers (CAS and CGM) extracted outcomes data from each individual study. Missing 
data was obtained by contacting authors or estimated using the methods endorsed by 
Cochrane Collaboration (Higgins & Green, 2009). We adopted median scores for missing 
means and used standard deviation values from baseline (or the most similar eligible study) 
as a substitute for missing SDs.  
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An adapted version of the GRADE criteria (Atkins et al., 2003) endorsed by the Cochrane 
Back Review Group was used to evaluate the strength of recommendations and the overall 
quality of the evidence for a given intervention. Here, the quality of evidence was 
downgraded a level for each of the four factors considered in this review: poor study design 
(25% or more of trials, weighted by sample size,  have a low PEDro score [<7/10]), 
inconsistency of results (25% or more of the trials, weighted by sample size, have results 
which are not in the same direction), imprecision (sample size <300 for each outcome) and 
indirectness (where the trial context e.g setting, patients, intervention, comparison or 
outcomes is not exactly the same as the review question). We did not assess for publication 
bias using funnel plots as too few studies were included in the meta-analysis.   
Overall quality of evidence was defined as: high quality, moderate quality, low quality or 
very low quality (a detailed description of these grading levels is found in Chapter two). 
For each outcome, the quality of evidence was downgraded one level for indirectness as the 
interventions were not delivered specifically within the OTC setting. Single RCTs with sample 
sizes <300 provided “very low quality evidence” as these were also deemed both 
inconsistent and imprecise. 
Note: Results from single RCTs provided “inconsistent” data as there needed to be more 
than one trial to compare results with in order to determine consistency.  
3.2.4 Data synthesis and analysis 
 
Pain and disability measures were converted to a common 0-100 scale (0: no pain or 
disability to 100: worst possible pain or disability). This approach to transforming data has 
been described (Pinto et al., 2012b) and used (Pinto et al., 2012a; Pinto et al., 2012b) in 
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recent systematic reviews evaluating these outcome measures. A detailed description of this 
method is described in Chapter two. 
Results are presented in mean differences rather than standardised mean differences for 
the same reasons described earlier.  
Here, outcomes were grouped into four time categories: immediate (≤ two weeks after 
randomisation), short term (> two weeks, < three months), intermediate (≥ three months, < 
12 months) and long term (≥ 12 months). Where multiple time points were available for a 
single category, the time closest to one week was chosen for immediate term, eight weeks 
for the short term, six months for the intermediate term and 12 months for the long term.  
 
Results from dichotomous outcomes have been expressed as risk ratios (RR). Descriptive 
statistics were used to report on adverse events. 
 
Trials deemed clinically homogenous were grouped according to intervention, outcomes 
and time points. Meta-analysis was carried out using RevMan 5.1.  
Pooled effects were calculated only when inconsistencies among trials were low (I2 statistics 
< 40%) using a random effects model. When trials were not sufficiently homogenous, 
pooling of data via meta-analysis was not performed and individual effect sizes were 
reported. For calculation of effect size see Appendix Tables 13 to 15.  
3.3 RESULTS 
The database searches identified 4336 studies. After screening titles and abstracts from the 
database search and hand search of references, 22 potentially relevant RCTs were inspected 
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for full review with 13 found to be eligible. A summary of the search results is provided in 
Appendix Figure 8.  
Eligible studies investigated paracetamol/acetaminophen (Milgrom et al., 1993), non-
steroidal anti-inflammatory drugs (NSAIDs) (Dreiser et al., 2003; Milgrom et al., 1993), a 
capsicum-based topical rubefacient (Ginsberg & Famaey, 1897), local heat application 
(Nadler et al., 2003a; Nadler et al., 2003b), bed rest vs normal activity (Gilbert et al., 1985; 
Malmivaara et al., 1995; Rozenberg et al., 2002; Wilkinson, 1995) and advice delivered by a 
health care provider either as a standalone intervention (Pengel et al., 2007), in addition to 
written educational material (Jellema et al., 2005) or involving referral to an allied health 
care professionals (HCPs) such as a physiotherapist (Indahl et al., 1995; Storheim et al., 
2003) (excluding physical interventions).  
The risk of bias (PEDro rating) of each trial is summarised in Table 3.1.  
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Table 3.1. PEDro ratings for eligible trials. 
Study 1 2 3 4 5 6 7 8 9 10 Total  
Dreiser, 2003 1 1 1 1 1 1 1 0 1 1 9 
Milgrom, 1993 1 0 0 0 0 0 1 0 1 1 4 
Nadler, 2003a 1 0 1 0 0 1 1 1 1 0 6 
Nadler, 2003b 1 0 1 0 0 1 1 1 1 0 6 
Pengel, 2007 1 1 1 1 0 1 1 1 1 1 9 
Ginsberg, 1987 1 0 0 1 0 1 1 0 1 1 6 
Jellema, 2005 1 0 0 1 0 0 1 1 1 1 6 
Indahl, 1995 1 0 1 0 0 0 1 1 1 1 6 
Storheim, 2003 1 1 1 0 0 1 0 1 1 1 7 
Gilbert, 1985 1 1 1 1 0 0 0 1 0 1 6 
Malmivaara, 1995 1 1 1 0 0 1 1 0 1 1 7 
Wilkinson, 1995 1 1 1 0 0 0 0 0 1 1 5 
Rozenberg, 2002 1 1 1 0 0 0 1 1 1 1 5 
 
1) Randomisation; 2) concealed allocation; 3) baseline comparability; 4) subject blinding; 5) therapist/physician blinding; 6) assessor 
blinding; 7) adequate follow-up (>85%); 8) intention-to-treat analysis; 9) between group statistical comparisons; 10) point measures 
and measures of variability.  
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The overall quality of evidence for OTC interventions, bed rest or advice in acute LBP is of 
low to very low quality. Most studies on OTC interventions (medicines, local heat 
application) were either single studies with small sample sizes (i.e. <300) and/or had 
deficiencies in study design i.e. low PEDro rating. Common limitations with the advice trials 
centred on poor study design and inconsistency in findings (25% or more of the trials, 
weighted by sample size, have results which are not in the same direction).  
The characteristics of all eligible studies have been summarised in Table 3.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
Table 3.2. Characteristics of Included Studies. 
Study  Patient Population  Setting Intervention Comparison Length of 
Treatment  
Follow up  Eligible 
outcome 
measure  
Nadler, 
2003a 
219 patients (119 ♀ 
100 ♂) mean age 
36.1 with acute (less 
than three months) 
non-specific LBP). 
Pain intensity had to 
be more than one on 
a six point scale  
Two community-
based research 
centres 
 
Heat wrap (Thermacare Heat 
wrap, Proctor and Gamble); 
heats to 40 degrees Celsius 
within 30 minutes of 
exposure to air; maintains 
this temperature 
continuously for eight hours 
N=92 
Oral placebo 
2 tablets 3 
times daily 
spaced 6 
hours apart  
N=88 
 
Heat wrap 
worn for 3 
consecutive 
days  
 
 
Day 5 
 
Disability - 
RMDQ 0-24 
Nadler, 
2003b 
76 patients (49 ♀ 27 
♂) with acute non-
specific LBP  
Five clinical testing 
research sites 
As above. Heat wrap applied 
15-20 minutes before sleep 
and worn for 8 hours for 3 
consecutive nights 
N=31 
Oral placebo 
two tablets 
taken 15-20 
minutes 
before bed 
each night for 
three 
consecutive 
nights  
N=32 
Heat wrap 
worn for 3 
consecutive 
nights.  
 
Day 5  
 
Pain affect (0-
100)  
RMDQ 
Dreiser, 
2003 
369 patients (187 ♀ 
182 ♂) mean age 
40.8 with untreated 
acute LBP; onset 
within two days. Pain 
> 50mm on a 100mm 
VAS  
Fifty four clinics of 
General Practitioners 
in France 
Diclofenac 12 mg (rapid 
acting formulation), initial 
dose 2 tablets, seven days 
flexible dose 4-6 tablets a day  
N=119 
 
 
 
 
Ibuprofen initial dose 2 
Placebo initial 
dose 2 
tablets, 7 
days flexible 
dose 4-6 
tablets/day 
N=116 
 
 
Placebo initial 
Seven days 
 
 
 
 
 
 
 
 
 
Variable 
Day 8 
 
 
 
 
 
 
 
 
Pain (100mm 
VAS) mean 
changed score 
(SD)   
Side effects  
RMDQ 0-24 
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tablets, 7 days flexible dose 
to 4-6 tablets a day 
N=118 
dose 2 
tablets, 7 
days flexible 
dose 4-6 
tablets/day 
N=116 
As above As above  
 
As above 
Milgrom, 
1993  
395 male infantry 
recruits mean age 18 
with acute over 
exertion back pain. 
Israeli infantry 
recruits 
Ibuprofen 800 mg 3 times a 
day for 7 days  
N=24 
 
Paracetamol 100mg three 
times a day for seven days  
N=24 
No drug 
treatment 
n=22. 
 
No treatment 
N=22 
Seven days 
 
 
 
Seven days  
Variable 
time  
 
 
End of 
basic 
training 
(14 weeks) 
Cure/No Cure 
 
 
 
Cure/No Cure 
 
Ginsberg, 
1987 
40 patients with 
acute mechanical LBP   
Each patient was 
given 45 paracetamol 
250mg tablets. No 
other analgesic, anti-
inflammatory drug or 
physical treatment 
was allowed during 
the 12 week period 
Clinical setting – 
access to radiological 
examination and 
laboratory tests 
Rado-Salil ointment 
(containing 17.64 mg 
ethylsalicylate 26.47 mg 
methylsalicylate, 8.82 mg 
glycosalicylate etc. in the 
form of a 40 g stick applied as 
needed 
N=20 
Placebo 
(containing 
only the 
excipient with 
3 times the 
amount of 
lavendula and 
bergamot 
essences) 
matched for 
appearances 
N=20 
Fourteen 
days 
 
immediate 
 
Pain 
evaluation on 
a 10cm linear 
scale. 
Gilbert, 
1985 
252 patients (124 ♀ 
128 ♂) mean age 
40.6 with acute LBP 
with or without 
radiation down the 
leg and free from LBP 
for more than 30 
Family practice  Bed rest. Patients instructed 
to stay in bed for at least four 
days and given written 
instructions depicting 
appropriate positions for bed 
rest 
N=47 
No 
instruction or 
treatment 
N=48 
Four days 10 days, 6 
weeks and 
12 weeks 
Pain 0-100 
point scale 
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days before the 
current episode.  
Storheim, 
2003 
93 patients (48 ♀ 45 
♂) mean age 40.8 
sick listed for 8-12 
weeks due to acute 
LBP  
 
Initial clinical 
examination was 
followed by an 
appointment at an 
outpatient clinic 
Cognitive group N=34 (ITT) 
Baseline intervention: 
standard clinical examination 
where back was examined, 
imaging results explained and 
patients were encouraged to 
continue with normal activity 
Cognitive intervention took 
place at the outpatient clinic 
and was a collaborative effort 
between a specialist in 
physical medicine and a 
physical therapist. It involved 
a discussion of pain 
mechanisms, completion of a 
questionnaire, functional 
examination, instruction on 
movement methods, re-
assurance and advice on how 
to manage new attacks     
Two consultations offered 
each lasting 30-60 minutes 
Control group 
received 
usual care (no 
referral) n=29 
(ITT) 
Two 
consultations 
were offered 
(duration of 
each 30-60 
minutes) 
Reported 
at 18 
weeks  
Pain (VAS) 
Disability 
(RMDQ) 
Pengel, 
2007 
259 patients (124 ♀ 
135 ♂) mean age 
49.9 with subacute 
LBP (excluding recent 
surgery) 
Seven university 
hospitals and 
primary care clinics 
in Australia and New 
Zealand 
Advice sessions followed that 
of Indahl et al., 1995 where 
the health provider 
(physiotherapist) encouraged 
a graded return to normal 
activities, explained the 
benign nature of the 
condition, addressed any 
unhelpful beliefs about back 
Sham advice 
and sham 
exercise 
n=68 
Six weeks Six weeks, 
3 months, 
12 months 
Pain (0-10 
linear scale) 
Disability 
(RMDQ) 
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pain, cautioned against being 
overly careful e.g. avoiding 
light activity as this could 
delay recovery 
N=63 
Rozenberg, 
2002 
278 patients (147 ♀ 
131 ♂) mean age 
43.6 with acute LBP 
with pain >40mm on 
VAS.  
Multi-centre study 
involving ambulatory 
patients recruited by 
rheumatologists and 
general practitioners  
Bed rest for at least 16 of 24 
hours for the first 4 days. 
Patients instructed to remain 
in bed except to eat and for 
personal care  
N=138 
Advised to 
continue with 
normal daily 
activity (in so 
far as pain 
allowed) 
N=140 
Four days – 
total trial 
period 3 
months  
One week, 
1 month, 3 
months 
Pain intensity 
(VAS) 
Disability 
(Eifel index) 
Wilkinson, 
1995 
33 patients with 
acute LBP of less than 
7 days duration. 
Mean age 35.2 and 
41.2 (bed rest and 
control group 
respectively). 
Recruitment of 
participants by nine 
general practitioners 
from practices in 
West Midlands  
48-hours of strict bed rest  
N=15 
Advised to 
stay active 
and avoid 
daytime rest 
N=18 
Forty eight 
hours 
One week, 
4 weeks  
Disability 
(Oswestry 
index) 
Malmivaara, 
1995 
186 patients (124 ♀  
62 ♂) mean age 40.3 
with acute LBP 
Occupational health 
care centre in 
Helsinki Finland 
Bed rest for two days with 
only essential walking e.g. to 
go to bathroom allowed. 
N=62 
Continuation 
of normal 
activities as 
tolerated 
n=61 
Two days  Three and 
12 weeks 
Pain scale (0-
10) 
Indahl, 1995 975 patients (37 ♀ 
597 ♂) mean age 
42.5 with subacute 
LBP on sickness leave 
from work for more 
than 8 weeks 
County of Oetsfold 
Spine Clinic  
Examination whereby 
participants received advice 
largely following principles of 
a bio-psychosocial model. 
The condition was explained 
to the patient, light activity 
was encouraged, emotional 
aspects of pain discussed, 
address fears about the 
Control group 
did not 
receive a 
formal 
examination 
but instead 
received 
standard 
care. N=512 
Over 
consultation 
200 days 
and 400 
days  
Number (n)  
not on 
sickness leave 
56 
 
condition. Information was 
reinforced at 3 months and 1 
year during follow up 
appointments. Initial 
consultation ~ 2.5 hours.  
N=463 
Jellema, 
2005  
314 patients with LBP 
of less than 12 weeks 
duration 
Sixty general 
practitioners in 41 
general practices 
GP consultation with 
emphasis on psychosocial 
prognostic factors (at least 
one consultation of 20 
minutes) plus educational 
booklet  
N=142 
Usual care 
N=163 
Over period 
of 
consultation 
Six weeks, 
13 weeks 
and 1 year 
Pain (VAS) 
Disability 
(RMDQ) 
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3.3.1 Pain and Disability 
The effects of OTC interventions and advice on pain and disability are shown in Figures 3.1 
and 3.2 respectively. Clinically significant effects on both pain and disability were identified 
for NSAIDs alone, whilst heat wrap treatment showed clinically important effects for pain 
only. None of the trials evaluating advice or bed rest reported statistically and clinically 
important effects at any time point. 
 
Pooled results from two trials (Jellema et al., 2005; Pengel et al., 2007) on advice following a 
bio-psychosocial model to patient care showed no significant effect on pain in the 
intermediate and long terms, MD -0.8 (95%CI -4.7,3.2) and MD, -0.2 (95%CI -4.2, 3.9) 
respectively. The GRADE classification for these effects is very low quality for each time 
point (combined sample size >300 but downgraded for inconsistency, indirectness and poor 
study design).    
 
The effects of advice on disability are similar to those for pain with pooled results showing 
no clinically significant effect for the short (Jellema et al., 2005; Pengel et al., 2007), and 
long terms (Jellema et al., 2005; Pengel et al., 2007), MD -1.4 (95% CI -5.8, 3.0) and MD -0.2 
(95% CI -2.9, 2.6) respectively. Similarly the GRADE classification for these effects at each 
time point is very low quality (combined sample size >300 but downgraded for 
inconsistency, indirectness and poor study design).     
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Figure 3.1.  Effects of OTC remedies on pain. Pain is measured on a 0 (no pain) -100 (maximum) scale. Effects are mean differences in 
outcome with 95%CI. For Storheim et al., 2003 and Dreiser et al., 2003 the effects are computed from change scores from baseline. NSAID 
1= Ibuprofen 200 mg when required (prn); NSAID 2=Diclofenac 12.5 mg when required (prn). 
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Figure 3.2. Effects of OTC remedies on disability. Disability is measured on a 0 (no disability) -100 (maximum) scale. Effects are mean 
differences in outcome with 95%CI. For Storheim et al., 2003 and Dreiser et al., 2003 the effects are computed from change scores from 
baseline. NSAID 1= Ibuprofen 200 mg when required (prn); NSAID 2=Diclofenac 12.5 mg when required (prn). 
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Three RCTs (Gilbert et al., 1985; Malmivaara et al., 1995; Rozenberg et al., 2002) 
investigating the effect of bed rest on pain were identified. Pooling showed no effect of bed 
rest in the immediate, short and intermediate terms, MD 3.4 (95% CI -0.7, 7.5), 3.9 (95% CI 
0.3, 7.5) and 4.9 (95% CI 0.5, 9.2), respectively, with results favouring normal activity. The 
GRADE classification for these effects is low quality (total sample size >300 however 
downgraded for indirectness and poor study design). The effects of bed rest on disability 
match those for pain with pooled estimates from three studies (Malmivaara et al., 1995; 
Rozenberg et al., 2002; Wilkinson, 1995) similarly showing no significant effect of bed rest in 
the immediate, short and intermediate terms, MD 4.6 [95% CI 1.3,8.0], 4.7 [95% CI 1.9, 7.4] 
and 3.2 [95% CI 0.8, 5.7] respectively. The overall quality of evidence is considered low 
quality (downgraded for indirectness and poor study design).  
 
A single RCT of heat wrap therapy (Nadler et al., 2003b) reported statistically significant and 
clinical important pain relief in the immediate term, MD -13.5 [95% CI -21.3, -5.7], however, 
no outcomes were available beyond day 5. The GRADE classification for this effect is very 
low quality (single study downgraded for imprecision, indirectness and poor study design). 
 
Pooled results from 2 low quality RCTs on heat wrap treatment (Nadler et al., 2003a; Nadler 
et al., 2003b) showed a statistically significant but not clinically significant effect on 
disability, MD -8.90 [95% CI  -13.7, -4.0] (Figure 3.2). The individual studies provide 
imprecise estimates of treatment effect (sample size <300) and the GRADE classification is 
very low quality for this intervention (downgraded for imprecision, indirectness and poor 
study design). 
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Evidence around NSAIDs was limited with only one study (Dreiser et al., 2003) reporting on 
eligible pain and disability measures. This study (Dreiser et al., 2003) used a 3 arm study 
design (ibuprofen 200 mg prn vs diclofenac 12.5 mg prn vs placebo prn) with treatment 
effects for each intervention described in Figures 3.1 and 3.2. There was not enough clinical 
data (pain and disability) on NSAIDs to allow pooling of effects, as such individual effect sizes 
have been reported.   
There were clinically significant effects on pain with ibuprofen 200 mg and diclofenac 12.5 
mg prn (when required) dosing, MD -10.9 [95% CI -17.6, -4.2] and -11.3 [95% CI -17.8, -4.9] 
respectively (Figure 3.1) but there are no outcomes available beyond day 8 of treatment. 
Ibuprofen 200 mg and diclofenac 12.5 mg prn dosing were also found to have clinically 
significant effects on reducing disability in the immediate term, MD -10.0 (95% CI -15.6, -4.4) 
and -12.1 (-17.9, -6.2) respectively (Figure 3.2) but similarly there are no outcomes beyond 
day 8 of treatment. The GRADE classification for these effects on both pain and disability 
(GRADE) is very low quality (single study, downgraded for inconsistency, imprecision and 
indirectness).  
 
One RCT (Ginsberg et al., 1987) investigating a capsicum-based topical rubefacient showed a 
statistically significant improvement in pain compared to placebo at day 3 (mean score 19.0 
vs 1.5, respectively), MD 17.5, (p<0.001) and provides very low quality evidence for the 
effectiveness of this formulation in acute LBP (single study downgraded for imprecision, 
indirectness and poor study design).   
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3.3.2 Recovery 
Two RCTs (Jellema et al., 2005; Milgrom et al., 1993) reported on recovery. Studies reporting 
on recovery measured perceived recovery as reported by the patients themselves. In one 
trial (Jellema et al., 2005) this was reported on a Likert scale ranging from ‘slightly improved’ 
to ‘very much worse’ with data on ‘no recovery’ used as a primary outcome measure. In the 
other trial (Milgrom et al., 1993) recovery was simply expressed as cure versus no cure.  
Note: Data on no recovery/ no cure has been presented in this review.   
One study (Milgrom et al., 1993) on NSAIDs found no significant difference between 
unrecovered participants treated with paracetamol 1000 mg three times daily for seven 
days and the control group treated with placebo RR 2.52 (95% CI 0.96, 6.77). The same 
study reported no significant difference between unrecovered participants treated with 
ibuprofen 800 mg three times daily for seven days compared with the control group RR 1.38 
(95% CI 0.67, 2.81). The GRADE classification for these effects is very low quality (single 
study downgraded for imprecision, indirectness and poor study design).  
 
One RCT (Jellema et al., 2005) investigating advice accompanied by an educational booklet 
found no significant difference between unrecovered participants in the intervention and 
control (usual care) groups in the short, intermediate and long terms, RR 1.03 (95% CI 0.75, 
1.42), RR 1.05 (95% CI 0.75, 1.47) and RR 1.15 (95% CI 0.81, 1.65) respectively (Appendix 
Table 15). The GRADE classification is very low quality for each time point (single study, 
downgraded for inconsistency, indirectness and poor study design). 
3.3.3 Sickness leave 
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Two studies investigating advice delivered by a health professional (Indahl et al., 1995; 
Jellema et al., 2005) following a bio-psychosocial model to patient care and three studies on 
bed rest (Malmivaara et al., 1995; Rozenberg et al., 2002; Wilkinson, 1995) reported on 
sickness leave as a study outcome. Studies reporting on sickness leave were included if they 
reported the number (n) of people on sickness leave (as opposed to the number of sickness 
days) at any time point specified in this review (immediate, short, intermediate, long term).  
Pooling of data shows a significant effect of advice in the intermediate term, RR 0.5 (95% CI 
0.43, 0.58) (Figure 3.3) with the GRADE classification for this effect considered low quality 
(downgraded for indirectness and poor study design).  
 
Pooled results from two studies on bed rest (Malmivaara et al., 1995; Rozenberg et al., 
2002) showed a statistically significant negative effect of bed rest in the immediate term, RR 
1.8 (95% CI 1.5, 2.2) with results favouring normal activity. The GRADE classification for this 
effect is very low quality (downgraded for imprecision, inconsistency and poor study 
design).  
However pooled estimates from two trials (Malmivaara et al., 1995; Wilkinson, 1995) 
showed no statistically significant effect of bed rest in the short term, RR 1.3 (0.9, 1.9) 
(Figure 3.4) with the GRADE classification for this effect considered low quality (downgraded 
for imprecision and indirectness).  
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Figure 3.3. Effects of advice on Sickness Leave. 
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Figure 3.4. Effects of bed rest on Sickness Leave. 
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3.3.4 Adverse events 
Data on adverse events of interventions were identified for heat application, a topical 
capsicum-based rubefacient and NSAIDs. One study on heat wrap therapy (Nadler et al., 
2003a) reported one case of local skin discolouration by day five of the study however this 
resolved without treatment. The study intervention was well tolerated among 94/95 
participants. The study of a capsicum-based rubefacient (Ginsberg & Famaey, 1987) 
reported one case of skin irritation on day seven of treatment and three more cases 
between days ten and 12. These effects resolved spontaneously.  
 
One study on NSAIDs (Dreiser et al., 2003) reported that adverse events were more 
common in the placebo group (19/122) compared with the diclofenac (16/124) and 
ibuprofen treatment group (14/122). Common adverse events for the NSAIDs were 
gastrointestinal: abdominal discomfort, diarrhoea, nausea and vomiting. There was one case 
of rectum haemorrhage in the ibuprofen group. Somnolence was reported by a total of 
three participants in the diclofenac group and other ‘nervous system reactions’ reported by 
a further four participants treated with NSAIDs (three diclofenac, one ibuprofen). Sixteen 
participants were withdrawn from the study due to an adverse event (eight placebo, four 
diclofenac, four ibuprofen; specific event not described).  
3.4 DISCUSSION 
There is not convincing evidence of effectiveness for any intervention available OTC, or 
advice in the management of acute LBP. At best there is very low quality evidence that heat 
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wrap, NSAIDs and rubefacients provide an immediate analgesic effect but no information 
about longer term effects on pain. There is low to very low quality evidence that best rest 
and advice are ineffective. This review has highlighted an area of practice where there is a 
paucity of research to inform clinical decision making.  
 
Current LBP management guidelines (van Tulder et al., 2006) recommend that individuals 
avoid bed rest and make a gradual return to normal activity. Findings from this review have 
shown no favourable effect of bed rest on pain or disability with results favouring normal 
activity, concordant with previous analyses which also suggest that bed rest can delay 
recovery from LBP (Dahm et al., 2010). However, encouragement of physical activity and 
avoidance of bed rest in LBP are not to be considered in isolation. Guidelines (van Tulder et 
al., 2006) have emphasised the importance for HCPs to re-assure individuals of a favourable 
prognosis, recognising that catastrophising and fear-avoidance among patients represent 
potential barriers to recovery (Pincus et al., 2002). Whilst this is a component of first-line 
care echoed in most advice trials (Indahl et al., 1995; Pengel et al., 2007), this review found 
only low quality evidence that advice delivered by HCPs has some benefit on sickness leave.  
 
The majority of advice trials delivered an intervention principally aligned with a bio-
psychosocial model of care (Waddell, 1987). With this model, there is the opportunity to 
address any concerns or negative beliefs the individual has about their condition. Individuals 
are provided re-assurance of a favourable outcome and encouraged to stay active. With all 
the advice trials, the intervention was compared with usual care; however, differences such 
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as the accompaniment of written educational material may have affected the overall 
results. Written information may serve to reinforce verbal advice (NPS, 2012), although the 
clinical benefits with this combination remains largely unclear in acute LBP.  
 
Another explanation for the lack of effect of advice may be related to variable times spent 
with the patient. In the pooled analysis of the advice trials shown in Figures 3.1 and 3.2 
(Jellema et al., 2005; Pengel et al., 2007; Storheim et al., 2003), the length of single 
consultations varied from 20 minutes (Jellema et al., 2005) to 30-60 minutes (Storheim et 
al., 2003) and also follow-up of participants varied between these studies. Furthermore, the 
interventions were delivered by different HCPs, physiotherapists (Pengel et al., 2007) in one 
and primary care physicians in another trial (Jellema et al., 2005). Evidence suggests that 
patients with acute LBP are more likely to benefit from comprehensive consultations 
(Engers et al., 2008), although this is not loosely characterised by the length of time spent 
with the patient but includes appropriate information gathering and quality of advice 
delivered. Furthermore, the training that the HCPs received may have impacted the delivery 
of the intervention. Most of these studies made no reference to the nature or length of 
training received by the HCPs. Previously it had been suggested that short term (<10 hours) 
training sessions may not allow HCPs to deliver adequate care (Lewin et al., 2001), although 
more recent findings suggest that training periods of <10 hours may be equally effective as a 
more intensive training program (Dwamena et al., 2012). There may however have been 
inter-health professional variability so that even if the training was uniformly delivered, 
personal delivery of the intervention by the HCP affected the overall results.     
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Pooled estimates from two studies (Indahl et al., 1995; Jellema et al., 2005) showed a 
statistically significant effect of advice on sickness leave in the intermediate term. Results 
from one of these studies (Indahl et al., 1995) involving referral to an allied HCP and 
reinforcement of key messages at follow up visits showed significant effects in the 
intermediate and long term. This represents preliminary evidence of the potential benefits 
of multidisciplinary management whilst highlighting a need for ongoing review of individuals 
with non-specific LBP. There are efforts underway (Berenguera et al., 2011) to evaluate the 
effectiveness and cost-effectiveness of a bio-psychosocial multidisciplinary intervention in 
LBP. Results from such research are important to inform the evidence around the benefits 
of these interventions, which may support their inclusion as part of a government 
reimbursed service.  
 
With regards to pharmacological management, current guidelines recommend paracetamol 
(4 g/day in divided doses) as first-line treatment ahead of NSAIDs (NHMRC: Evidence based 
management of acute musculoskeletal pain, 2004; van Tulder et al., 2006) This is supported 
by evidence which identified no benefit with the addition of diclofenac 50 mg twice daily to 
simple first line care (advice and paracetamol) (Hancock et al., 2007). This review identified 
a paucity of evidence around simple interventions (NSAIDs and paracetamol) as standalone 
interventions, with very low quality evidence that rapid acting diclofenac 12.5 mg (the 
potassium formulation as opposed to the sodium formulation) and ibuprofen 200 mg taken 
on a ‘prn’ (when required) regimen has clinically significant effects on pain and disability. 
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However a significant limitation with this study (Dreiser et al., 2003) was that assessment of 
outcome measures was available for the immediate term only. A better analysis would have 
been to follow up patients over a longer period to ascertain the short, intermediate and 
long term clinical benefits of these interventions. There was also no statistical evaluation on 
the side effect profile of these low-dose NSAIDs compared with placebo, however no 
marked dissimilarities were noted with the primary complaint in each study arm being 
gastrointestinal (GI) complications (e.g. abdominal discomfort, nausea). Gastrointestinal 
complications are the most common side effects reported with NSAIDs (Garcia Rodriguez, 
1998; Munir et al., 2007; Sostres et al., 2010) although ibuprofen and diclofenac taken at 
low doses appear to have the least risk of GI complications compared with any other NSAID 
(Garcia Rodriguez, 1998; Sostres et al., 2010).  
 
There was an absence of pain data with the high dose of ibuprofen (Milgrom et al., 1993) 
investigated in this review (800 mg three times daily) to allow a comparison with the simpler 
prn regimen of ibuprofen (Dreiser et al., 2003) evaluated. There are suggestions that 
starting with a higher dose of a short-acting NSAID e.g. ibuprofen, then lowering the dose 
once analgesic efficacy is reached may be favourable (Garcia Rodriguez, 1998). However 
given that ibuprofen has a ceiling analgesic effect at doses of 400 mg (Laska et al., 1986) 
(the initial dose administered to participants in the trial by Dreiser et al., (2003) [2x200 mg 
tablets]), there seems little rationale to administering doses higher than this, particularly 
with there being “no evidence of a dose-response relationship between 400 mg and 800 mg 
in terms of clinical efficacy” (Laska et al., 1986). Based on the analgesic and side effects dose 
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response curves for NSAIDs, higher doses are associated with an increased risk of side 
effects but may produce very little additional pain relief (Laska et al., 1986; Munir et al., 
2007; Sostres et al., 2010). 
In the absence of evidence of clinical benefits with higher doses of NSAIDs in acute LBP, a 
trial of simpler regimens is encouraged initially to avoid possible dose related complications.  
 
Among the single interventions investigated, the greatest effect observed was on pain 
reduction with a topically applied rubefacient, MD 17.5 (p<0.001). Most other interventions 
produced differences too small to be clinically significant or, in the case of NSAIDs and heat 
application, changes in pain and/or disability were only slightly above the minimum clinically 
significant threshold of 10-points on a 0-100 point scale. We adopted the most lax criterion 
for clinically significant changes in pain and disability (Chou et al., 2007b; Chou et al., 2007c; 
Dworkin et al., 2008; Farrar et al., 2000; Giraudeau et al., 2004; Ostelo et al., 2008) 
suggested in the literature, and given these findings, it is compelling to postulate that a 
combination of pharmacological and non-pharmacological interventions e.g. simple 
analgesic or rubefacient plus heat application may have a synergistic effect and 
subsequently clinically superior outcomes, however future research is needed to support 
this.  
 
It is noteworthy that acute LBP has a favourable prognosis, with up to 90% recovering within 
the first month of pain onset (Andersson, 1999). This provides a plausible explanation for 
the lack of effect of interventions not compared with placebo. However the theory that the 
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small treatment effects of interventions in trials of acute LBP could largely be attributed to 
the favourable natural history of this condition has been challenged in the placebo-
controlled setting. Findings from a systematic review (Machado et al., 2009) evaluating 
mean baseline and follow up pain scores (on a 0-100 point scale) from 18 placebo-controlled 
trials of interventions for acute LBP found that mean differences of up to 40 points can be 
demonstrated between placebo and treatment groups.  
Of the four placebo-controlled trials included in the analysis of this review, the smallest MD 
observed was 10.9 points (dicofenac 12.5 mg vs placebo). Whilst low, this is a clinically 
significant result and represents a difference of 15% from baseline, concordant with the 
findings from the aforementioned review (Machado et al., 2009). 
 
This review has identified an absence of quality evidence in an important area, particularly 
given the enormity of OTC products marketed for LBP management and the confusion 
surrounding effectiveness which often arises. Our findings provide reliable information to 
safeguard against elaborate or poorly substantiated claims.  
 
The strengths of this review include an extensive and highly sensitive search strategy 
including OTC interventions universally available which are either indicated or marketed for 
use in LBP, making the findings globally relevant. Furthermore, we excluded interventions 
that are no longer available, therefore findings have not been skewed by out-dated data and 
are immediately relevant to current practice.  
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The PEDro scale was used to rate the quality of individual trials as it has been found to be a 
reliable and valid rating tool (De Morton, 2009; Macedo et al., 2010; Maher et al., 2003) 
whereas limitations have been reported for the Cochrane risk of bias scale (Armijo-Olivo et 
al., 2012; Hartling et al., 2009). 
 
Limitations of this study include possible publication bias, as only published studies included 
in peer reviewed journals were included. Furthermore only English language studies were 
included in the analysis.   
3.5 CONCLUSION 
There is limited evidence that NSAIDs, heat wrap and rubefacients provide immediate pain 
relief for acute LBP and that bed rest and advice are both ineffective. There is a need for 
future, high-quality research to inform the rational use of OTC remedies and advice in acute 
LBP. 
Chapter two and Chapter three have systematically evaluated the evidence for interventions 
that can be used for acute and or chronic LBP to inform recommendations by pharmacists 
and other health care professionals. The next chapter will evaluate how pharmacists who 
collaborated on a LBP clinical trial reported managing people with LBP and their experiences 
whilst collaborating on the trial.   
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CHAPTER FOUR 
Participation of Pharmacists in clinical trial recruitment for low back 
pain 
A manuscript of this chapter is published in the International Journal of Clinical Pharmacy: 
Abdel Shaheed, Maher C. G. et al. (2014c). Abdel Shaheed, Maher C. G. et al. (2014). 
“Pharmacists’ participation in clinical trial recruitment for low back pain.” International 
Journal of Clinical Pharmacy 36(5): 986--994.  
4.1 INTRODUCTION 
Physicians and pharmacists are among the most common health care professionals (HCPs) 
sought for advice by people with LBP (Silcock et al., 2007; Walker et al., 2004) and can 
therefore play an important role in optimising the management of common musculoskeletal 
conditions in primary care. In recent decades, the pharmacists’ role has evolved beyond 
medication management toward a broader commitment to the health and wellbeing of 
people in the community. This is evidenced by their expanding role into clinical trials 
research e.g. through screening, assessing and recruiting eligible patients (Lowres et al., 
2014). Pharmacists are well trusted health professionals who are readily accessible and 
encounter a variety of symptom and product-related enquiries. As such they can help 
address important research questions through their collaboration in clinical trials (McKesson 
StudyLink Program, 2013).  
Recruitment of patients to clinical trials has traditionally been a challenge due to a number 
of factors ranging from administrative considerations e.g informed consent to difficulties 
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recruiting eligible patients (Gul & Ali, 2010; Williams et al., 2014b). Nevertheless identifying 
strategies to overcome such challenges is important given that clinical trials research 
increases clinician understanding of disease states and reveals new information on the 
efficacy and safety of treatment for a broad range of conditions. 
In Australia, pharmacists have been involved in the first placebo-controlled study of 
paracetamol (acetaminophen) for acute LBP, (Williams et al., 2010b) screening people for 
trial eligibility and recruiting suitable patients to the study. Current guidelines (Australian 
Acute Musculoskeletal Pain Guidelines Group, 2004; Koes et al., 2010; van Tulder et al., 
2006) recommend regular use of paracetamol (4/g daily in divided doses), although up until 
recently the benefit of this regimen was largely unclear (Davies et al., 2008). The LBP clinical 
trial that pharmacists collaborated in addressed an important research question as it helped 
to determine whether paracetamol is an effective treatment for acute LBP compared with 
placebo and whether regular or ‘when required’ dosing of paracetamol is favourable. 
The aim of this chapter was to explore the views and experiences of pharmacist-recruiters 
and pharmacist non-recruiters who collaborated on the LBP clinical trial on: 
1) Participation in recruitment for a placebo-controlled trial and the challenges they 
experienced;  
2) Screening and management of people with LBP in primary care. 
It is anticipated that findings from this research will inform strategies to enhance 
recruitment of patients into clinical trials of this nature and address the educational needs 
of pharmacists in an effort to optimise primary care management of LBP. 
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4.2 METHODS 
A convenience sample of 30 pharmacists selected from 124 pharmacists who received 
training for the LBP clinical trial was invited to complete an open ended questionnaire. 
Recruitment of pharmacists for this study took place between July 2012 and March 2013. 
Pharmacists collaborating on the LBP clinical trial (known as paracetamol for LBP [PACE] 
clinical trial) (Williams et al., 2010b) received a 0.5-1 hour face-to-face individualised 
training session with one of the researchers involved to screen patients presenting with 
symptoms of acute LBP for eligibility. This training took place from the period December 
2010 to December 2012. Patients who met the trial’s eligibility criteria were invited to 
participate and were provided with a copy of the trial’s patient information sheet. Patients 
who consented were provided with a study kit which contained the study medicine and 
other relevant paperwork. Follow up of patients recruited through community pharmacies 
was then carried out remotely by trial researchers. 
Among the pharmacists selected to participate, 15 were recruiters i.e. pharmacists who 
enrolled eligible candidates into the clinical trial and 15 were non-recruiters i.e. pharmacists 
who received training and collaborated in the trial but were unable to enrol patients to the 
trial. 
4.2.1 Questionnaire 
The questionnaire consisted of six open-ended questions (see Table 4.1) which were framed 
to draw pharmacists’ opinions on the two core areas specified in the aims.  
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Table 4.1. Questionnaire items.  
Item  
1. Please describe your experience while collaborating on the PACE trial. 
2. We are aware that some pharmacists have found it challenging trying to recruit people with 
LBP to the trial. What do you think are the main barriers to patient recruitment? 
3. We would like your thoughts on how some of these barriers can be overcome, please 
provide some strategies you feel may assist us with patient recruitment. 
4. How common is LBP in your practice? In a week, roughly how many patients would you 
directly encounter with symptoms of acute non-specific LBP (pain of duration < 6 weeks)? 
5. What advice do you generally give to people presenting with a complaint of acute non-
specific LBP to your pharmacy? 
6. How do you screen people with LBP for signs/symptoms of serious disease? Have you come 
across any ‘red flag’ conditions while collaborating on the trial and how did you manage 
these? 
 
Pharmacists were invited to provide as much detail in their responses as they felt was 
necessary. Collection of demographic variables was to allow a comparison between 
pharmacist recruiters and non-recruiters. 
The questionnaire was available to be completed online and pharmacists were sent the 
survey link via email.  
Pharmacists who did not respond within one week of being contacted were sent a reminder 
email. Pharmacists who did not respond within one month of the reminder email were 
considered non-respondents. 
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Ethics Approval: This study received ethics approval from Sydney University Human 
Research Ethics Committee HREC Approval: 13799. 
4.2.2 Data Analysis 
An inductive exploration of pharmacists’ responses was carried out by one reviewer and 
responses were grouped into relevant themes. A second reviewer (AM) reviewed and 
validated the findings. 
Responses from pharmacist recruiters were compared to those of non-recruiters to 
determine similarities and differences in opinions on questionnaire items.  
Statistical analysis was carried out using Statistical Package for the Social Sciences (SPSS) 
version 20. 
4.3 RESULTS 
A total of 37 pharmacists (18 recruiters and 19 non-recruiters) were invited to participate 
and 30 completed the open-ended questionnaire (15 from each group). The response rate 
was 81%. The mean age of recruiters was 33.1 (SD 8.5) years and 47% of pharmacists were 
male. The mean age of non-recruiters was 38.4 (SD 14.8) and similarly 47% were male. This 
distribution of age and gender is broadly representative of NSW pharmacists according to 
the 2006 Australian census and Pharmacy Board Registrant Data (AIHW, 2009b) that 
reported a mean age of 42 and that 44% of NSW pharmacists were male. 
There was a significant difference based on role between pharmacist recruiters and non-
recruiters (p=0.04). Pharmacists in charge and pharmacist managers represented the 
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majority of pharmacist recruiters (n=6 and n=6 respectively) whereas pharmacy owners 
represented the majority of pharmacist non-recruiters (n=8) (Table 4.2).  
Over the trial period, a total of 101 patients were screened by the pharmacist recruiters 
surveyed with 65 enrolled into the trial. The total number of people screened by pharmacist 
non-recruiters was significantly less (n=7; p<0.01). Pharmacist recruiters reported 
encountering more cases of acute LBP on a weekly basis compared with their counterparts 
(median 5 [range 1-150] vs 3 [range 1-30] p=0.35) providing a plausible explanation for the 
higher enrolment of eligible patients among pharmacist recruiters. This result was not 
considered statistically significant.  
Table 4.2 Characteristics of included participants. 
Characteristic Recruiters n=15 Non-recruiters 
n=15 
P value* 
Gender  
Male n (%) 
Female n (%) 
 
7 (47%) 
8 (53%) 
 
7 (47%) 
8 (53%) 
1.0 (NS) 
 
Age (mean [SD]) 33.1 [8.5] 38.4 [14.8] 0.55 (NS) 
Practice years (mean [SD]) 9.5 [7.5] 14.7 [14.9] 0.70 (NS) 
Role: 
Owner 
Pharmacist in Charge 
Manager 
 
3 (6 screened, 5 recruited) 
6 (59 screened, 36 (61%) recruited) 
6 (36 screened, 24 (67%) recruited) 
 
8 (2 screened) 
5 (3 screened) 
2 (2 screened) 
0.04** 
Total No. people screened 101 7 <0.01 
Total No. people recruited 65 0 <0.001 
Number of acute LBP cases 
encountered per week 
(mean [SD]) and median 
(range) 
17 (37.8) and 5 (1-150) 7.1 (8.8) and 3 (1-
30) 
0.35 (NS) 
*NS: not-significant i.e. p>0.05; Mann-Whitney U test. **Kruskall-Wallis test.  
4.3.1 Questionnaire responses 
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There was no marked variation in group responses between pharmacist recruiters and non-
recruiters, although there was a greater focus on the challenges encountered whilst 
collaborating on the clinical trial among pharmacist non-recruiters. 
Pharmacists’ responses reflected a general contentment with the way in which the trial was 
managed by the researchers. However most pharmacists conceded that while there was 
enthusiasm and a greater sense of commitment to collaborating at first, this slowly declined 
with time as their attention turned to competing clinical and business priorities in the 
pharmacy. 
“All members involved were very helpful and knowledgeable. They understood the busy 
pharmacy environment and were willing to detail patients about the study. They provided on 
going support and re-training [of pharmacists] if required.”    
        Pharmacist Non-recruiter -1 
“When first introduced, all pharmacist team members were keen to recruit patients... 
However, other in-store targets superseded the LBP study (not a priority). Many patients 
have back pain, but often patients [are] already on a treatment, or had tried paracetamol or 
had a chronic condition.”      Pharmacist Recruiter – 13 
Nevertheless pharmacists saw their collaboration as an opportunity to take on a more 
clinical role and learn strategies to optimise the management of people with LBP. 
“A good learning experience. Good to be part of new research.” 
         Pharmacist Non-recruiter -6 
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4.3.2 Challenges to recruitment 
Challenges to recruiting patients to the trial centred on three areas:  
1) Time pressure; 
2) Patient reluctance to participate and; 
3) Meeting trial eligibility criteria  
Time pressure was identified as the main barrier to patient recruitment with 12 pharmacists 
(seven recruiters, five non-recruiters) reporting that there was a paucity of time to go 
through the recruitment process with patients.  
“In the retail pharmacy environment, time to discuss such a complex recruitment process is 
very limited, even inhibitory. From a patient's point of view, they do not often expect or are 
not often approached to take part in some form of clinical trials. They are often in a hurry, or 
their pain leaves them in an unsuitable state of mind for discussing complicated matters.” 
                     Pharmacist Non-recruiter -
15  
I think time was probably the biggest barrier. To encourage people to join a study requires a 
lot of time and effort, which unfortunately is a very rare commodity in community pharmacy 
         Pharmacist Recruiter -8              
An interesting difference was that more recruiters suggested lack of time among 
pharmacists was the main barrier to recruitment, whereas non-recruiters suggested time 
constraints among patients was also a significant barrier. 
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Six pharmacists (two recruiters vs four non-recruiters p=0.36) reported that some people 
were sceptical and reluctant about the possibility of being randomised to a placebo group as 
this offered no guarantee of pain relief in the immediate term. An equal number of 
pharmacists (four recruiters vs two non-recruiters p=0.36) reported that patients were 
reluctant to take paracetamol for their pain. In pharmacists’ experiences, many patients had 
already tried paracetamol and were now seeking what they perceived to be stronger pain 
relief for their back pain e.g combination opioid analgesic medicine or anti-inflammatory 
drug.    
“Patients are sceptical particularly when they have moderate to severe back pain and they 
are offered a trial of paracetamol or worse placebo to relieve their pain. They come into the 
pharmacy as the first port of call for relief and advice and we offer something that may not 
guarantee relief. This is one of the issues why it is so difficult to recruit more patients. A lot of 
patients already take regular paracetamol for pain relief. Most patients with back pain have 
either tried paracetamol already and it didn't give them the relief they are after so why 
participate in this study? By this time they need some stronger pain relief such as ones with 
codeine or anti-inflammatories or even heat patches or rubs. They do not generally associate 
paracetamol with moderate back pain relief. You have products like Panadeine, Mersyndol 
[combination medicines containing codeine +/- doxylamine succinate] which have become 
widely accepted as a very strong pain reliever over the counter. So this makes it difficult to 
offer something less effective in their opinion. We need to change their way of thinking 
about pain relief.”        Pharmacist Recruiter -7 
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Five pharmacists (one recruiter, four non-recruiters) also felt that targeting the people who 
met the trial’s eligibility criteria was a challenge due to the acute nature of the condition. 
Those who did meet trial eligibility were generally more interested in a ‘quick solution’ 
rather than committing to a clinical trial which is perhaps more relevant to the chronic 
situation.   
“A large majority of people seeking analgesics for pain are suffering from long term pain. 
Secondly, many people were not interested in being involved - Just wanted to grab and go. 
People are interested in a quick fix. My theory is that probably people with chronic long term 
pain would be the ones to commit to many weeks of treatment as they know there is no 
quick fix.”        Pharmacist Recruiter -14 
“Many people cannot be bothered to wait for help or be part of a prolonged treatment 
period when it comes to acute pain. They just want something right there and then to give 
them relief as they are usually grumpy at the point where they are most eligible for the 
study.” 
               Pharmacist Non-recruiter -14  
 
A more detailed overview of pharmacists responses around these themes are found in table 
4.3  
Table 4.3 Differences in responses between recruiters and non-recruiters around time 
barriers. 
Theme 
(Time) 
Recruiters Non-recruiters 
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PATIENT 
TIME 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACIST 
TIME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACIST 
AND 
PATIENT 
TIME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Time consuming” PR-1 
 
“Lack of time. Other targets were a 
priority.” PR-13 
 
“[Lack of] Time , Busy in the shop, Short 
staff” PR-9 
 
“I think time was probably the biggest 
barrier. To encourage people to join a study 
requires a lot of time and effort, which 
unfortunately is a very rare commodity in 
community pharmacy, especially in the ones 
that I practice in as they are extremely 
busy.” PR-8 
 
“Difficulty associated with time and also 
with regards to sometimes being unable to 
get through to the operators.” PR-10 
 
 
“…Sometimes there is no time to explain the 
study to people and try and recruit them. 
Especially given we are right in the city, 
people are short on time. 3. ….With all the 
new responsibilities given to pharmacists 
including MedScreens … the majority of the 
pharmacist's time has been taken up.” PR-
11 
 
“Time- especially if you are in a situation 
like myself, where you don't just wear the 
pharmacist hat, but also being busy with 
other admin work within the pharmacy. - 
 
“Many people cannot be bothered to wait 
for help or be part of a prolonged 
treatment period when it comes to acute 
pain. They just want something right there 
and then to give them relief as they are 
usually grumpy at the point where they are 
most eligible for the study.” PNR-14 
 
“Patient didn't want to spend time.” PNR-1 
 
 
 
 
“The main barrier is lacking of time. It 
needs us to find out the history of the 
patient, and we have to explain to the 
customers what is the trial about and it is 
not feasible when we have other customers 
waiting to be served.” PNR-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“In the retail pharmacy environment, time 
to discuss such a complex recruitment 
process is very limited, even inhibitory. 
From a patient's point of view, they do not 
often expect or are not often approached 
to take part in some form of clinical trials. 
They are often in a hurry, or their pain 
leaves them in an unsuitable state of mind 
for discussing complicated matters. From a 
pharmacist's point of view, the fast paced 
nature of running dispensary and pharmacy 
store, and dealing with multiple patient's 
and their issues/prescriptions require not 
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patient time, thinking that it will be 
inconvenient for them to participate…” PR-6 
 
 
 
only most of our time, but also most of our 
concentration. This leaves very little time or 
effort to be spent on extra curricular 
activities.” PNR-15 
 
“The time it takes to explain the study as 
well as the survey itself. Patients also 
believe that it consumes too much of their 
time.” PNR-7 
 
 
Note: PR: Pharmacist recruiter PNR: Pharmacist non-recruiter 
4.3.3 Overcoming challenges to recruitment 
Pharmacist recruiters and non-recruiters alike suggested that strategies to reduce the time 
taken to recruit patients would be key to improving participation in such clinical trials, 
however most barriers may be difficult to overcome, particularly if patients are uneasy 
about participating. 
“I think that these barriers will always exist and I cannot think of a strategy that would 
overcome these barriers easily. Firstly those patients that are uncomfortable with 
participating in studies/trials will always have difficulty unless their illness is grave, e.g. 
cancer. Identifying genuine patients will always be difficult and can only be assessed by the 
pharmacist at the time which can be difficult for the pharmacist. The final barrier can only be 
overcome in the long term by a shift in the perception of the general population about the 
role of pharmacist as health professionals and is unrelated to any study.”    
                Pharmacist Recruiter -12 
  
The most common suggestion (made by four recruiters, seven non-recruiters) was greater 
advertising e.g. easy to read brochures, posters and campaigns to raise patient awareness. 
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Five pharmacists (two recruiters, three non-recruiters) suggested a greater patient incentive 
was needed. Non-recruiters (n=3) also suggested simplification of the paperwork was 
necessary.  
“Easy to understand handouts for the candidates to read but not too many words.”  
         Pharmacist Recruiter -9 
“Simplification of the paperwork. Or a greater reward to participants [patients] for their time 
and effort. Both would be nice.” 
        Pharmacist Non-recruiter -11 
“Anything that reduces time taken to recruit would be of benefit. I found the forms quite 
time consuming; a simpler, more streamlined, single paged form would've been ideal, and 
maybe a simplified consent form for the patient, with carbon copies for record keeping. 
Perhaps a simple colour brochure, tear-off pad, to explain roughly what is involved and what 
to expect.”     
                                          Pharmacist Non-recruiter -15 
Other suggestions included collaboration with allied HCPs such as general practitioners and 
incorporating such major trials as part of a professional clinical service/intervention. 
“It is very hard to say how to overcome these barriers in normal everyday practice. However, 
with the advent of ‘Meds-check’ where we use the Guild care program [a professional, 
nationally-recognised pharmacy care program] that flags patients that could potentially 
benefit from a medications check, I could see trials like this being carried out in a similar 
vein. It would mean a partnership with the Guild so that patients that are suitable for a 
particular trial could be flagged through the same program… We would get better at 
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recruiting patients and be reminded about it regularly rather than left to own devices to 
remember… Proper medication trials after all are important for the future of best practice.” 
            
        Pharmacist Non-recruiter -4 
“Asking GPs to assist in identifying and recruiting participants [patients]… “  
        Pharmacist Non-recruiter -9 
 
4.3.4 Pharmacists’ recommendations for LBP 
The most common pharmacological recommendation for acute LBP (independent of the 
trial) was paracetamol (66.7%), followed by over-the-counter NSAIDS (56.7%) and topical 
rubefacients (20%). There was no preference for a particular NSAID, however 13% of 
pharmacists indicated diclofenac would be the most likely choice, followed by ibuprofen 
(10%). Common non-pharmacological recommendations included advice to rest (33.3%), 
cold application (20%), avoid risks (20%) and maintain physical activity/exercises (16.7%). 
Pharmacists’ recommendations have been summarised in Table 4.4.  
Table 4.4. Pharmacological and non-pharmacological recommendations made by 
pharmacist recruiters (n=15) and non-recruiters (n=15). 
Recommendation Recruiters (n) Non-recruiters (n) Total (%) 
Paracetamol 10 10 20 (66.7) 
NSAIDs 7 10 17 (56.7) 
Rest 7 3 10 (33.3) 
Referral to GP 6 4 10 (33.3) 
Rubefacient 2 4 6 (20.0) 
Ice 3 3 6 (20.0) 
Avoid risks 5 1 6 (20.0) 
Activity  4 1 5 (16.7) 
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Heat 3 2 5 (16.7) 
Physiotherapy 1 1 2 (6.7) 
Codeine combination 1 1 2 (6.7) 
Back support 0 1 1 (3.3) 
4.3.5 Screening for ‘red flags’ 
For the majority of pharmacists (29/30) the general approach to screening for red flag 
conditions involved individual methods of questioning and did not follow any specific 
protocol. Note: a red flag is a symptom (e.g. numbness or weakness in the legs) or 
characteristic (e.g elderly age, history of cancer) of a serious underlying condition. 
Pharmacists suggested a need for screening tools which could help them identify red flags 
associated with acute onset LBP and could easily be referred to in practice.  
There were two red flag conditions (1.9% of all patients screened) reported by pharmacists. 
One pharmacist reported encountering a patient with Paget’s disease and this was referred 
immediately to the GP. Another pharmacist who, after evaluating and referring on the 
patient to their GP, was later informed that medical scans had revealed a tumour. The most 
common potential indicators for serious disease identified by pharmacists included:  
1. the nature of complaint (n=21) e.g weakness in the legs, associated nerve pain, 
fever, numbness of the lower extremities;  
2. severity of pain affecting the person’s ability to carry out normal, everyday tasks 
(n=13); 
3. particular subgroups of patients (n=10) e.g those with a previous history of 
undertaking surgery, people with injuries, comorbidities or the elderly; 
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4. treatment failure (n=6) (particularly if strong analgesics did not sufficiently alleviate 
the pain);   
Such cases were viewed as being significantly at-risk and referral to the GP was the 
immediate option. However, whilst pharmacists were particularly concerned about taking a 
thorough history regarding the nature and duration of pain, three pharmacists identified 
medication history as a significant screening question. Pharmacists agreed that adequate 
time would be required to appropriately screen patients for signs/symptoms of complex 
disease and that training of pharmacists was required to instil confidence in their ability to 
identify red flags and appropriately triage patients. 
“I do not at this stage have a method to clearly identify signs and symptoms of serious 
disease since I am not aware of any diagnostic method to exclude serious pathology… I 
would deduce how it begun, what aggravates the pain and if other treatment options have 
been trialled. If through this questioning I conclude that there is a risk of serious disease or 
that I cannot help this patient sufficiently, a referral to the GP would be recommended. 
Obviously if medications have previously proven unsuccessful then a referral would be 
given.” 
         Pharmacist Recruiter -12 
“Screening a patient should involve more one on one time (10-15 minutes). More seminars to 
better educate pharmacists.” 
         Pharmacist Recruiter -7 
4.4 DISCUSSION 
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This study has identified lack of time (affecting both patients and pharmacists) and patient 
reluctance to participate as the major challenges to recruiting patients to the LBP clinical 
trial. Pharmacological management of acute LBP by recruiters and non-recruiters was similar 
and complied with guideline recommended care, although more emphasis on appropriate 
non-pharmacological management strategies such as staying active is required. Pharmacists 
identified a need for further education and training in the triage of patients with possible 
red flag conditions. 
In pharmacists’ views, patient reluctance to participate was often precipitated by the 
amount of paperwork required of them. Pharmacists therefore suggested that a greater 
incentive be offered in order to adequately reimburse patients for the time spent 
completing the questionnaires. The inclusion of an incentive for patients taking part in 
clinical trials is justified, provided they are not excessive or offered persuasively (Grant & 
Sugarman, 2004). However pharmacists’ responses seemed to suggest that an incentive 
alone would not address the challenges around time, which was also perceived to be a 
major barrier to recruitment for them. This was despite there being a reasonable number of 
people presenting with acute LBP on a weekly basis and who may have been eligible for 
inclusion into the trial. Pharmacists therefore suggested a more streamlined paperwork 
system was needed in order to speed the recruitment process and appear less daunting for 
both patients and themselves. Given that time pressure was the most common barrier to 
recruitment reported by pharmacists, researchers running these major clinical trials may 
consider simplifying the recruitment process using a combination of strategies. These may 
include promoting the clinical trial through visible posters and flyers at the pharmacy.  
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Training (for trial recruitment) may also be extended to the pharmacy staff e.g. pharmacy 
assistants who are in regular contact with patients. Use of online social media is known to 
improve patient recruitment rates (Shere et al., 2014) and is a logical step forward for 
researchers wishing to speed up or improve this process. This would potentially overcome 
issues such as loss motivation to recruit patients by pharmacy staff. 
 
Pharmacists’ pharmacological management of acute LBP was similar to guideline 
recommended care (van Tulder et al., 2006; Australian Acute Musculoskeletal Pain 
Guidelines Group, 2004; Koes et al., 2010), and the majority (> 66%) indicated they usually 
recommend paracetamol. Whether or not this finding represents common practice is largely 
unclear, however, it provides a plausible explanation as to why it was difficult to recruit 
people into a trial of paracetamol for LBP, reinforcing comments that many people may 
have already tried this medicine. Pharmacists’ commitment to recruiting patients into the 
trial was additionally challenged by the perception among some people that paracetamol is 
a weak analgesic and would not provide optimum relief from strong pain. This finding is 
concordant with previous reports which show that poor expectation of trial treatment is a 
significant barrier to clinical trial recruitment (Lowres et al., 2014; Lee et al., 2005; Gifford, 
1995; Kao et al., 2003). However pharmacists did express confidence in their abilities to 
influence patient perception and choice of treatment, stating that they had a role to play in 
dispelling myths that these medications are considered weak analgesics. Findings from a 
recent study suggest paracetamol has benefits in moderate to severe acute LBP when taken 
regularly (Hancock et al., 2007), whereas evidence around NSAIDs (diclofenac and 
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ibuprofen) and combination medicines containing opioids is limited or lacking (Abdel 
Shaheed et al., 2014a). The transfer of such findings to the broader community may help to 
shape public perception around paracetamol and inform patient decision-making.  
Nevertheless, many pharmacists conceded that other challenges, such as the inclusion of a 
placebo, appear less likely to be remedied and represent a continuing challenge in research 
of this nature. The use of placebo in clinical trials research continues to be an area of 
contention (Edwards et al., 1998; Foddy, 2009; Kaptchuck et al., 2009; Perrot et al., 2006; 
Rosner, 1987). Whilst placebos have traditionally been used as a gold standard control in 
clinical trials, adding to the rigour and validity of the study (Barnhill, 2012; Justman, 2011), 
the debate against the inclusion of placebo is predominantly fuelled by ethical issues around 
not administering a more effective treatment option (Edwards et al., 1998; Foddy, 2009; 
Kaptchuck et al., 2009; Perrot et al., 2006; Rosner, 1987). 
With regards to non-pharmacological treatment strategies, more pharmacists reported they 
would advise people with acute LBP to rest compared with engaging in physical activity (ten 
vs five respectively; p=0.13) exposing an area of current practice that conflicts with 
guideline recommendations. However pharmacists did provide recommendations for 
avoiding aggravating factors (e.g lifting heavy objects), concordant with guideline endorsed 
recommendations. More pharmacists also reported recommending ice packs compared to 
heat application (six vs five; p=0.74), though this is not a statistically significant result. 
Recent evidence in this area has identified clinically significant reduction in pain and 
disability with heat application and a paucity of evidence to inform the use of cold 
application [Abdel Shaheed et al., 2014a). 
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The implementation of evidence-based practice depends largely on how well the latest 
evidence is relayed to health providers (Henderson et al., 2006). Facilitating health 
providers’ awareness of the body of knowledge around LBP can be achieved through a 
number of means, e.g. seminars, online training and face-to-face education such as was 
delivered to pharmacists at the start of their collaboration on the LBP trial. Pharmacist 
recruiters and non-recruiters shared similar management strategies for acute LBP, reflecting 
positively on the training delivered by the LBP clinical trial researchers. 
To date, however little is known about how pharmacists manage possible cases of red flag 
conditions associated with acute onset LBP. The prevalence of red flags presenting in 
primary care has been estimated to be <5%, consistent with findings from this study where 
1.9% of patients screened by pharmacists were identified as having a red flag condition 
(Chou et al., 2007a; Henschke et al., 2009). Nevertheless, pharmacists agreed that they 
would benefit from stepwise and easy to understand diagnostic tools for identifying red 
flags. Given that pharmacists demonstrated a good ability to enquire about the nature and 
duration of pain, however were somewhat lax with regards to taking a medication history, it 
would seem appropriate to include a prompt for collecting information on medication 
history in the development of such tools. Encouraging a discussion with patients about their 
medication has emerged as an important screening item for possible vertebral fracture in 
people presenting with acute-onset LBP, particularly as certain classes of drugs such as 
antiepileptics and long term use of corticosteroids can increase the risk of bone fracture 
(Henschke et al., 2008; Jette et al., 2011; Williams et al., 2013).  
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A possible limitation of this study was that it evaluated responses from pharmacists who 
collaborated on a LBP clinical trial and as such it is questionable whether these findings can 
be generalised to all community pharmacists. There may be possible selection bias as 
pharmacists were not randomly selected and not all pharmacists collaborating on the 
clinical trial were invited to complete the questionnaire. Future research, including 
interventions, should focus on a greater number of pharmacists in order to help optimise 
primary care management of LBP. 
4.5 CONCLUSION 
This study has identified lack of time and patient reluctance to participate in clinical trials as 
the most significant barriers to recruiting people into the LBP clinical trial. Patient incentives 
and a more streamlined paperwork system have been identified as key strategies to 
overcoming these challenges. There is a need to educate pharmacists on screening for 
possible ‘red flag’ conditions and appropriate non-pharmacological management strategies 
for people with LBP. 
This chapter has identified some gaps in the self-reported management of LBP by 
pharmacists, particularly with respect to pharmacological management. The next chapter 
will explore pharmacists’ knowledge, attitudes and beliefs towards LBP and evaluate the 
influence of different educational interventions on these parameters.  
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CHAPTER FIVE 
How does participation in an educational workshop or clinical trial 
influence pharmacists’ knowledge, attitudes and beliefs towards 
Low Back Pain (LBP)? 
A manuscript of this chapter was published online on April 14 2015 in the International 
Journal of Clinical Pharmacy: Abdel Shaheed C., C. G. Maher, et al. (2014b). Does 
participation in an educational workshop or clinical trial improve pharmacists’ knowledge, 
attitudes and beliefs towards low back pain (LBP)? International Journal of Clinical Pharmacy 
IJCP-D-14-00268R1. 
5.1: INTRODUCTION 
Pharmacists are commonly approached about LBP management. An Australian study 
estimated 10% of people seeking advice for LBP will present to the pharmacist (Walker et al., 
2004), whilst in England over 50% of surveyed pharmacists reported LBP as a commonly 
encountered condition (Silcock et al., 2007). Many treatments used for the management of 
LBP can be purchased over the counter from a community pharmacy (Abdel Shaheed et al., 
2014a), and many people with LBP presenting initially to the GP will subsequently present to 
the pharmacy with a  prescription, making pharmacists an ideal portal for the translation of 
evidence-based information on LBP. Pharmacists are therefore well positioned to provide 
evidence based advice on LBP and contribute to patient’s health outcomes and quality of 
life. 
To date few studies have evaluated pharmacists’ knowledge, attitudes and beliefs towards 
LBP (Silcok et al., 2007), yet evidence suggests these factors significantly influence a HCP’s 
recommendations (Buchbinder et al., 2009; Houben et al., 2005b; Linton et al., 2002). For 
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example, physician surveys have identified gaps in knowledge and negative beliefs as being 
barriers to the uptake of evidence-based LBP guidelines, even among GPs with a special 
interest in LBP (SILBP) (Buchbinder et al., 2009). Such discrepancies in practice are 
highlighted by reports that around one-quarter of acute LBP patients are referred for 
imaging, (Williams et al., 2010a) despite evidence that this can delay recovery (Chou et al., 
2009). 
Over 80% of LBP cases presenting to primary care are non-specific (Kent & Keating 2004) 
and typically require simple interventions. Evidence-based guidelines recommend staying 
active, avoiding prolonged periods of bed rest and the regular use of simple analgesics such 
as paracetamol as first-line therapy (van Tulder et al., 2006). However, surveys of practice in 
Australia (Williams et al., 2010a) and overseas (Frankel et al., 1999; Gonzalez-Urzelai et al., 
2003; Wilk et al., 2010) have shown that these steps are often ignored, increasing health 
risk to consumers and costs to society.  
An over-cautious attitude towards LBP among HCPs may result in the inappropriate 
management of this condition. Conversely, positive attitudes and beliefs among HCPs are 
associated with the successful implementation of guideline recommendations 
(Buchbinder et al., 2001; Houben et al., 2005b). 
Interventions targeting the clinicians commonly consulted by LBP patients can serve an 
important role in aligning practice with evidence-based guidelines. Numerous studies have 
investigated interventions designed to change GP behaviour in the management of LBP 
(Bishop and Wing, 2006; Dey et al., 2004; Eccles et al., 2001; Kerry et al., 2000) however, 
no such studies involving pharmacists have been identified. 
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The aim of this study was to investigate pharmacists’ knowledge, attitudes and 
beliefs towards LBP and to determine whether participation in a clinical trial or 
educational workshop can influence these. 
Findings from this chapter provide important insights into pharmacists’ knowledge, 
attitudes and beliefs towards LBP and identify gap areas which need to be addressed. This 
information is anticipated to inform educational interventions for pharmacists as part of a 
broader effort to translate evidence based information on LBP into practice. 
5.2 METHODS  
Ethics approval for this project was obtained from the University of 
Sydney’s Human Research Ethics Committee (HREC) Approval No. 13799. 
5.2.1 Instrument  
Knowledge, attitudes and beliefs were measured using the 25-item 
‘Pharmacists’ Back Beliefs Questionnaire’ (PBBQ), developed with items taken from two 
back beliefs questionnaires (Buchbinder et al., 2009; Symonds et al., 1996). The first 14 
items were identical to the validated 14-item Back Beliefs Questionnaire whilst items 15-
25 were sourced from the 11-item Buchbinder scale (Buchbinder et al., 2009) (Table 5.1). 
Participants indicated their agreement with statements about LBP on a 5-point Likert 
scale of ‘Strongly Disagree’ (1) to ‘Strongly Agree’ (5). The PBBQ took pharmacists 
approximately 5 minutes to complete. 
Note: Items 10 and 11 of the Buchbinder scale (corresponding to items 24 and 25 of the 
PBBQ) changed from ‘doctors’ to ‘doctors and pharmacists’ to accommodate for this 
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population. Furthermore, the subject of item 6 of the Buchbinder scale (corresponding to 
item 20 of the PBBQ) was changed from first person ‘I’ to ‘doctor‘ to make it clear that 
the item referred to medical referral for imaging.  
Table 5.1. Pharmacists’ Back Beliefs Questionnaire. 
 
Survey Item Correct Response 
(1) There is no real treatment for back trouble Disagree 
(2) Back trouble will eventually stop you from working Disagree 
(3) Back trouble means periods of pain for the rest of one’s life Disagree 
(4) Doctors cannot do anything for back trouble Disagree 
(5) A bad back should be exercised Agree 
(6) Back trouble makes everything in life worse Disagree 
(7) Surgery is the most effective way to treat back trouble Disagree 
(8) Back trouble may mean you end up in a wheelchair Disagree 
(9) Alternative treatments are the answer to back trouble Disagree 
(10) Back trouble means long periods of time off work Disagree 
(11) Medication is the only way to relieve back trouble Disagree 
(12) Once you have had back trouble there is always a weakness Disagree 
(13) Back trouble MUST be rested Disagree 
(14) Later in life back trouble gets progressively worse Disagree 
(15) Patients with acute LBP should be recommended complete bed rest until 
the pain goes away 
Disagree 
(16) Patients should not return to work until they are almost pain free Disagree 
(17) X rays of the lumbar spine are useful in the work up of patients with acute 
LBP 
Disagree 
(18) Encouragement of physical activity is important in the recovery of LBP Agree 
(19) Interventions by doctors and other health care providers have very little 
positive impact on the natural history of acute LBP 
Disagree 
(20) Doctors are likely to order x rays for LBP because patients often expect 
them to do so 
Disagree 
(21) There is nothing physically wrong with many patients with chronic back 
pain 
Agree 
(22) Well motivated patients are unlikely to have long term problems with LBP Agree 
(23) I have no difficulty in assessing the motivation of people with LBP Agree 
(24) Practice guidelines are useful to help doctors and pharmacists in the 
management of medical conditions 
Agree 
(25) Doctors and pharmacists would find practice guidelines helpful in the 
management of LBP 
Agree 
* Based on current evidence-based management guidelines. Responses on Likert scale of 1: Strongly Disagree 2: Disagree 3: Neither 
Disagree or Agree 4: Agree 5: Strongly Agree.Items 1-14 taken from Symonds et al., 1996; Items 15-25 taken from Buchbinder et al., 2009 
Note: Disagreement: Disagree / Strongly Disagree; Agreement: Agree / Strongly Agree 
Bold items: 9-inevitabililty items: disagreement correct response.  
 
5.2.2 Data analysis 
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We evaluated the inevitability score (sum of mean [SD] for the nine inevitability items: 
1,2,3,6,8,10,12,13,14 which are identical to those of the original BBQ) as this is a validated 
measure of intervention effect with respect to LBP education (George et al., 2009; Gross et 
al., 2013). The inevitability items are knowledge-based items encompassing issues around 
physical activity, bed rest, return to work and recovery within the context of acute LBP. 
Disagreement with these items is considered the correct response based on 
recommendations in the LBP literature (Australian Acute Musculoskeletal Pain Guidelines 
Group, 2004; van Tulder et al., 2006). Given the direction of the Likert scale used in this 
study, a lower inevitability score was considered more favourable. A mean change in 
inevitability score of three was considered to be a meaningful effect, concordant with 
previous LBP intervention studies investigating changes to these same items (Gross et al., 
2013). An analysis of a composite score (sum of transformed mean score [SD] for all 25-
items) is also presented. We have chosen to present and compare the total mean 
inevitability and composite scores rather than present median scores for each item to 
allow an overall evaluation of knowledge, attitudes and beliefs. This analysis also allows a 
comparison to previous population based interventions (Buchbinder et al., 2001) which 
assessed HCP knowledge, attitudes and beliefs towards LBP using the same outcome 
measure (total mean inevitability score).  
Demographic data (age, professional role, place of practice and years of practice) were 
collected from pharmacists to determine the impact of these on questionnaire responses. 
Three groups of pharmacists were surveyed using the PBBQ: Pharmacists collaborating in 
participant recruitment for the PACE LBP clinical trial (described in detail below), 
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pharmacists who participated in a two hour long educational workshop on LBP 
management and a control group of pharmacists. This was to allow an evaluation of the 
effects of different educational interventions delivered as part of this study. 
5.2.3 Recruiting clinical trial pharmacists to complete the PBBQ  
The PACE clinical trial (Williams et al., 2010b) is a randomised double-blind placebo 
controlled trial of paracetamol in people with acute LBP. Community pharmacists who 
received training by a PACE researcher between December 2010 and May 2011 (n=102) to 
screen and recruit participants with non-specific LBP to participate in the PACE clinical trial 
were contacted and invited to complete the PBBQ at six months from the time of training. 
The intervention involved a one-to-one training session of half an hour to one hour 
duration with one of the PACE researchers. The training delivered information on the 
evidence based management of LBP and screening people for eligibility into the trial.  
Pharmacists were given the option of completing the questionnaire online (via an email 
link) or on a hard copy version. Follow-up telephone calls were made to pharmacists at 
ten and 14 days as a reminder to complete the questionnaire. Pharmacists who had not 
completed the questionnaire after the two phone follow-ups were considered non-
respondents. 
5.2.4 Recruiting pharmacists for the control group 
Recruitment of pharmacists from the control group took place between August 2012 and 
January 2013. A convenience sample of NSW pharmacists n=107 selected from an online 
database ‘Sydney chemists and pharmacies by location’ (Doctors4U: Sydney Doctors 
Medical Directory, 2011) were contacted by telephone and email with an invitation to 
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complete the PBBQ online. Pharmacies on the database were contacted in order of 
alphabetical listing by suburb. These pharmacists had no prior involvement in any clinical 
trial and were not involved in the educational workshops delivered as part of this study. 
Follow-up of these pharmacists followed the same pattern as for PACE recruiting 
pharmacists. 
5.2.5 LBP Educational Workshop 
Telephone invitations were made to 379 community pharmacies in Sydney (systematically 
chosen in order of alphabetical listing by suburb) identified via an online database 
(Doctors4U: Sydney Doctors Medical Directory, 2011) and each hospital pharmacy 
department in the Sydney inviting pharmacists to a two-hour long workshop (no cost) on the 
evidence-based management of LBP. The workshops were conducted on eight occasions 
between October 2011 and April 2012 and were delivered by two health professionals / 
research experts with combined expertise in the areas of pain management, quality use of 
medicines and musculoskeletal disorders. 
The workshop covered focal areas of LBP education including (Charlton, 2005; Mezei et al., 
2011):  
 Prevalence, economic and social burden; 
 Health-seeking behaviour among people with LBP; 
 Pharmacological management; 
 Non-pharmacological management (including follow up and review); 
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 Identifying simple back ache and distinguishing this from signs/symptoms of 
more complex disease (information gathering, screening for possible ‘red 
flags’). 
Learning objectives incorporated standards on pain education developed by the 
International Association for the Study of Pain (IASP) (Charlton, 2005). 
Pharmacists were surveyed using the PBBQ before and after the workshop (pre- and post- 
responses) to investigate changes in knowledge, attitudes and beliefs towards LBP.  
5.2.6 Six month follow up of workshop pharmacists 
At six months from the completion of the workshops pharmacist participants n=204 were 
contacted by telephone or email with an invitation to participate in a follow-up 
questionnaire. Pharmacists who agreed to participate were sent a link via email to complete 
the questionnaire. A follow-up telephone call was made to pharmacists at ten and 14 days 
as a reminder to complete the questionnaire. Pharmacists who had not completed the 
questionnaire after the two phone follow-ups were considered non-respondents. 
5.2.7 Data Analysis  
Data analysis was carried out using Statistical Package for the Social 
Sciences (SPSS®) version 20. The analysis compared the inevitability and composite 
score between the clinical trial pharmacists (n=66) and the control group (n=65) and 
also workshop pharmacists (n=204) and the control group (n=65) using an independent 
samples t-test. A paired t-test was used to compare pre- and post- inevitability and 
composite scores from pharmacists participating in the educational workshop (n=204). 
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A p-value of <0.05 was considered significant. 
An independent samples t-test was used to evaluate the effect of demographic variables on 
inevitability and composite scores. A Mann-Whitney U test was used to compare 
demographic variables between two groups of pharmacists. For continuous variables e.g. 
practice years and age, these were split into dichotomous groups (>15 years of experience, ≤ 
15 years of experience and ≥ 35 years old, < 35 years old respectively). A one way ANOVA 
was used to compare pre-inevitability and pre-composite scores across all three groups of 
pharmacists. 
5.3 RESULTS 
5.3.1 Key findings 
Two hundred and nine pharmacists from 137 community pharmacies and ten different 
hospitals in Sydney participated in the educational workshop. The response rate was 
98% with 204 pharmacists successfully completing both the pre- and post- PBBQ. The 
response rate from the clinical trial pharmacists and the control group was 65% and 61% 
respectively (66 clinical trial pharmacists and 65 control pharmacists completed the 
questionnaire). The mean age in the control group was 40.8 (SD 14.8) years and 51% of 
pharmacists were male. The distributions of age and gender in this group are broadly 
representative of NSW pharmacists (AIHW, 2009b) (mean age 42, 40% male) Participant 
characteristics for all three groups of pharmacists are presented in Table 5.2.  
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Table 5.2. Demographic characteristics of pharmacists participating in this study. 
 
 
Characteristic PACE 
(n=66) 
Number 
(%) 
p-valuea Control 
(n=65) 
Number (%) 
p-valueb Workshop 
Participants 
(n=204) 
Number (%) 
Gender   0.26  <0.01  
      Male 27 (41)  33 (51)  62 (30) 
      Female 39 (59)  32 (49)  142 (70) 
Age: mean (SD) 36.8 (11.0) 0.21 40.8 (14.6) 0.19 38.2 (14.1) 
Practice years: mean 
(SD) 
13.5 (11.3) 0.03 17.0 (15.0) 0.04 13.6 (14.1) 
Role:  <0.01  0.02  
      Pharmacist in charge 17 (26)  11 (16.9)  79 (38.7) 
      Pharmacy owner 30 (46)  22 (33.8)  34 (16.7) 
      Pharmacist manager 12 (18)  3 (4.6)  15 (7.4) 
      Full-time pharmacist 3 (4)  1 (1.5)  25 (12.3) 
      Part-time/casual   
pharmacist 
4 (6.0)  7 (10.7)  14 (10) 
      Hospital pharmacist 0 (0)  4 (6.2)  12 (6.7) 
      Intern pharmacist 0 (0)  1 (1.5)  18 (8.8) 
      Other 0 (0)  16 (24.8)*  7 (3) 
Previous self-reported 
back trouble: 
 0.32  0.28  
      Yes 32 (49)  25 (38.5)  92 (45) 
      No 34 (51)  40 (61.5)  112 (55) 
Recent CME in LBP  <0.01  0.73  
      Yes  33 (50)  7 (10.8)  23 (11) 
      No 33 (50)  58 (89.2)  181 (89) 
PACE –  pharmacists who have participated in recruitment for the PACE clinical trial. 
Control –  pharmacists who have not participated in a clinical trial or the educational workshop. 
Workshop –  pharmacists  who  attended  the  study’s  educational  workshop  on  low  back  pain. 
*Other: Locum pharmacist (4), Research pharmacist (4) Academic pharmacist (3) Medical writer/professional services pharmacist  
(5). Note: recent training within the past six months. 
a) Clinical trial (PACE) vs control pharmacists; Mann-Whitney U test. 
b) Workshop vs control pharmacists; Mann-Whitney U test. 
 
The two hour workshop on LBP management led to a favourable change in pharmacists’ 
knowledge, attitudes and beliefs towards LBP so that it more closely aligned with 
evidence-based guidelines. This was demonstrated by the significant shift towards 
correct responses on the post-workshop inevitability score compared with the pre-
workshop inevitability score, mean difference (MD) 7.23, p<0.01. There was also a 
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significant shift towards correct responses on the post- workshop composite score 
compared with the pre-workshop composite score, MD 15.48, p<0.01. The provision of 
one-to-one training employed in the training of clinical trial pharmacists had less impact 
overall, however these pharmacists felt more confident assessing the motivation of 
people with LBP compared with the control group; 3.12 [0.99] vs 2.66 [0.82]; p<0.01 
respectively. Detailed comparisons are presented below.  
Table 5.3. Comparison of mean (SD) and composite scores on the PBBQ between PACE 
(n=66) and Control pharmacists (n=65) and Pre- and Post- scores from workshop 
participants n=204. 
 
 Item 
Mean (SD) Transformed 
mean 
Mean 
(SD) 
Transformed 
mean  
Mean (SD) Transformed 
mean 
Mean 
(SD) 
Transformed 
mean  
PACE n=66 PACE n=66 Control n=65 Control n=65 Workshop 
PRE n=204 
Workshop 
PRE n=204 
Workshop 
POST n=204 
Workshop 
POST n=204 
 1 1.83 (0.83)       1.17 (0.83) 1.80 (0.83) 1.20 (0.83) 1.89 (1.01) 1.11 (1.01) 1.60 (0.97) 1.39 (0.97) 
2 2.55 (1.10) 0.45 (1.10) 2.43 (1.00) 0.57 (1.00) 2.86 (1.30) 0.15 (1.30) 2.03 (1.23) 0.96 (1.23) 
3 2.67 (1.06) 0.33 (1.06) 2.58 (1.03) 0.42 (1.03) 2.79 (1.20) 0.21 (1.20) 1.91 (1.09) 1.09 (1.09) 
4 1.74 (0.71) 1.26 (0.71) 1.83 (0.68) 1.17 (0.68) 1.81 (0.94) 1.18 (0.94) 1.74 (1.03) 1.25 (1.03) 
5 3.52 (0.88) 0.52 (0.88) 3.65 (0.80) 0.65 (0.80) 3.63 (1.07) 0.63 (1.07) 4.24 (0.98) 1.24 (0.98) 
6 3.21 (1.02) -0.21 (1.02) 3.22 (0.99) -0.22 (0.99) 3.31 (1.19) -0.30 (1.19) 2.61 (1.25) 0.38 (1.25) 
7 2.08 (0.83) 0.92 (0.83) 2.14 (0.75) 0.86 (0.75) 2.03 (0.86) 0.97 (0.86) 1.36 (0.65) 1.64 (0.65) 
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8 1.91 (0.92) 1.09 (0.92) 2.11 (1.00) 0.89 (1.00) 2.02 (1.01) 0.98 (1.01) 1.55 (0.91) 1.44 (0.91) 
9 2.77 (0.78) 0.23 (0.78) 2.57 (0.87) 0.43 (0.87) 2.73 (1.03) 0.27 (1.03) 2.06 (1.09) 0.94 (1.09) 
10 2.73 (0.94) 0.27 (0.94) 2.57 (0.81) 0.43 (0.81) 2.75 (1.02) 0.25 (1.02) 2.05 (1.10) 0.94 (1.10) 
11 2.78 (0.72) 0.82 (0.72) 1.94 (0.63) 1.06 (0.63) 2.10 (1.01) 0.89 (1.01) 1.88 (1.00) 1.11 (1.00) 
12 2.89 (1.05) 0.11 (1.05) 2.75 (1.15) 0.25 (1.15) 3.13 (1.11) -0.12 (1.11) 2.20 (1.09) 0.81 (1.09) 
13 2.97 (1.09) 0.03 (1.10) 3.08 (1.05) -0.08 (1.05) 2.79 (1.21) 0.22 (1.21) 1.29 (0.72) 1.71 (0.72) 
14 3.20 (0.85) -0.20 (0.85) 2.95 (0.93) 0.05 (0.93) 3.31 (1.04) -0.30 (1.04) 2.31 (1.10) 0.69 (1.10) 
15 2.15 (0.79) 0.85 (0.79) 2.14 (0.79) 0.86 (0.79) 2.09 (0.93) 0.91 (0.93) 1.13 (0.47) 1.87 (0.47) 
16 2.50 (0.92) 0.50 (0.92) 2.42 (0.90) 0.58 (0.90) 2.41 (1.05) 0.60 (1.05) 1.53 (0.75) 1.47 (0.75) 
17 3.08 (0.87) -0.08 (0.87) 3.29 (0.81) -0.29 (0.81) 3.22 (1.05) -0.21 (1.05) 1.49 (0.88) 1.51 (0.88) 
18 3.85 (0.85) 0.85 (0.85) 4.00 (0.69) 1.00 (0.69) 3.95 (0.83) 0.95 (0.83) 4.66 (0.69) 1.66 (0.69) 
19 2.12 (0.89) 0.88 (0.89) 1.92 (0.71) 1.08 (0.71) 1.93 (0.85) 1.07 (0.85) 1.82 (1.16) 1.18 (1.16) 
20 3.33 (0.87) -0.33 (0.87) 3.43 (0.79) -0.43 (0.79) 3.24 (1.12) -0.25 (1.1) 3.52 (1.29) -0.52 (1.29) 
21 2.71 (0.92) -0.29 (0.92) 2.43 (0.98) -0.57 (0.98) 2.64 (1.11) -0.35 (1.11)  3.02 (1.31) 0.03 (1.31) 
22 3.56 (0.84) 0.56 (0.84) 3.29 (0.95) 0.29 (0.95) 3.37 (1.06) 0.37 (1.06) 3.95 (1.06) 0.94 (1.06) 
23 3.12 (0.99) 0.12 (0.99) 2.66 (0.82) -0.34 (0.82) 2.86 (0.96) -0.14 (0.96) 3.45 (1.00) 0.45 (1.00) 
24 4.32 (0.59) 1.32 (0.59) 4.14 (0.58) 1.14 (0.58) 4.31 (0.66) 1.30 (0.66) 4.56 (0.75) 1.56 (0.75) 
25 4.39 (0.55) 1.39 (0.55) 4.23 (0.61) 1.23 (0.61) 4.46 (0.63) 1.46 (0.63) 4.61 (0.73) 1.60 (0.73) 
IS 23.96 (5.43) - 23.49 (5.19) - 24.81 (5.91) - 17.58 (5.88) - 
CS - 12.56 (10.38) - 12.23 (8.29) - 11.86 (9.21) - 27.34 (9.90) 
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NOTE: Bold items are the 9-inevitability items.  
Inevitability score (IS): sum of mean (SD) for the 9-inevitability items. Lower inevitability score favourable.  
Composite score (CS): sum of transformed mean (SD) for items 1-25. Higher composite score favourable.   
Note: With this method, responses on the Likert scale were transformed to a score ranging from -2 to +2 for each item, where for 
agreement items, 2 points were allocated for ‘strongly agree’, 1 point for ‘agree’, 0 for ‘neither disagree or agree’, -1 for ‘disagree’ and -2 
for ‘strongly disagree’, whereas for disagreement items 2 points were allocated for ‘strongly disagree’, 1 point for ‘agree’, 0 for ‘neither 
disagree or agree’, -1 for ‘agree’ and -2 for ‘strongly agree’. Here a higher composite score (range -50 to 50) was indicative of more 
positive responses. 
Composite and inevitability scores did not follow a normal distribution. One way ANOVA showed no significant difference between PACE 
recruiting pharmacists, the control group and workshop participants (pre- scores) on mean inevitability score or composite score 
(p=0.30 and p=0.60 respectively).  
5.3.2 PACE recruiting (n=66) VS Control (n=65) pharmacists 
There was no significant difference in inevitability score [SD] between the clinical trial 
and control pharmacists; 23.96 [5.43] and 23.49 [5.19] respectively, MD 0.47 [95% CI -
1.35 to 2.29; p=0.61]. 
There was no significant difference in the composite score between the two groups 
12.56 [10.38] and 12.23 [8.29], MD 0.33 [95% CI -2.89 to 3.54; p=0.84] see Table 5.3.  
There was, however, a notable difference on responses to item 23, ’I have no difficulty 
in assessing the motivation of people with LBP’, with clinical trial pharmacists scoring 
more favourably on this item compared with the control group 3.12 [0.99] vs 2.66 
[0.82] respectively; p<0.01.  
Table 5.4 presents a comparison between these two groups of pharmacists based on 
“correct” responses to the PBBQ items.  
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Table 5.4. Percentage of PACE (n=66) and control (n=65) pharmacists with “correct” or 
positive responses to the 25-item Pharmacy Back Belief Questionnaire (PBBQ). 
 
Item Positive response* PACE 
n=66 (%) 
Control 
n=65 (%) 
P 
1 Disagreement 54 (81.8) 56 (86.2) 0.50 
2 Disagreement 37 (56.1) 39 (60.0) 0.65 
3 Disagreement 34 (51.5) 36 (55.4) 0.66 
4 Disagreement 60  (91) 59 (90.8) 0.98 
5 Agreement 35 (53) 40 (61.5) 0.33 
6 Disagreement 17 (25.8) 17 (26.2) 0.96 
7 Disagreement 50 (75.8) 44 (67.7) 0.30 
8 Disagreement 50 (75.8) 46 (70.8) 0.52 
9 Disagreement 20 (30.3) 31 (47.7) 0.04 
10 Disagreement 30 (45.5) 29 (44.6) 0.92 
11 Disagreement 48 (72.7) 56 (86.2) 0.06 
12 Disagreement 26 (39.4) 34 (52.3) 0.14 
13 Disagreement 25 (37.9) 21 (32.3) 0.50 
14 Disagreement 13 (19.7) 22 (33.8) 0.67 
15 Disagreement 48 (72.7) 47 (72.3) 0.96 
16 Disagreement 37 (56.1) 39 (60.0) 0.65 
17 Disagreement 16 (24.2) 9 (13.8) 0.13 
18 Agreement 51 (77.3) 52 (80.0) 0.70 
19 Disagreement 54 (81.8) 57 (87.7) 0.35 
20 Disagreement  10 (15.2) 8 (12.3) 0.64 
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21 Agreement 13 (19.7) 9 (13.8) 0.37 
22 Agreement 40 (60.6) 30 (46.2) 0.10 
23 Agreement 26 (39.4) 9 (13.8) 0.001 
24 Agreement 62 (93.9) 60 (92.3) 0.71 
25 Agreement 64 (97) 61 (93.8) 0.39 
* Disagreement: Disagree/Strongly Disagree; Agreement: Agree/Strongly Agree. 
Z test of proportions: comparison of positive responses. 
PACE – pharmacists who have participated in recruitment for the PACE clinical trial. 
 
There was no significant difference between the two groups based on age or gender 
(p=0.21 and 0.26 respectively), however there were significant differences based on 
number of years in practice, role and recent training/CME. On average, the control group 
had been in practice for longer than the clinical trial pharmacists, (mean years in practice 
[SD] 17.0 [15.0] vs 13.5 [11.3]; p=0.03) however had less training/CME in LBP (10.8% vs 
50.0% respectively, p<0.01). There were more pharmacist owners among clinical trial 
pharmacists compared with the control group (45.5% vs 33.8%; p<0.01). 
5.3.3 Workshop (n=204) VS Control (n=65) pharmacists 
There was no difference between workshop and control pharmacists on pre- inevitability 
(24.81 [5.91] vs 23.49 [5.19] respectively; p=0.13) or pre- composite score (11.86 [9.21] vs 
12.23 [8.29] respectively; p=0.91).  
A Mann-Whitney U test showed a significant difference between the workshop pharmacists 
and the control group based on practice years (p=0.04), gender (p=0.004) and role (p=0.018) 
Workshop participants had, on average, fewer years in practice (13.63 [14.13] vs 16.98 
[15.01] respectively), more female participants (70% vs 49% respectively) and there were 
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more full-time pharmacists and pharmacists in charge in the workshop group and fewer 
pharmacy owners than in the control group. There was no significant difference based on 
age, recent training or previous back trouble (p=0.19, 0.73 and 0.28 respectively).  
5.3.4 LBP Educational Workshop 
A comparison of pre- and post- inevitability scores showed a large and significant change 
in pharmacists’ responses; mean [SD] 24.81 [5.91] and 17.58 [5.88] respectively, MD 7.23; 
p<0.001. In particular there were large and favourable changes on items regarding bed 
rest ‘13.Back trouble must be rested’, MD 1.50; p<0.001, recovery and chronicity of LBP 
‘12.Once you have had back trouble there is always a weakness’, MD 0.93; p<0.001 and 
‘14.Later in life back trouble gets progressively worse’, MD 1.00; p<0.001 as well as return 
to work ‘2.Back trouble will eventually stop you from working’, MD 0.83; p<0.001. 
Similarly, there was a large and significant difference in pre- and post- composite scores 
11.86 (9.21) vs 27.34 (9.90) respectively, MD -15.48; p<0.001. The most notable change 
observed centered on the need for imaging in acute LBP ‘17.X –rays of the lumbar spine are 
useful in the workup of patients with acute LBP’, MD 1.73; p<0.001. There was also a notable 
change with respect to perceived confidence among pharmacists to assess patient 
motivation, ‘23. I have no difficulty assessing the motivation of people with LBP’, MD -0.59; 
p<0.001.  
Table 5.5 presents a comparison between total number of pharmacists scoring “correct” 
responses pre- and post- workshop.  
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Table 5.5 Percentage (%) positive or “correct” pre- and post- responses on the PBBQ (i.e. 
before and after the workshop (n=204). 
 
Item Positive  
response  
PRE survey  
No. (%) positive response 
POST survey  
No. (%) positive response 
p value
a
 
1  Disagree 153 (75) 179 (87.7) 0.001 
2 Disagree 92 (45.1) 150 (73.5) <0.001 
3 Disagree 86 (42.2) 158 (77.5) <0.001 
4 Disagree 165 (79.9) 164 (80.4) 0.90 
5 Agree 127 (62.3) 177 (86.8) <0.001 
6 Disagree 52 (25.5) 65 (48.9) <0.16 
7 Disagree 148 (72.5) 194 (95.1) <0.001 
8 Disagree 147 (72.1) 180 (88.2) <0.001 
9 Disagree 86 (42.2) 133 (65.2) <0.001 
10 Disagree 84 (41.2) 144 (70.6) <0.001 
11 Disagree 141 (69.1) 161 (78.9) 0.02 
12 Disagree 64 (31.4) 140 (68.6) <0.001 
13 Disagree 88 (43.1) 190 (93.1) <0.001 
14 Disagree 47 (23) 121 (59.3) <0.001 
15 Disagree 146 (71.6) 200 (98) <0.001 
16 Disagree 121 (59.3) 186 (91.2) <0.001 
17 Disagree 43 (21.1) 181 (88.7) <0.001 
18 Agree 160 (78.4) 195 (95.6) <0.001 
19 Disagree 165(80.9) 163 (79.9) 0.80 
20 Disagree  57 (27.9)  43 (21.1) 0.11 
21 Agree 46 (22.5) 79 (38.7) <0.001 
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22 Agree 103 (50.5) 156 (76.5) <0.001 
23 Agree 48 (23.5) 104 (51) <0.001 
24 
 
Agree 186 (91.2) 191 (93.6) 0.35 
25 
 
Agree 193 (94.6) 192 (94.1) 0.83 
Note: positive or “correct response” based on current available evidence . 
a) Z test for 2 population proportions. 
 
Effects of demographic variables on inevitability and composite scores are outlined in Table 
5.6.  
Table 5.6. Effects of variables on inevitability and composite score. 
Study group Score Variable Description of results; Mean [SD]  P value* 
Workshop 
participants 
(n=204) 
Pre-
inevitability 
Age People aged 35 or over (n=95) scored 
more favourably on the pre-
inevitability score compared to their 
counterparts (n=109) (23.79 [6.56] vs 
25.70 [5.15]). 
 
0.021 
Workshop 
participants 
(n=204) 
Pre-
inevitability 
Practice years People with greater than 15 years of 
experience (n=68) scored more 
favourably on the pre- inevitability 
score compared with their 
counterparts (n=136) (23.26 [6.51] vs 
25.58 [5.45] respectively). 
0.008 
Workshop 
participants 
(n=204) 
Pre-
composite 
Age People aged 35 or over (n=95) scored 
higher on the pre- composite score 
than those aged less than 35 years 
(n=109) (13.56 [9.96] vs 10.38 [8.25] 
respectively).  
 
0.013 
Workshop 
participants 
(n=204) 
Pre-
composite 
Gender Females (n=141) scored more 
favourably on the pre- composite 
score than their male counterparts 
(n=63) (12.96 [7.96] vs 9.40 [11.21] 
respectively). 
0.010 
Workshop 
participants 
(n=204) 
Pre-
composite 
Practice years People with greater than 15 years of 
experience (n=68) scored more 
favourably on the pre- composite 
0.012 
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score compared with their 
counterparts (n=136) (14.13 [10.21] vs 
10.72 [8.47] respectively); 
Workshop 
participants 
(n=204) 
Pre-
composite 
Previous back 
trouble  
Those with previous back trouble 
(n=94) scored more favourably on the 
pre- composite score than their 
counterparts (n=110) (13.50 [9.11] vs 
10.46 [9.10] respectively). 
 
0.018 
Control (n=65) Composite  Recent training  Those with recent training n=7 had 
more favourable composite scores 
than their counterparts n=58 (21.00 
[8.68] vs 11.17 [7.66] respectively).  
 
0.002 
Control (n=65) Inevitability  Recent training  Those with recent training had more 
favourable inevitability scores than 
their counterparts 19.57 (6.45) vs 
23.97 (4.87) 
0.033 
Clinical trial 
pharmacists 
(n=66) 
 NA NA NA 
*independent samples t-test. 
5.3.5 Six month follow up results 
Of the 204 pharmacists who attended the workshops 61 completed the questionnaire at six 
months follow up (29.9% response rate). Results from these pharmacists (Table 5.7) 
revealed a statistically significant increase in mean inevitability score 20.72 (4.33) [towards 
less favourable results] compared with post-workshop results, MD 3.14 (p<0.01). This 
exceeds the 3-point difference in inevitability score suggested to be comparably meaningful. 
The trend towards negative responses is further illustrated by the decline in composite 
score at six months towards less favourable results [20.51 (7.54)], MD 6.83; p<0.01 
compared with post-workshop results.  
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Table 5.7. Results from workshop participants (n=61) at six months follow up. 
Item 
Mean 
(SD) 
Mean (SD) Transformed 
mean  
Transformed 
mean (SD) 
 
Workshop 
POST n=204 
6 month follow up 
N=61  
Workshop 
POST n=204 
6 month 
follow up 
N=61  
 1 1.60 (0.97) 1.87 (0.91) 1.39 (0.97) 1.13 (0.90) 
2 2.03 (1.23) 2.07 (0.93) 0.96 (1.23) 0.93 (0.93)   
3 1.91 (1.09) 2.30 (1.04) 1.09 (1.09) 0.70 (1.04) 
4 1.74 (1.03) 1.69 (0.50) 1.25 (1.03) 1.31 (0.50) 
5 4.24 (0.98) 3.80 (1.03) 1.24 (0.98) 0.80 (1.03) 
6 2.61 (1.25) 2.98 (1.09) 0.38 (1.25) 0.02 (1.09) 
7 1.36 (0.65) 1.77 (0.69) 1.64 (0.65) 1.23 (0.69) 
8 1.55 (0.91) 1.82 (0.85) 1.44 (0.91) 1.18 (0.85)  
9 2.06 (1.09) 2.64 (0.88) 0.94 (1.09) 0.36 (0.88) 
10 2.05 (1.10) 2.21 (0.88) 0.94 (1.10) 0.79 (0.88) 
11 1.88 (1.00) 1.93 (0.54) 1.11 (1.00) 1.07 (0.54) 
12 2.20 (1.09) 2.77 (1.01) 0.81 (1.09) 0.23 (1.00) 
13 1.29 (0.72) 2.03 (0.86) 1.71 (0.72) 0.97 (0.86) 
14 2.31 (1.10) 2.67 (0.83) 0.69 (1.10) 0.33 (0.83) 
15 1.13 (0.47) 1.57 (0.78) 1.87 (0.47) 1.43 (0.78) 
16 1.53 (0.75) 1.95 (0.92) 1.47 (0.75) 1.05 (0.92) 
17 1.49 (0.88) 2.43 (0.87) 1.51 (0.88) 0.57 (0.87) 
18 4.66 (0.69) 4.10 (1.04) 1.66 (0.69) 1.10 (1.04) 
19 1.82 (1.16) 2.10 (0.79) 1.18 (1.16) 2.10 (0.79) 
20 3.52 (1.29) 3.39 (0.95) -0.52 (1.29) -0.39 (0.95) 
21 3.02 (1.31) 3.13 (0.94) 0.03 (1.31) 0.13 (0.94) 
22 3.95 (1.06) 3.77 (0.94) 0.94 (1.06) 0.77 (0.94) 
23 3.45 (1.00) 3.25 (0.98) 0.45 (1.00) 0.25 (0.98) 
24 4.56 (0.75) 4.16 (0.73) 1.56 (0.75) 1.16 (0.73) 
25 4.61 (0.73) 4.30 (0.64) 1.60 (0.73) 1.30 (0.64) 
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IS 17.58 (5.88) 20.72 (4.33) - - 
CS - - 27.34 (9.90) 20.51 (7.54) 
*Bold items represent inevitability items. 
Table 5.8. Demographic characteristics of workshop participants at six months follow up. 
Characteristic Six months follow up (N=61) 
Number n (%) 
Gender  
      Male 
      Female 
 
17 (27.9) 
44 (72.1) 
Age: mean (SD) 40.4 (13.7) 
Practice years: mean (SD) 16.0 (13.5) 
Role:  
Pharmacy owner 
Pharmacist in charge 
Part-time pharmacist 
Full time pharmacist 
Locum pharmacist 
Casual pharmacist  
Intern pharmacist 
Pharmacist manager 
Other 
 
13 
14 
9 
4 
2 
2 
2 
7 
8 
Previous self-reported back trouble: 
      Yes 
      No 
 
29 (47.5) 
32 (52.5) 
Recent CME in LBP 
      Yes  
      No 
 
26 (42.6) 
35 (57.4) 
5.4 DISCUSSION 
This study showed that a two-hour workshop on LBP management favourably influences 
pharmacists’ knowledge, attitudes and beliefs towards LBP so that it more closely aligns 
with evidence-based guidelines. The provision of one-to-one training employed in training 
the clinical trial pharmacists had less impact overall, however these pharmacists felt more 
confident assessing the motivation of people with LBP. The results at six months follow up 
highlight the need for ongoing education and training of pharmacists to ensure that 
evidence-based information is retained and therefore likely to be implemented in practice.  
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This study has served to address some of the educational requests of pharmacists 
particularly as a lack of knowledge, education and training have been identified as 
common barriers to providing adequate pain care among this group (Strassels et al., 
2008). In delivering evidence-based information this study has also addressed a 
preference among pharmacists for education which is free from bias (Mc Namara et al., 
2009). 
The favourable changes around items pertaining to patient motivation and 
encouragement of physical activity (post workshop) support an attitude towards LBP 
management consistent with the bio-psychosocial healthcare model. This model 
recognizes the complex interplay between psychological, social and biological factors that 
contribute to illness progression and management decisions. Assessing patient 
motivation and providing re-assurance of a favourable prognosis where appropriate are 
integral to the overall management of non-specific LBP, particularly as catastrophising 
and fear avoidance beliefs among LBP patients have been implicated in the transition 
from acute to chronic pain (Buer and Linton., 2002; Pincus et al., 2002). Conversely, well-
motivated patients are not likely to experience long term complications and are more 
likely to take up the recommended care which has been proven to speed recovery from 
LBP compared to other interventions (Gohner et al., 2006). 
Pharmacists in this study felt strongly about their ability to influence positive change in 
the natural progression of acute LBP and there was marked disagreement to items about 
clinicians not being able to do anything for back trouble. Well-informed interventions by 
clinicians, particularly around pain management, have been associated with a reduction 
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in healthcare costs and improved health outcomes and quality of life (Epstein et al., 
2007; Murinson et al., 2008). However, there are some reports which highlight a need 
for strengthened collaboration between pharmacists and prescribers (Strassels et al., 
2008) in particular, in order to optimise pain care. Increasingly, evidence around chronic 
back pain management support a patient- centered approach to care within a 
multidisciplinary framework (Artner et al., 2012), as it is unlikely such complex cases can 
be adequately managed by a single clinician acting independently. 
 
The impact of practitioner beliefs on patient’s treatment decisions is well documented in 
the LBP literature (Coudeyre et al., 2006; Houben et al., 2005a; Linton et al., 2002). So far 
however, attempts to change practitioner beliefs around LBP have not been very successful 
(Buchbinder et al., 2009; Engers et al., 2005; Jackson and Browning, 2005; Somerville et al., 
2008). The workshops in this study led to the appropriate discard of negative beliefs 
regarding bed rest and the need for imaging in acute LBP. Pharmacists are well positioned 
to relay information regarding the appropriate use of imaging for LBP and can help to dispel 
common misconceptions that the back must be rested which has been shown to delay 
recovery (Dahm et al., 2010). The content of the workshops is also relevant to a global 
medical audience and can be extended to allied health providers who commonly encounter 
this condition, such as physicians and physiotherapists. This could facilitate the broader 
transfer of clinically reliable knowledge and evidence-based information on LBP to the 
public. A strength of this study was the large sample size of participants in the education 
arm and the high questionnaire response rate (98%). However it is questionable whether 
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these results can be generalized to all practicing pharmacists.  A limitation of this study was 
that there was no baseline data collected from the clinical trial pharmacists therefore it is 
not possible to measure the magnitude of change in scores over the six month period. 
However pharmacists’ responses at six months did not significantly differ from the control 
group. Previous studies evaluating mean changes in the inevitability score were able to 
demonstrate favourable differences between intervention and control groups years after 
the educational campaign ended (Buchbinder et al., 2001). Given these trends, it is 
reasonable to have expected a favourable difference in inevitability score at six months post 
one-to-one training had the intervention been effective. A possible reason for the lack of 
effect may include the variable time spent with the pharmacist and the fact that different 
researchers carried out the training, such that delivery of the content may have varied. 
Furthermore, the training did not deliver a comprehensive overview of the topic such as was 
covered in the workshops. Another observation was that the groups were different at 
baseline based on demographic data, perhaps contributing to these results. 
A comparison between this study and a population-level media campaign study involving 
GPs (Buchbinder et al., 2001) showed greater change on the inevitability score among 
workshop pharmacists, MD 7.23 (p<0.001) compared with a maximum improvement of 3.2 
for GPs over the 2.5 years follow-up. Obvious advantages of a media campaign include its 
potential to access a wider audience. In the study by Buchbinder et al (2001), key health 
messages on LBP management were retained several years after the campaign was initiated. 
Follow up of participants in this study revealed a trend towards less positive responses at 
six months. The downward trend at six months (post workshop) could be attributed to the 
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lack of refresher training. This is evident from item based results presented in Table 5.7 
which show a downward trend on the inevitability items (knowledge-based items). However 
since the response rate was poor at follow up, it is unclear whether responses from more 
participants would have yielded a different outcome. Nevertheless these findings highlight 
the need for refresher courses at regular intervals to facilitate retention of the content and 
reinforce the key health messages which ought to be translated into practice. 
Nevertheless, the positive outcomes from the educational workshop support the need for 
further interventions of this nature to be made available to pharmacists and to develop 
strategies to reach a greater cohort of pharmacists, particularly those living in rural and 
remote locations. Online viewing is one such way of facilitating timely access of evidence-
based education to these pharmacists. There is also a need to develop LBP practice 
tools/guidelines that can support pharmacists in their recommendations. Future research 
should also consider expanding these interventions to the clinicians most commonly sought 
by people with LBP as a way of promoting evidence-based LBP management on a broader 
scale. Results from existing studies suggest interventions are needed to help improve 
attitudes and beliefs towards LBP among medical, physiotherapy and nursing students. A 
workshop similar to the one conducted in the present study can be integrated in 
undergraduate programs for the health professions to help address these gaps.  
5.5 CONCLUSION  
An initial evaluation of pharmacists’ knowledge, attitudes and beliefs towards back pain 
revealed some gaps in knowledge and negative attitudes towards LBP. Post-survey 
responses from pharmacists participating in the educational workshop provided the most 
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compelling evidence that CPD aimed at delivering evidence-based education can be 
successful in changing practitioner knowledge, beliefs and attitudes towards LBP. 
Based on the success of the workshops, the next chapter examines the satisfaction of 
workshop participants and knowledge pertaining to the content delivered.  
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CHAPTER SIX 
Knowledge and satisfaction of pharmacists attending an 
educational workshop on evidence-based management of low back 
pain. 
A manuscript of this chapter was published online on May 7, 2014 in the Australian 
Journal of Primary Health: Abdel Shaheed C., C. G. Maher, et al (2014d). “Knowledge and 
Satisfaction of Pharmacists attending an educational workshop on evidence-based 
management of Low back Pain.” Australian Journal of Primary Health PY14020. 
6.1 INTRODUCTION 
Pharmacists are at the forefront of healthcare and can provide quality care in a timely 
manner. These healthcare professionals (HCPs) are particularly well versed in providing 
information on the quality use of medicines. Another important consideration in the context 
of LBP management is training pharmacists to recognise symptoms of serious disease and 
distinguish these from uncomplicated cases, particularly as the role of the pharmacist 
expands into areas such as triage and disease management. Fortunately most cases (~90%) 
of LBP presenting in primary care are examples of “simple backache” and typically require 
advice and simple analgesics (Goubert et al., 2004; Kent and Keating, 2004). However some 
cases may be associated with rare serious underlying conditions such as fracture, tumour or 
cauda-equina syndrome (Chou et al., 2007a), warranting urgent referral for medical review.  
Continuing professional development (CPD) provides an opportunity to train HCPs on the 
evidence-based management of health conditions. Recent evidence has identified a lack of 
education and training as being common barriers to providing adequate pain care by 
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pharmacists (Strassels et al., 2008). Interventions that deliver evidence-based information 
and which actively engage learners in the education e.g. through case-based learning, have 
preference among pharmacists (Mc Namara et al., 2007; Mc Namara et al., 2009). 
Additionally, the transfer of clinically reliable information through educational interventions 
may serve to bridge the gap between guideline recommended care and actual practice.  
The aim of this study was to investigate the knowledge and satisfaction of pharmacists who 
participated in the educational workshop (described in detail in Chapter Five) on the 
evidence-based management of LBP. The workshop aimed to educate pharmacists on 
providing appropriate pharmacological and non-pharmacological care for people with LBP 
and recognise symptoms of more serious disease. A secondary aim was to gauge 
pharmacists' opinions of the intervention and areas of improvement that could be 
addressed in subsequent CPD activities.  
6.2 METHODS 
6.2.1 Educational Workshop 
A description of the structure of the workshops (Abdel Shaheed et al., 2014b) has been 
described in Chapter Five.  
During the intervention, pharmacists were presented with a LBP care pathway (Figure 6.1), 
outlining simple screening strategies and when to refer the patient. This provided a 
recommended approach to care that would encourage a discussion with patients about 
medication and condition history and prompt a referral where necessary. Specific details 
around this care pathway were outlined in the presentation. 
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Community (primary care) and hospital (tertiary care) pharmacists from the Sydney 
Metropolitan Area were invited to attend (results from tertiary care pharmacists are not 
presented here). Community pharmacies were identified via an online database ‘Sydney  
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Low Back Pain Care Pathway (Adapted from Maher C, et al., 2011). 
Chemists and Pharmacies by location’ (A-Z: Sydney Chemists and Pharmacies by location) 
and contacted directly with an invitation to participate. 
Telephone invitations were made to three hundred and seventy-nine community pharmacies 
in Sydney. Interested pharmacists (n=296) were sent an invitation letter by e-mail or fax and 
Poor response  Poor response Poor response 
 No 
Yes 
Persistent NSLBP Associated Radiculopathy  Acute NSLBP 
Triage 
Low Back Pain 
Good general Health 
No red flags 
Serious Disease? 
Imaging 
Blood test 
Referral 
First line care 
Advice 
Simple analgesics 
Review 
First line care 
Advice 
Simple analgesics 
Physical Therapy 
Review 
First line care 
Advice 
Simple analgesics 
Review 
Second line care 
Stronger analgesics 
Physical therapies 
Second line care 
Stronger analgesics 
Interdisciplinary 
rehabilitation 
Surgical opinion 
Second line care 
Stronger analgesics 
Surgical opinion 
Non-specific Low 
back pain: NSLBP 
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asked to confirm their attendance by the appropriate RSVP date. There was no cost to 
pharmacists to attend and participation contributed mandatory credit points (accredited) 
towards their CPD. The in-house assessment facilitated the allocation of category two credits 
(knowledge with assessment) for pharmacists.  
Pharmacists’ knowledge of the content was assessed using a 10-item questionnaire 
consisting of nine multiple-choice and true/false questions on the content delivered. The 
tenth question was a vignette based on a real-life case scenario of cauda-equina syndrome 
(Dan-Phuong, 2003). 
Information from a real-life published case scenario of cauda-equina was used as this is a 
rare disorder and it is difficult to obtain an account of symptoms directly from patients or 
HCPs. The vignette encompassed the main complaints of the disorder: LBP, acute-onset 
incontinence, numbness of the saddle region and weakness down the legs, making it 
clinically distinguishable from other red flag conditions covered on the night (Table 6.1). 
6.2.2 Feedback and follow up 
 Pharmacists were asked to provide feedback on three items: “What did you like about 
tonight,” “What do you think can be improved” and “What are your recommendations for 
future events.”  
One week after the workshop was delivered, pharmacists were provided with individual 
performance reports summarising their responses and a detailed explanation of correct 
answers. 
6.2.3 Data Analysis 
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Responses to the questionnaire were analysed as the percentage of correct responses for 
each item (Table 6.2). Content analysis of pharmacists’ feedback was conducted by one 
reviewer and responses grouped into relevant themes. 
Ethics Approval: Ethics approval for this project was obtained from the University of 
Sydney’s Human Research Ethics Committee (13799).  
6.3 RESULTS 
6.3.1 Knowledge based items  
One hundred and ninety three community pharmacists (59 male, 134 female; mean age 38 
[SD 14]) from one hundred and thirty-seven community pharmacies attended the workshop 
(65% response rate) and completed the in-house assessment. Whilst males were 
underrepresented, the distribution of age is broadly representative of NSW pharmacists 
based on 2006 census data that reported a mean age of 42 (AIHW, 2009b). Pharmacists’ 
responses on knowledge-based questions reflected an accurate understanding of evidence-
based LBP guidelines and identifying a red flag condition (Tables 6.1 and 6.2).   
All pharmacists identified paracetamol as first line drug choice for the treatment of acute 
non-specific LBP (one blank response).  
Close to 96% (185 out of 193) of pharmacists correctly identified ankylosing spondylitis as an 
inflammatory condition more commonly diagnosed in younger persons as opposed to the 
elderly (6 incorrect answers, 2 answers blank). 
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Ninety-nine per cent (191 out of 193) of pharmacists correctly identified the symptoms 
presented in the vignette as most closely resembling cauda-equina syndrome (one incorrect 
answer, one answer blank). The mean score on the 10-question assessment was 9.89/10 
(range 8-10). 
Table 6.1. Alerting symptoms of serious underlying disease associated with acute LBP 
(Australian Acute Musculoskeletal Pain Guidelines Group, 2004; Chou et al. 2007).  
Condition Risk Factor/ Features 
Ankylosing spondylitis   Inflammation 
 Male 
 More common among younger persons 
 
Cauda equina syndrome  
 
 Numbness around the saddle region 
 Urinary retention (in 90% of patients) 
although overflow incontinence may 
occasionally occur 
 Fecal incontinence  
 Motor deficits at multiple levels 
 
Tumour 
 
 
 History of cancer with new onset of LBP 
 Age > 50 
 Pain at multiple sites 
 Pain at rest 
 Non responsive to treatment 
 Unexplained weight loss 
 Systemically unwell 
 
Infection  
 
 Symptoms and signs of infection (sore 
throat, fever) 
 Risk factors for infection (e.g. underlying 
disease process, immunosuppression, 
penetrating wound).  
Fracture At least 3 of the following: 
 Female 
 Age >70 years 
 Significant trauma 
 Prolonged use of corticosteroids 
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Aortic Aneurysm Absence of aggravating features  
 
Table 6.2. Assessment questions and correct responses. 
Question Options: Correct response No. correct response 
(%) 
The point prevalence of low 
back pain is estimated to be as 
high as:  
 
a. 93%  
b. 25.6%  
c. 46%  
d. 84%  
 
 
25.6%  
 
 
186 (96.4) 
Acute non-specific lower back 
pain is defined as pain of 
duration:  
 
a. Less than 2 weeks  
b. Less than 6 weeks  
c. Less than 3 
months  
d. Greater than 6 
weeks and less than 
3 months  
 
Less than 6 weeks  
 
 
193 (100) 
The prognosis of acute low 
back pain is generally good  
 
T/F True 
 
 
193 (100) 
Up to 90% of people with 
acute non-specific LBP are 
expected to recover within the 
first 6 weeks?  
 
T/F True 193 (100) 
Which of the following 
medicine should be 
recommended (if necessary) as 
part of the first line care 
endorsed by the NHMRC for 
LBP?  
 
a. Ibuprofen  
b. Combination 
tablet consisting of 
paracetamol, 
codeine and 
doxylamine 
succinate  
c. Paracetamol  
d. Combination 
tablet consisting of 
paracetamol and 
codeine  
 
 
Paracetamol 
 
193 (100) 
Back pain due to cancer occurs 
in less than what percentage 
of the population:  
a. 10%  
b. 5%  
c. 20%  
d. 1%  
Less than 1%  
 
 
193 (100) 
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Ankylosing spondylitis is an 
inflammatory condition that is 
more commonly diagnosed in 
the elderly  
 
T/F False 
 
 
185 (95.9) 
What advice should you NOT 
give when counselling a 
patient presenting to your 
pharmacy with symptoms of 
acute non-specific lower back 
pain?  
 
a. Tell patient to get 
plenty of bed rest  
b. Tell patient to 
avoid bed rest, try to 
stay active.  
c. Tell patient they 
can use paracetamol 
(4g/day in divided 
doses) where 
necessary.  
d. Provide re-
assurance and 
advise patient to see 
a doctor if 
symptoms worsen.  
 
 
Tell patient to get plenty 
of bed rest 
 
 
190 (98.4) 
Side effects of NSAIDs include 
which of the following  
 
a. Gastro-intestinal  
b. Sodium and fluid 
retention  
c. Bronchospasm  
d. All of the above  
 
 
Gastro-intestinal  
Sodium and fluid 
retention and   
Bronchospasm  
 
 
193 (100) 
*** Vignette: A 30 year old 
man comes into your 
pharmacy complaining that 
they are numb in both lower 
extremities and are having 
difficulty urinating. They have 
weakness of the left leg which 
is gradually getting worse and 
affecting their ability to walk. 
A few days ago they 
experienced sharp pain in the 
back and buttocks after doing 
some heavy lifting. These may 
be symptoms of which ‘red 
flag condition’? 
To select from red 
flags covered on 
night (see Table 6.1). 
Cauda Equina Syndrome 
 
 
191 (99) 
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6.3.2 Feedback 
A total of seventy-four pharmacists provided written feedback. The feedback was overall 
positive with four pharmacists suggesting font size on the handouts could have been larger 
to facilitate easier reading and six pharmacists suggesting improvements regarding start 
time and/or location (e.g. earlier starts, weekend delivery). Feedback from pharmacists 
revealed that the most desirable aspects of the workshop included its clarity (65/74), 
relevance and usefulness to everyday practice (57/74), particularly as there was a focus on 
new information around dose recommendations and advice to stay active, method of 
delivery i.e. interactive (36/74) and its no cost (14/74).  
Pharmacists also commented on the beneficial inclusion of the assessment, and the role it 
served to facilitate CPD points and reinforce the information delivered (21/74). 
 “Not only theoretical, but clinical and practical information on pain was provided.” P31 
“…liked the layout of the lecture – theory then scenarios. Case studies and examples were 
great.” P3 
Pharmacists also appreciated that they were getting complementary perspectives on the 
subject from two different health professionals – a pharmacist and a physiotherapist, 
particularly as it related to LBP. 
“Good to get information and perspective from a physiotherapist.” P19 
“Different health professionals together sharing their experience.” P51 
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Recommendations for future events included requests for specific topics to be covered and 
educational activities of this nature to be conducted more often and at varied locations to 
facilitate easier access for pharmacists. Pharmacists expressed a desire to learn about the 
management of chronic conditions including asthma, diabetes, as well as mental health and 
sleep-related disorders, biological therapies for inflammatory conditions, co-medication 
management and neuronal diseases.  
6.4 DISCUSSION 
The high percentage of correct responses on the assessment suggests that participating 
pharmacists have a current understanding of evidence based LBP management. Pharmacists 
appreciated the interactive method of delivery and the feedback suggests that the 
relevance/usefulness of the information may serve to inform their clinical decision making.  
There is an established preference among pharmacists for education that follows key adult 
learning principles (Mc Namara et al., 2007) including actively involving participants in the 
learning (Kauffman, 2003). Pharmacists were actively involved in the education through an 
informal discussion of mock case scenarios which allowed an interactive exchange of ideas 
and experience between researchers and pharmacists. The purpose of the summary 
performance reports was to allow pharmacists to reflect on what they learnt and review 
their practice.  
However, a limitation of this study is that the assessment was not administered at the start 
of the workshop rather was completed during the workshop in order to facilitate timely 
allocation of CPD points, hence a pre- and post- comparison of knowledge pertaining to the 
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assessment items is not possible. However, separate findings from the workshops described 
in chapter five revealed gaps in pharmacists’ knowledge of LBP management at the start 
and a significant improvement by the end of the workshop.  It is therefore plausible that the 
high percentage of correct responses observed in the present study could similarly be 
attributed to the educational workshop, particularly as the content e.g drug dose/frequency 
of use items, revolved predominantly around recently published research of the presenters 
themselves (Hancock et al., 2007). 
Another limitation is that it is not possible to generalise the findings from the sample of 
metropolitan pharmacists who attended the workshop to all practicing pharmacists.   
All community pharmacists, however, represent an important target for interventions 
designed to educate them about evidence-based LBP management, particularly as they are 
among the top five most commonly sought HCPs among LBP sufferers (Walker et al., 2005). 
A previous study identified that pharmacists could benefit from educational interventions 
on LBP (Silcock et al., 2007). Previous LBP interventions have targeted GPs’ with varying 
levels of success (Kerry et al., 2000; Oakeshott et al., 1994). This study has delivered 
important health messages to a group of HCPs who commonly encounter LBP and who can 
make a significant contribution towards its management in primary care. For example, 
providing advice on the right medicines for non-specific LBP as well as the recommended 
dose and frequency of use has emerged as a critical counselling point in light of recent 
evidence that over 80% of consumers trial a sub-therapeutic dose of paracetamol to 
manage their LBP (Wilk et al., 2010). The current evidence in this area suggests paracetamol 
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needs to be taken at the maximum therapeutic dose (4g daily in divided dose) and regularly 
for patients to receive optimal pain relief (Hancock et al., 2007).   
Pharmacists’ responses to the vignette also demonstrated they could successfully identify a 
hypothetical case of cauda-equina syndrome, a serious disorder and in many cases a surgical 
emergency (Dan-Phuong, 2003). Delay in its diagnosis and treatment can cause life-long 
complications such as irreversible loss of bladder control (Chou et al., 2007a). This 
intervention has presented pharmacists with a recommended care pathway for LBP 
sufferers, including advice on how to identify symptoms associated with a range of red flag 
conditions and when to refer. An authentic approach to determining the uptake of 
knowledge acquired from educational interventions into real-life practice may involve a 
combination of simulated patient studies and clinical audits. Another challenge is to develop 
interventions to target a larger number of pharmacists, particularly those living in rural and 
remote areas. These may include strategies such as online viewing of such workshops.   
Few pharmacists raised the absence of an attendance fee when commenting upon the 
desirable aspects of the workshop, a result consistent with previous findings (Mc Namara et 
al., 2009). Presently however, the majority of educational events that are freely accessible 
to HCPs are industry-run, with the possibility of content and promotional bias. Though the 
risk of bias is considerably less with accredited programs, as the content must satisfy and 
accrediting board, the cost of accreditation is often transferred to the HCP creating an 
interesting discussion around the desire for free post-tertiary education versus the 
requirement for HCPs to meet continuing education costs as part of their commitment 
towards personal professional development. Furthermore, the distribution of health funding 
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is perhaps better targeted towards the services delivered to consumers as a result of the 
education rather than funding the education itself.   
6.5 CONCLUSION 
Participation in this educational workshop has provided pharmacists with evidence-based 
knowledge of LBP management and identifying symptoms of red flag conditions. The 
feedback suggests there is continued need for educational interventions addressing 
important and familiar health conditions to be delivered to pharmacists. 
So far in this dissertation there has been an evaluation of the effectiveness of educational 
interventions on pharmacists’ knowledge, attitudes and beliefs towards LBP and a self-
report evaluation of pharmacists’ management of LBP. The next chapter is a cross sectional 
observational study employing a simulated patient approach to authentically evaluate how 
LBP is managed in community pharmacies. 
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CHAPTER SEVEN 
Investigating the management of low back pain in community 
pharmacies in Australia: A national simulated patient study 
This study was conducted in collaboration with the Pharmacy Guild of Australian and the 
Australian College of Pharmacy. 
7.1 INTRODUCTION 
Pharmacists, physicians and chiropractors are the primary health care professionals 
commonly consulted for advice regarding management of LBP (Goubert et al., 2004; Walker 
et al., 2003).  A survey of pharmacists from the United Kingdom showed that over 50% 
reported LBP as a condition for which they are commonly consulted for advice (Silcock et al., 
2007). In Australia, 10% of people with LBP seeking health care will present to a pharmacist 
(Walker et al., 2004). Additionally, treatment of LBP with over-the-counter (OTC) medicines 
is common (Consumer Reports, 2013) providing pharmacists with the opportunity to make 
an important contribution to the management of LBP.  
International guidelines for the management of non-specific LBP (Australian Acute 
Musculoskeletal Pain Guidelines Group, 2004; Chan et al., 2002; van Tulder et al., 2006) 
recommend appropriate triage to exclude a serious patho-anatomical cause then advice 
about the nature of non-specific LBP, reassurance of a favourable prognosis, the need to 
remain active, avoid prolonged periods of bed rest (Dahm et al., 2010) and the use of a 
simple analgesic as first line care. Paracetamol or NSAIDs are recommended ahead of 
combination analgesic medicines containing an opioid analgesic (Australian Acute 
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Musculoskeletal Pain Guidelines Group, 2004; Chan et al., 2002; van Tulder et al., 2006). 
Referral for medical review and imaging is only indicated where there is suspected vertebral 
compression fracture or signs/symptoms of serious underlying disease.  
To date, much of the research evaluating health care practitioner behaviours in the 
management of LBP has focused on physicians, with findings from Australia (Williams et al., 
2010a) and overseas (Bishop & Wing; 2003; Frankel et al., 1999; Gonzalez-Urzelai et al., 
2003; Schers et al., 2000) revealing that first line recommended steps are often ignored or 
incompletely practised. Instead care begins with more complex interventions such as 
combination opioid medicines, referral to allied health professionals and imaging. However, 
a limitation of past research is that much of this evidence is based on clinicians reporting 
how they managed a real patient or would manage a patient described in a clinical vignette 
(Abdel Shaheed et al., 2014c; Schers et al., 2000; Walker et al., 2011; Williams et al., 2010). 
There are no studies where aspects of routine clinical care of LBP have been measured by 
direct observation of the clinical encounter by an independent assessor and compared with 
guideline endorsed recommendations.  
The primary aim of this study was to investigate the management of LBP in community 
pharmacies using an adapted simulated patient approach and to compare current practice 
to evidence-based LBP management guidelines. Simulated or pseudo-patient studies have 
the advantage of providing an authentic evaluation of what takes place in actual practice 
whereas self-report questionnaires may less accurately reflect the real-life situation.   
7.2 METHODS 
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Human research ethics approval for this study was granted by the Princess Alexandra 
Hospital Human Research Ethics Committee Reference 2009/090.  
Simulated patient studies (Berger et al., 2005; Chua et al., 2006; Norris, 2002; Schneider et 
al., 2009; Watson et al., 2008) normally entail a trained actor role-playing a patient with a 
disease and recording the health care advice offered by a clinician. This was not feasible 
particularly for the second patient scenario we wished to use so we adapted the approach 
for both scenarios and had the trained actor act as the relative of a person with back pain 
(refer to Appendix Table 16 and Appendix Table 17).  
7.2.1 Selection of pharmacies 
The simulated patient visits were carried out between August and September, 2013. Five 
hundred and thirty four community pharmacies located in urban, rural or remote locations 
across six states in Australia were conveniently selected from a national database containing 
all pharmacies accredited under the Quality Care Pharmacy Program (92.5% of all 
community pharmacies in Australia as at June 2014). The Quality Care Pharmacy Program is 
a quality assurance program for community pharmacy that assesses pharmacies’ 
compliance with Australian Standard 85000:2011 quality management system for 
pharmacies in Australia. 
7.2.2 Selection and training of actors 
Twenty one actors with previous experience in the national simulated patient program and 
who were familiar with the research process involved were selected to carry out the 
community pharmacy site visits. Of these, 16 were allocated to the non-specific scenario 
and 5 to the fracture scenario. Each actor received training material pertaining to their 
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scenario prior to conducting community pharmacy site visits. This included details of the 
case scenario, a case rationale, questions likely to be asked by pharmacist or non-
pharmacist staff and suggested responses (Appendix Table 16 and Appendix Table 17).   
7.2.3 Simulated patient scenarios 
We used two standardised back pain clinical scenarios adapted from a study by Walker et al 
(2011) described in detail in Appendix Table 16. The first simulated patient scenario was an 
uncomplicated case of acute non-specific LBP in a middle-aged male who is generally active 
and healthy. The second scenario was a vertebral compression fracture in an elderly woman 
with a cluster of red flags (older age, female gender, previous history of bone fracture, 
taking medications for osteoporosis) that would increase the likelihood of vertebral 
compression fracture. For both scenarios there was standardised case information that was 
mandatory to convey to the clinician and other information that would only be elicited if the 
pharmacist or non-pharmacist staff member asked the relevant question.  
 
During the pharmacy visit the actor entered the pharmacy, approached the dispensary and 
made a verbal request to the first pharmacist or non-pharmacist staff member to approach 
them. 
For the non-specific LBP scenario the encounter began with one of two questions: 
1.  “Hi, I’d like some diclofenac please - is this the best thing for low back pain?”  
2.  “Hi, can I get something for low back pain please…” 
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With the compression fracture scenario the encounter began with the following question: 
“Hi, my mother/grandmother had a fall and hurt her lower back. She has been taking regular 
paracetamol but it doesn’t seem to be enough. What else can you recommend?” 
For both scenarios it was mandatory to ask the pharmacist or non-pharmacist staff member 
whether the patient should see the doctor for an x-ray. Beyond this the actors were 
instructed to: 
 not volunteer any information unless asked; 
 not provide additional information that was not specified in the case;  
 respond that they were “not sure” if asked any question not included in the training 
manual.  
All actors conducting the fracture scenario were provided with the complete list of 
medications supposedly taken by the elderly woman who was the subject of the case 
scenario. If asked about medication history, actors were advised to produce the medication 
list to help avoid recall bias and misinformation which could confound the findings. At the 
completion of each visit the actor’s supervisor returned to the community pharmacy and 
provided specific feedback on their response to the scenario.  
 
To describe the quality of care we extracted key indicators from evidence-based guidelines 
(Australian Acute Musculoskeletal Pain Guidelines Group, 2004; Chan et al., 2002; van 
Tulder et al., 2006) and tallied the percentage (%) of encounters where the indicator was 
met.  
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For the two scenarios the indicators and preferred responses are highlighted in Table 7.1. 
Medications supplied were grouped according to drug class and specific non-
pharmacological advice was grouped according to the nature of the recommendation. 
Table 7.1. Key Indicators and preferred responses based on evidence based guidelines. 
Indicator Preferred response for 
Non-specific low back 
pain scenario 
Preferred response for 
Fracture case 
Recommendation of a simple 
analgesic (paracetamol or NSAID) 
Yes (if paracetamol or 
NSAID supplied) 
Yes (if NSAID is recommended 
and appropriate) 
Reassurance of a favourable outcome Yes No 
Advice to stay active and avoid bed 
rest 
Yes No 
Prompt medical referral No Yes 
Imaging is indicated No Yes 
Recommendation of a more complex 
pain medicine (combination medicine 
containing opioid analgesic) 
No Yes 
7.2.4 Information gathering and medicines information provision  
We also determined the percentage of encounters where key indicators pertaining to 
responsible clinical information gathering and provision of medicines information were met. 
These included: actual symptoms, duration of symptoms, severity of symptoms, history of 
LBP, co-morbid conditions, concomitant medications, and whether the patient had tried any 
previous treatment for the pain as well as appropriate dose directions, maximum daily dose, 
side effects and screening for precautions/contraindications to medicines. These are 
considered standard screening items which are used to assist in determining safe and 
appropriate practice (Benrimoj et al., 2009).  
Each pharmacy visit was audio-recorded by the actor to enhance the reliability of data 
capture and assessments (Werner et al., 2008). As a condition of ethical requirements, each 
participating pharmacy was notified in writing that the anticipated audio-recorded 
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simulated patient visit would occur within the ensuing six months (specific time and nature 
of request was not specified). The research program had prior permission of the pharmacy 
to record the interaction. The recordings were used to validate and review the findings from 
the interaction by the study researchers (CAS and BM).   
7.3 RESULTS 
Simulated patient visits were carried out across a total of 534 community pharmacies in 
Australia (336 for the non-specific LBP scenario and 198 for the fracture scenario) between 
August and September 2013. A total of 21 actors carried out the visits (16 for the non-
specific scenario and five for the fracture scenario). For the non-specific scenario, 95% of 
visits were made to pharmacies that were located in urban and rural settings and 5% of 
visits were to remote locations (based on the Pharmacy Access/Remoteness Index of 
Australia [PHARIA]). For the fracture scenario the majority of visits (>99%) were made to 
pharmacies that were located in urban and rural settings. Pharmacist and non-pharmacist 
staff recommendations regarding management for the non-specific LBP and fracture 
scenario aligned closely with guidelines for approximately half of the primary indicators 
(Table 7.2). Specific recommendations and clinical information gathering are summarised in 
Tables 7.3, 7.4 and 7.5. Characteristics of pharmacist and non-pharmacist staff and 
geographic locations of pharmacies are described in Table 7.3 and Appendix Table 18 
respectively.  
Table 7.2. Results on key indicators.  
 
Indicator Non-
specific 
scenario  
Fracture 
scenario 
N=198 (%)  
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N=336 (%) 
Recommendation of a simple analgesic* 296 (88.6) 65 (35.7) 
Reassurance of favourable outcome 26 (7.7) 0 (0)  
Advice to stay active  15 (4.5) 3 (1.5) 
Advice to rest  10 (3.0) 2 (1.0) 
Avoid bed rest 0 (0) 0 (0) 
Prompt medical referral  6 (1.8) 91 (46.0) 
Imaging is indicated** 46 (22.7) 117 (71.8)  
Supply of a more complex pain medicine 
(combination opioid analgesic)  
27 (8.1) 112 (61.5) 
 
*Orally administered paracetamol or NSAID for the non-specific scenario and NSAID for the fracture scenario were considered 
appropriate and are reported here.  
**As a percentage of visits where the question on imaging was asked (203 non-specific scenario visits and 163 fracture scenario 
visits). 
Note: Where medicines are reported, percentages are out of 334 non-specific scenario visits and 182 fracture scenario visits 
where a medicine was supplied. 
 
Table 7.3. Demographic details of pharmacist and non-pharmacist staff and other 
information gathered or provided. 
 Non-specific 
scenario 
n=336 (%) 
Red flag n=198 
n (%) 
Served by whom 
Served by a Pharmacy Assistant Only?  98 (29.2) 17 (8.6) 
Served by a Pharmacy Assistant and Referred to the Pharmacist? 156 (46.4) 84 (42.4) 
Served by a Pharmacist Only?  82 (24.4) 97 (49.0) 
Gender of pharmacist 
Male 
Female  
Not determined  
109 
143 
84 
88 
93 
17 
Gender of pharmacy assistant 
Male 
Female 
NA 
6 
234 
96 
4 
99 
95 
Information recommended by pharmacist or non-pharmacist staff* 
Product use  
Take with or after food 
Use short term (up to 2 weeks) 
 
178 (53.3) 
96 (28.7) 
 
70 (38.5) 
36 (19.8) 
Dose directions 
1-2 tablets/capsules three times a day (including up to tds) 
1-2 tablets/capsules four times a day (including up to qid) 
None 
Other  
 
144 (43.1) 
31 (9.3) 
126 (37.7) 
35 (10.5) 
 
62 (34.1) 
42 (23.1) 
72 (39.6) 
22 (12.1) 
Information elicited by pharmacist or non-pharmacist staff 
Symptoms:   
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Pain exact location 
Visible bruising, swelling 
113 (33.6) 
0 (0) 
23 (11.6) 
33 (16.7) 
Other: 
Possible cause of pain 
Age 
Affecting mobility   
 
160 (47.6) 
19 (5.7) 
10 (3.0) 
 
68 (34.3) 
64 (32.3) 
43 (21.7) 
tds: Three times a day; qid: Four times a day. 
*percentage out of 334 non-specific visits and 182 fracture visits where a medicine was supplied. 
7.3.1 Pharmacological management recommendations  
Non-specific LBP: Of the 336 visits carried out for this scenario, a medicine was supplied in 
334 visits. Recommendations regarding pharmacological management for the non-specific 
LBP scenario aligned with guidelines in the majority of cases (Table 7.2). An orally 
administered simple analgesic was supplied in 89% (n=296) of visits (correct response) with 
NSAIDs being supplied most often (86% [n=286] of visits where a medicine was supplied; 
Table 7.4). Diclofenac was the most commonly supplied NSAID (74% [n=246]) followed by 
ibuprofen (12% [n=40]). More complex pain medicines (combination analgesic medicines 
containing codeine) were supplied in 8% (n=27) of visits. Paracetamol was supplied in only 
3% (n=10) of visits and was mainly verbally recommended for additional pain relief to be 
used in conjunction with the NSAID supplied. Out of the 172 visits where diclofenac was 
specifically requested by the actor for uncomplicated LBP, this was supplied in 166 (97%) 
cases.   
Fracture scenario: Pharmacological management recommendation for the fracture scenario 
closely aligned with guideline endorsed care and more complex pain medicines containing 
an opioid analgesic or NSAIDs were commonly supplied (Table 7.4). Combination medicines 
containing paracetamol and codeine were supplied in 49% (n=90) of visits where a medicine 
was supplied for this scenario ahead of single ingredient NSAIDs (supplied in 32% [n=59] of 
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visits). Ibuprofen was supplied more often than diclofenac (19% [n=34] versus 14% [n=25]) 
and it was apparent from reviewing the audio recordings that this was considered to be 
better tolerated for the older woman in the fracture scenario.  
7.3.2 Non-pharmacological advice 
Non-pharmacological advice was often sub-optimal. For the non-specific LBP scenario, 
actors were provided with advice to stay active in less than 5% (n=15) of cases. Reassurance 
of a favourable prognosis was provided in less than 8% (n=26) of visits. There were no 
specific recommendations to avoid prolonged periods of bed rest in any visit.   
For the fracture scenario, advice to delay activity (or rest) was recommended in only 1% 
(n=2) of cases. Actors were not provided with reassurance of a favourable prognosis at this 
early stage and a bone fracture had been suspected in 64% (n=127) of visits. Non-
pharmacological advice generally centred on heat application (8%; n=15) and offsetting the 
potential side effects of the medicine supplied (increase fluid and fibre intake to minimise 
the constipating side effects of codeine: 4%; n=7).  
7.3.3 Recommendations related to imaging 
Imaging was too frequently suggested for the non-specific LBP scenario (22.7% [n=46] of 
visits) and too infrequently for the fracture scenario (72% [n=117] of visits where the 
imaging question was asked). 
7.3.4 Referral to the health care professional  
Pharmacist and non-pharmacist staff members inadequately identified the fracture scenario 
as a medical emergency and only recommended a prompt referral to the general 
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practitioner or physiotherapist in less than half (n=91) of visits. Prompt referrals, which were 
not considered appropriate for the non-specific LBP scenario, were recommended in less 
than 2% (n=6) visits. Remaining referrals related to these scenarios were conditional (seek 
medical advice if the pain does not improve or becomes worse; see Table 7.4).  
Few pharmacists (n=3) indicated that the patient with non-specific LBP may consider coming 
in person for review to discuss other over-the-counter products or a higher strength should 
the supplied medicine be ineffective. 
Table 7.4. Referrals, nature of pharmacological and non-pharmacological management 
recommendations. 
 Non-specific scenario 
n=336  
N (%)  
Fracture scenario n=198 
N (%)  
Referral  
GP and/or physiotherapist (total)* 
Conditional referrals  
193 (57.4) 
187 (55.7) 
148 (74.7) 
57 (28.8) 
No referral  137 (40.8)  50 (25.3) 
Non-pharmacological recommendations  
Heat application 81 (24.1) 15 (7.6) 
Ice application 9 (2.7) 7 (3.5) 
Increase water and or fibre  5 (1.5) 7 (3.5) 
Total (No. visits where non-pharmacological advice was 
provided) 
107 (31.8) 32 (16.2) 
Pharmacological recommendations** 
Diclofenac (12.5 mg to 25 mg) tablets 246 (73.2) 25 (13.7) 
Ibuprofen (200 mg) tablets/capsules 40 (11.9) 34 (18.7) 
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Ibuprofen 200mg + codeine (12.8 mg) tablets 22 (6.5) 22 (12.1) 
Paracetamol 500 mg + codeine (10 mg to 15 mg) 
tablets 
5 (1.5) 90 (49.5) 
Paracetamol (500 mg to 665 mg) tablets 10 (3.0) 6 (3.3) (modified 
release) 
Topical NSAID 9 (2.7) 4 (2.2) 
None 2 (<0.01) 16 (all immediate 
referrals) 
Paracetamol recommended (continuation of or use in addition to the product supplied) 
Yes 
No 
65 (19.3) 
271 (80.7) 
97 (49.0) 
101 (51.0) 
*Total number of referral includes prompt and conditional referrals.  
** Percentages out of 334 non-specific scenario visits and 182 fracture scenario visits where a medicine was supplied. 
Note: Of the 96 visits where a paracetamol-containing medicine was supplied in the fracture scenario (paracetamol/codeine combination 
or paracetamol modified release formulation), 34 provided appropriate advice regarding the need for the elderly woman to stop the 
paracetamol she is taking or factor the new medication in her current regimen such that the maximum daily dose of paracetamol is not 
exceeded. In 43 of these visits maximum dose per day was emphasised. 
 
7.3.5 Information gathering and medicines information provision 
There was good evidence of clinical information gathering around key items such as 
concomitant medications and medical conditions (Table 7.5). However medicines 
information provision was incomplete in many encounters. For example, advice relating to 
possible side effects and how to manage these was provided in 44% (n=80) of visits for the 
fracture scenario (where a medicine was supplied) and dosing directions were omitted in a 
third of all visits. Furthermore, there was little emphasis on the maximum quantity of 
medicine per day.  
Of the 96 visits where a paracetamol-containing product (paracetamol/codeine combination 
or paracetamol modified release formulation) was supplied in the fracture scenario, 35% 
(n=34) highlighted that the elderly lady should either stop the paracetamol she is taking or 
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factor in the supplied medication to avoid exceeding the maximum paracetamol daily dose. 
In 45% (n=43) of these visits, maximum dose per day was emphasised.  
Table 7.5. Information gathering and medicines information provision. Safe and 
appropriate practice. 
Item Non-specific 
LBP scenario 
N=336 (%)  
Fracture 
scenario 
N=198 (%) 
Information gathering 
The actual symptoms that prompted the request 333 (99.1) 198 (100.0) 
Duration of symptoms 152 (45.2) 88 (44.4) 
Severity of symptoms 66 (19.6) 50 (25.3) 
If the patient has previous history of LBP  32 (9.5) 19 (9.6) 
If the patient takes any other medication 264 (78.6) 174 (87.9) 
If the patient has any other medical conditions 258 (76.8) 153 (77.3) 
If the patient has tried any other treatment for these 
symptoms  
211 (62.8) 197 (99.5) 
Medicines information provision* 
Appropriate dose directions (and spacing intervals specified) 210 (62.9) 126 (69.2) 
Maximum dose per day 109 (32.6) 68 (37.4) 
Side effects 97 (29.0) 80 (44.0) 
Screened for precautions or contraindications to medicine 
supplied** 
208 (62.3) 85 (46.7) 
In all except two non-specific scenario visits an attempt was made to establish who the request was for. 
*In percentages of total medicines supplied (n=334 and n=182 respectively). 
**including allergy or sensitivity to the medicine. 
From the information elicited from the actor, fracture was suspected in 127 fracture scenario visits. NOTE: Supply of a topical agent was 
not considered appropriate since there would not be enough systemic exposure to the drug and as there is a suspected fracture, rubbing 
should be avoided. 
 
Note: Common precautions to medications elicited by pharmacists or non-pharmacist staff 
included ulcer, asthma, allergy and hypertension (see Figures 9 and 10). Differences relating 
to nature of request (symptom based vs product based) have also been explored and results 
are summarised in Appendix Tables 19 to 21.  
7.3.6 Comparison between pharmacist and non-pharmacist staff involvement  
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A comparison between pharmacist and non-pharmacist staff involvement on key items 
showed that more pharmacists made a prompt medical referral for the fracture scenario 
compared with their non-pharmacist counterparts. However, prompt referral was still 
provided in under half of the visits where pharmacists provided the counselling (Table 7.6). 
This suggests that more education of non-pharmacist staff is required to help them identify 
potential red flag conditions and refer the case to the pharmacist for further investigation. 
In addition to this, further education and training of pharmacists is needed to help them 
identify cases with a potentially serious underlying medical cause and support their decision 
making. For the non-specific scenario, more pharmacists enquired about medication history 
and previous history of LBP compared with their non-pharmacist counterparts (Table 7.7). 
This reinforces the need to educate non-pharmacist staff on important screening questions 
and the need to ask these questions during requests for OTC medicines. 
Table 7.6. Comparison between pharmacist and non-pharmacist staff on primary outcome 
measures. 
 
 
Indicator Non Specific 
Scenario 
Pharmacist 
involvement  
N=252 (%) 
Non-
pharmacist 
only 
involvement 
N=84 
p-
value*  
Fracture 
scenario 
Pharmacist 
involvement 
N=181 (%)  
Fracture 
Scenario 
Non-
pharmacist 
only 
involvement 
N=17 
p-
value  
Recommendation 
of a simple 
analgesic* 
212 (84.8) 68 (81.0) 0.41 62 (34.8) 3 (17.6) 0.15 
Reassurance of 
favourable 
outcome 
22 (8.7) 4 (4.8) 0.23 0 (0)  0 (0) - 
Advice to stay 
active  
14 (5.5) 1 (1.2) 0.09 3 (1.5) 0 (0) 0.59 
Advice to rest  9 (3.6) 1 (1.2) 0.26 2 (1.0) 0 (0) 0.66 
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Avoid bed rest 0 (0) 0 (0) - 0 (0) 0 (0) - 
Prompt medical 
referral  
5 (2.0) 1 (1.2) 0.63 89 (46.0) 2 (11.8) <0.01 
Imaging is 
indicated** 
33 (13.1) 13 (15.5) 0.60 109 (49.2)  8 (47.1) 0.25 
Supply of a more 
complex pain 
medicine 
(combination 
opioid analgesic)  
17 (6.7) 10 (11.9) 0.14 102 (57.3) 10 (58.8) 0.90 
*Z test of proportions. Percentages are out of n=250 where orally administered simple 
analgesic was supplied for non-specific LBP scenario (pharmacist only involvement) and 
n=178 where an orally administered simple analgesic was supplied for the fracture scenario 
(pharmacist only involvement).  
Table 7.7. Comparison between pharmacist and non-pharmacist staff on items pertaining 
to information gathering and medicines information provision.  
Item Non Specific 
Scenario 
Pharmacist 
involvement  
N=252 (%) 
Non-
pharmacist 
only 
involvement 
N=84 (%) 
p-
value* 
Fracture 
scenario 
Pharmacist 
involvement 
N=181 (%)  
Fracture 
Scenario 
Non-
pharmacist 
only 
involvement 
N=17 (%) 
p-
value 
Information gathering   
The actual 
symptoms that 
prompted the 
request 
250 (99.2) 83 (98.8) 0.74 181 (100) 17 (100) - 
Duration of 
symptoms 
120 (47.6) 32 (38.1) 0.13 82 (45.3) 6 (35.3) 0.43 
Severity of 
symptoms 
47 (18.7) 19 (22.6) 0.43 44 (24.3) 6 (35.3) 0.32 
If the patient has 
previous history 
of LBP  
30 (11.9) 2 (2.4) <0.01 18 (9.9) 1 (5.9) 0.59 
If the patient 
takes any other 
medication 
207 (82.1) 57 (67.9) <0.01 161 (89.0) 13 (76.5) 0.13 
If the patient has 198 (78.6) 60 (71.4) 0.18 140 (77.3) 13 (76.5) 0.94 
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*Z test of proportions. Percentages are out of n=250 where orally administered simple 
analgesic was supplied for non-specific LBP scenario (pharmacist only involvement) and 
n=178 where an orally administered simple analgesic was supplied for the fracture scenario 
(pharmacist only involvement).  
7.4 DISCUSSION 
This study showed that pharmacy recommendations regarding the pharmacological 
management of LBP were largely concordant with guideline endorsed care but that non-
pharmacological recommendations were not. The key problems were inadequate advice 
about engagement in physical activity versus rest and failing to appropriately recommend 
imaging or medical review where it was indicated.   
This study is the first to compare management advice from community pharmacists to 
recommendations in practice guidelines for acute low back pain using a simulated patient 
study design. The results will inform strategies to promote the evidence-based management 
of LBP in this primary care setting. This study was carried out across several states in 
Australia and visits were made to pharmacies in urban, rural and remote settings, hence the 
findings involve a broad sample of community pharmacy. It was also apparent from 
reviewing the audio recordings that there was good internal consistency and actors gave 
appropriate responses to questions as outlined in the training material. However a 
any other 
medical 
conditions 
If the patient has 
tried any other 
treatment for 
these symptoms  
162 (64.3) 49 (58.3) 0.98 180 (99.4) 17 (100) 0.76 
Medicines information provision*   
Maximum dose 
per day 
87 (34.5) 22 (26.2) 0.16 62 (34.3) 6 (35.3) 0.93 
Side effects 78 (31.0) 19 (22.6) 0.14 70 (38.7) 10 (58.8) 0.10 
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limitation was the omission of the imaging question in some visits, a consequence of the 
closed nature of the interaction. Another limitation was that variables such as age and years 
of experience of pharmacist and non-pharmacist staff were not collected, hence it was not 
possible to explore the effects of these on management outcomes.  
 
Much of the evidence around health care provider management of LBP is based on results 
from self-report questionnaires or responses to clinical vignettes (Abdel Shaheed et al., 
2014c; Schers et al., 2000; Walker et al., 2011; Williams et al., 2010a). The few studies which 
have evaluated what takes place in practice by direct observation (Chua et al., 2006; Vella et 
al., 2009) did not compare practice with the overall care prescribed in LBP management 
guidelines or evaluate recommendations in response to a clinical red flag. Rather, these 
studies have evaluated the nature of questions commonly asked by pharmacists and non-
pharmacist staff and medicines information provided. There is limited evidence from a self-
report questionnaire (Abdel Shaheed et al., 2014c) that pharmacists’ recommendations 
regarding pharmacological management of acute non-specific LBP are consistent with 
guideline recommendations, and that paracetamol is commonly recommended. However, 
this evidence comes from pharmacists who participated in recruitment of participants for a 
LBP clinical trial and who had received training on LBP management, hence this may not be 
broadly representative. This study has shown that pharmacy recommendations regarding 
the management of non-specific LBP focused on the provision of a simple analgesic, with a 
greater preference for NSAIDs over paracetamol. This is consistent with findings from 
another simulated patient study conducted in Malaysia (Chua et al., 2006) which showed 
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that diclofenac was most commonly supplied for acute back pain. In the present study, 
combination medicines containing paracetamol plus codeine (third line therapy) were not 
commonly supplied for NSLBP although were supplied twice as often as paracetamol alone.  
Previous studies evaluating how LBP is managed by HCPs reveal gaps in practice compared 
with guideline endorsed recommendations (Dey et al., 2004; Engers et al., 2005; Evans et 
al., 2010; Williams et al., 2010a; Schetman et al., 2003). Among GPs, for instance, care often 
begins with more complex regimens such as combination opioid analgesics. Furthermore, up 
to one quarter of cases of acute non-specific LBP are referred for imaging (Williams et al., 
2010) despite evidence this can delay recovery (Chou et al., 2009). A recent study has shown 
there are similar gaps in pharmacists’ knowledge around the need for imaging in acute LBP 
(Abdel Shaheed et al., 2014b). This is reflected by findings from the present study which 
showed almost one quarter of non-specific cases were suggested for imaging where it was 
not indicated.  
This study has identified gaps in practice with regards to the provision of appropriate non-
pharmacological advice for non-specific LBP, particularly around advice to stay active and 
avoid prolonged periods of bed rest. A recent consumer health survey conducted in the USA 
(Consumer Reports, 2013), showed that less than a third of those who tried an OTC 
medicine for their back pain reported it was very helpful. This reinforces the need to counsel 
on non-pharmacological therapies with known benefits such as exercise, as this may have a 
synergistic effect. Reassurance of a favourable outcome was largely missing suggesting 
pharmacists may not consider this advice to be important or perhaps require more training 
in distinguishing between non-specific LBP and serious underlying disease. However recent 
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reports highlight the importance of encouraging activity and providing appropriate 
reassurance (after screening for and excluding potential red flag conditions) amid evidence 
that fear avoidance beliefs and catastrophising are implicated in the transition from acute to 
chronic LBP (Buer et al., 2002; Elfving et al., 2007; Pincus et al., 2002).  
Findings from this study support previous research (Abdel Shaheed et al., 2014d) which has 
identified a need to educate and train pharmacists and non-pharmacist staff in identifying, 
triaging and appropriately managing red flag conditions, as under half did not provide a 
prompt medical referral for the fracture scenario. Educating pharmacists on the appropriate 
use of imaging would also help to ensure that accurate and reliable information is provided 
to people presenting with symptoms of LBP.  
It is unclear why paracetamol was far less commonly supplied for non-specific LBP 
compared with NSAIDs. It is possible these findings reflect the perceived or actual benefits 
of over-the-counter medicines for the management of LBP or perhaps that pharmacists are 
taught at graduate level that NSAIDs are the preferred drug class for musculoskeletal pain. 
Pharmacists have identified in a previous study that there is a public perception of 
paracetamol being a relatively weak analgesic, highlighting concerns among some 
consumers that it would not provide optimum relief from moderate to strong pain (Abdel 
Shaheed et al., 2014c). A recent systematic review (Abdel Shaheed et al., 2014a) identified 
no evidence of clinically significant pain relief with paracetamol (compared to placebo) for 
acute LBP whereas there is limited evidence that ‘when required dosing’ of diclofenac and 
ibuprofen  does provide clinically significant pain reduction. Importantly, a large randomised 
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controlled trial of paracetamol for acute non-specific LBP (Williams et al., 2014b), published 
after this study was completed, has revealed there is no benefit of paracetamol (time 
contingent or ‘when required’ dosing) compared with placebo for pain relief, supporting 
pharmacists’ recommendations to supply an NSAID initially.  
However, whilst simple analgesics were commonly supplied for non-specific LBP, provision 
of medicines information with regards to dose directions, maximum daily quantity and side 
effects were somewhat lax, exposing an area of practice which needs to be addressed. 
Studies suggest that consumers often find it challenging to interpret or even find the 
directions on the labels of OTC medicines (Drake, 2002; Roumie & Griffin, 2004). Taken 
together, these findings highlight the importance of communicating information on the 
appropriate use of medicines in order to avoid complications related to inappropriate use.  
Of concern was the omission of advice to either discontinue paracetamol or factor in the 
new medicine (such that the maximum daily dose of paracetamol was not exceeded) in two 
thirds of visits where a paracetamol-containing product was supplied for the fracture 
scenario. Furthermore, screening for precautions (e.g. sensitivity to codeine) or 
contraindications to medicines was evident in less than half of fracture visits despite the 
knowledge that drowsy effects of codeine may potentiate falls and therefore further 
fractures in the elderly (Buckeridge et al., 2010; Iedema, 2011). 
Whilst this study has evaluated recommendations regarding the management of LBP in 
community pharmacies, it is not possible to ascertain the real impact on patients’ health 
from these findings.  The results do however suggest future research should focus on 
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designing educational tools to assist both pharmacists and their assistants in identifying 
cases of simple, non-specific LBP and distinguishing these from serious red flag conditions. It 
is unclear how many pharmacists had prior knowledge of, or access to, existing LBP 
guidelines and whether this could have influenced their decision making. Interventions 
should, however, focus on raising the level of awareness of LBP guidelines, either at 
undergraduate or postgraduate level, and increasing access to them. This could facilitate the 
implementation of evidence-based practice in the primary care setting. It is also important 
to include counselling aids to encourage provision of appropriate non-pharmacological 
advice and medicines information.   
7.5 CONCLUSION 
This study shows that while pharmacological recommendations provided in community 
pharmacies typically align with clinical practice guidelines for LBP, non-pharmacological 
advice does not. Provision of education on appropriate non-pharmacological advice for LBP 
and medicines information are areas that require greater emphasis in entry level and post 
graduate training. 
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CHAPTER EIGHT 
CONCLUSION and FUTURE DIRECTION 
 
The findings from this thesis have shed new light onto the efficacy of commonly used 
interventions and advice for the management of LBP. Muscle relaxants, NSAIDs, 
rubefacients and local heat application are effective in the management of acute LBP, whilst 
opioid analgesics have shown some benefit on pain (but not disability) in chronic LBP. The 
recommendations that have emerged from this thesis around dosing requirements and 
treatment duration for certain medications, particularly opioid analgesics and muscle 
relaxants, reinforce the complex nature of this condition and the need for ongoing 
monitoring and review of patients. The findings also support the decision making of both 
pharmacists and doctors, identifying that pain relief at opioid analgesic doses beyond the 
maximum recommended, is not likely to be clinically significant. However it is clear that 
there are significant safety considerations at high doses of opioid analgesics.  
This thesis has also identified gaps in knowledge and practice among pharmacists, 
highlighting the need for ongoing support and education of these primary health care 
providers as a way of promoting the evidence-based management of LBP. Pharmacists 
themselves have requested the development of decision support tools to assist them in the 
management and triage of people with LBP. 
Given the findings from the simulated patient study, the tools must serve to promote 
evidence-based non-pharmacological management of LBP since this was an area that was 
broadly lacking. A greater focus on LBP education at the undergraduate or postgraduate 
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pharmacy training level may serve to bridge these. Encouraging effective counselling around 
non-pharmacological management of LBP and providing appropriate self-care advice will 
strengthen the management of this condition in primary care.    
Pharmacists would also benefit from educational interventions that would help them 
identify signs/symptoms of serious underlying disease as this could help to ensure that 
urgent cases are appropriately referred for further investigation. Based on the preferences 
of pharmacists for a support tool which is simple and concise, it is important that 
pharmacists are presented with a decision aid they can refer to several times and which can 
ideally be tailored to the condition of the patient. 
Medication management, health promotion, screening and risk assessment all represent 
core areas of pharmacist-led initiatives. Pharmacists are suitably positioned to provide 
appropriate intervention strategies to people with a range of disease conditions. 
Importantly, this thesis has highlighted how the role of the pharmacist expands far beyond 
the medicines provider to encompass a broader commitment to providing quality health 
care for people in the community. Pharmacists’ role in the triage of those who require 
closer examination by a physician is a particularly important one, given their unique access 
to consumers and their medication and disease history. On a global level, pharmacists are 
playing an increasingly important role in the management of disease states such as 
hypertension, hyperlipidaemia and respiratory conditions.  
Such pharmacy–led services have established benefits on clinical outcomes and health-
related quality of life outcomes for patients. However the current focus of these programs is 
on cardiovascular or respiratory health. Little is known of pharmacist-led interventions for 
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back pain despite this being the single most common cause of morbidity on a global level 
according to findings from the recent Global Burden of Disease Study. To date, there is no 
specific pain management service being delivered in community pharmacies in Australia 
which is supported as part of a broader Disease State Management Program. 
Disease State Management programs delivered in community pharmacies are part of a 
nationwide effort to promote health on a broad level. These programs involve the direct 
intervention by pharmacists typically during a face-to-face interaction with the patient at 
the pharmacy. Such programs recognise that pharmacists are suitably positioned to provide 
appropriate intervention strategies to people with a range of disease conditions.  
It is anticipated future work in this area will help to address the present gaps in practice and 
optimise management of LBP among pharmacists. The logical next step, therefore, would be 
to create and validate decision support tools for pharmacists then pilot these to test how 
well they can be integrated in practice. As with any intervention of this nature, it would be 
necessary to evaluate the direct benefits to people with LBP as a result of the intervention. 
This work would ideally require the support from key stakeholders in the profession since 
the existing gaps in practice are evident on a national level, warranting a national and 
streamlined solution.  
In 2013 my associate supervisor worked with NPSMedicineWise and GP colleagues to 
develop an online decision support tool, BackPainChoices (Peiris et al., 2014), that 
addressed the common evidence-practice gaps in the GP management of back pain (Peiris 
et al., 2014). At present I am collaborating with this team, the Pharmacy Guild and 
pharmacy colleagues to develop an iPad version of BackPainChoices for use in community 
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pharmacies that accommodates the different workflow environment to that in general 
practice. When development is complete we will conduct a randomised controlled trial 
comparing pharmacy care informed by the application to usual pharmacy care. The trial will 
use a simulated patient approach (as used in my original study that identified the evidence-
practice gaps) to directly observe the management recommendations for back pain 
provided in community pharmacies.  
The thesis has also established the benefits of educational interventions which are based on 
guideline endorsed recommendations. Pharmacists’ knowledge, attitudes and beliefs 
towards low back pain were significantly improved as a result of the workshops however the 
slight decline in knowledge at 6 months reinforces the need for ongoing refresher training of 
pharmacists. This means that when an intervention is developed to promote the 
management of LBP by these health care professionals, it is important that the training of 
these health professionals is revisited throughout the course of the program/intervention. 
This may help to ensure that consumers are receiving appropriate and consistent care over 
the course of the intervention. 
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Appendix 
Table 1. Search Strategy ONE (OVID resources: MEDLINE, AMED, CENTRAL, PsycINFO, 
Cochrane database of Systematic Reviews). 
Terms Searches MEDLINE 
Study types 1.         REVIEW, ACADEMIC.pt. OR REVIEW, TUTORIAL.pt. OR     META–
ANALYSIS.pt. OR META–ANALYSIS.sh. OR systematic$ adj25 review$ OR 
systematic$ adj25 overview$ OR meta-analy$ or metaanaly$.tw or (meta adj25 
analy$).tw OR Randomized controlled trial.pt OR controlled clinical trial.pt or 
randomized controlled trials.mp OR controlled clinical trials.mp OR random 
allocation.sh OR double-blind method.sh OR single-blind method.sh OR clinical 
trial.pt OR exp clinical trial/ OR clin$ adj25 trial$.tw OR (singl$ or doubl$) adj25 
(blind$ or mas$).tw OR placebos.sh OR placebo$.tw OR random$.tw OR 
research design.sh OR comparative study.sh OR exp evaluation studies/ OR 
follow-up studies.sh OR prospective studies.sh OR cross-over studies.sh OR 
(control$ or prospective$ or volunteer$).tw OR parallel-stud$.tw OR (parallel 
adj25 stud$).tw or (parallel.sh adj25 trial$).tw 
 
 2. 
ANIMAL/ not HUMAN/ 
 3. 
1 NOT 2 
Low back pain  4. 
Low back pain.sh OR low back ach$.tw OR lumbago.mp OR (low$ adj25 back 
pain).tw OR (low$ adj25 back ach$).tw OR low back strain.tw OR low$ back 
pain$.tw OR (simpl$ adj25 low$ back pain).mp. OR (mechanic$ adj25 low$ back 
pain).mp OR (non-specific adj25 low$ back pain).mp. backache.mp OR back 
pain.sh OR back pain.mp OR  exp "sprains and strains"/ and exp SPINE/ OR exp 
Intervertebral Disk Displacement/ OR Intervertebral Disk Displacement.mp OR 
back pain.tw OR  simple back pain.tw OR  low back syndrome.tw OR low back 
dysfunction.tw OR non-specific back pain.tw OR lumbar pain.tw 
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 5. 
3 and 4  
Opioids  6. 
NO2A$.tw OR (opioid$ adj25 analges$).tw OR opioid$.tw OR (opioid$ adj25 
med$).tw OR (opioid$ adj25 drug$).tw OR narcotic$.tw OR (narcotic$ adj25 
drug$).tw OR (narcotic$ adj25 analges$).tw OR morphine.tw OR (morphine 
adj25 sul$).tw OR ordine.tw OR hydromorphone.tw OR dilaudid.tw OR oxy$.tw 
OR oxycodone.tw OR endone.tw OR targin.tw OR oxymorphone.tw OR 
OPANA$.tw OR codeine.tw OR dihydrocodeine.tw OR (opi$ adj25 alkaloid$).tw 
OR ketobemidone.tw OR (phenylpiperidine adj25 deriv$).tw OR pethidine.tw 
OR Fentanyl.tw OR durogesic.tw OR diphenylpropylamine.tw OR 
dextromoramide.tw OR piritramide.tw OR dextropropoxyphene.tw OR di-
gesic.tw OR capodex.tw OR bezitramide.tw OR methadone.tw OR 
physeptone.tw OR (benzomorphan adj25 deriv$).tw OR pentazocine.tw OR 
phenazocine.tw OR (oripavine adj25 deriv$).tw OR buprenorphine.tw OR 
norspan.tw OR suboxone.tw OR subutex.tw OR etorphine.tw OR (morphinan 
adj25 deriv$).tw OR tilidine.tw OR trama$.tw or tramadol.tw OR dezocine.tw 
OR tapendatol.tw OR meptazinol.tw  
 
Muscle relaxants 7. 
M03$.tw OR (muscle adj25 relax$).tw OR anti-spasm$ OR calmative.sh OR 
carisoprodol.sh OR cyclobenzaprine.sh OR flexeril.sh OR metaxalone.sh OR 
methocarbamol.sh OR baclofen.sh OR orphenadrine.sh OR tizanidine.sh OR 
Zanaflex.sh OR dantrolene.sh OR Dantrium.sh  OR Quinine.sh OR 
chlorzoxazone.sh OR norflex.tw OR norgesic.tw 
 
Benzodiazepines 8. 
NO5BA.sh OR  alprazolam.sh OR xanax.sh OR  Triazolam.sh OR  Brotizolam.sh 
OR  Oxazepam.sh OR  Serepax.sh OR Loprazolam.sh OR  Lormetazepam.sh OR  
Lorazepam.sh OR Ativan.sh OR Temazepam OR Normison.sh OR Temaz$.tw OR 
Estazolam.tw OR  Bromazepam.tw OR Chlordiazepoxide.sh OR  Clobazam.sh OR 
Nimetazepam.sh OR Flunitrazepam.sh OR  Nitrazepam.sh OR Clonazepam.sh 
OR Quazepam.sh OR Diazepam.sh OR Valium.sh OR  Phenazepam.sh OR 
Medazepam.sh OR  Prazepam.sh OR  Flurazepam.sh OR  Clorazepate.sh OR 
Nordazepam.sh 
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 9. 
6 or 7 OR 7 or 8  
 10.  
5 and 9 
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Table 2. Pedro ratings for eligible trials.  
 Eligibility 
criteria 
Randomisation Concealed 
allocation 
Baseline 
comparability 
Subject 
blinding 
Therapist/physician 
blinding 
Assessor 
blinding 
Adequate 
follow-up 
(>85%) 
Intention-
to-treat 
analysis 
Between 
group 
statistical 
comparisons 
Point 
measures 
and 
measures 
of 
variability 
Total 
Score 
Opioid analgesic trials  
Allan, 2005 0 1 0 0 0 0 0 0 1 1 1 4 
Buynak, 2010 0 1 1 1 1 1 1 0 0 1 1 8 
Chu 2012 1 1 1 1 1 1 1 0 0 1 1 8 
Cloutier, 2013 1 1 1 1 1 1 1 0  0 1 1 8 
Gordon, 2010 0 1 1 0  1 1 1 0 0  1 1 7  
Hale, 2010 0 1 1 1 1 1 1 0 0 1 1 8 
Hale, 2005 0 0* 1 0 1 1 1 0 0 1 1 6 
Hale, 2007 0 1 1 1 1 1 1 0 0 1 1 8 
Katz 2007 1 1 1 1 1 1 1 0 0 1 1 8 
Khoromi, 
2007 
1 1 1 0 1 1 1 0 0 1 1 7 
Peloso, 2004 1 1 1 1 1 1 1 1 1 1 1 10 
Perrot, 2006 0 1 1 1 1 1 1 1 0 1 1 9 
Ruoff, 2003 0 1 1 1 1 1 1 0 0 1 1 8 
Schnitzer, 
2000 
0 1 0 0 1 1 1 0 0 1 1 6 
Steiner, 
2011a 
0 1 1 1 1 1 1 0 0 1 1 8 
Steiner, 
2011b 
1 1 1 1 1 1 1 1 1 1 1 10 
Uberall, 2012 1 1 1 1 1 1 1 1 1 1 1 10 
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Vorsanger, 
2008 
0 1 1 1 1 1 1 0 0 1 1 8 
Webster, 
2006 
0 1 1 1 1 1 1 0 0 1 1 8 
Muscle relaxant trials 
Aksoy, 2002 0 1 0 1 0 0 0 0 0 1 1 4 
Berry, 1988 1 1 1 0 1 1 1 1 0 1 1 8 
Cabitza, 2008 1 1 1 1 1 1 1 1 0 1 0 8 
Chandanwale, 
2011 
1 1 1 1 1 1 1 1 0 1 1 9 
Hindle, 1972  1 unclear unclear 0 1 1 1 1 0 1 0 5 
Ketenci, 2005 0 1 1 0 1 1 1 1 1 1 1 9 
Pareek 2009 1 1 1 1 1 1 1 1 0 1 1 9 
Pipino, 1991 1 unclear unclear 1 0 0  Unclear 1 1 1 1 5 
Ralph, 2008 1 1 1 1 1 1 1 1 0 1 1 9 
 
Rollings, 1983 1 1 0 1 1 1 1 1 0 1 0 7 
 
Rossi, 2012 0 1 0 1 0 0 0 0 0 1 1 4 
Serfer, 2010 0 1 1 1 1 1 1 0 0 1 1 8 
Tuzun, 2003 1 1 1 1 1 1 1 1 0 1 1 9 
*randomisation took place in the oxycodone vs oxymorphone phase, but not opioid vs placebo phase.  
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Table 3. Data extraction Table.  
Study Outcome 
measure 
Mean (SD) 
Treatment 
Number Mean (SD) 
Control 
Number Mean 
difference 
Clinically 
significant  
Opioid analgesic trials  
Vorsanger, 2008 
Tramadol ER 300mg vs 
placebo 
Note: SD from 
randomisation used for 
placebo and treatment 
groups 
VAS (0-100) 
 
 
Week: 
1 
 
8 
 
12 
 
 
 
 
38 (23·7) 
 
34 (23·7) 
 
33 (23·7) 
 
 
 
 
127 
 
127 
 
127 
 
 
 
 
45 (25·9) 
 
40 (25·9) 
 
39 (25·9) 
 
 
 
 
126 
 
126 
 
126 
 
 
 
 
-7 (-13·1 to 
-0·9) 
-6 (-12·1 to 
0.1) 
-6 (-12·1 to 
0.12) 
 
 
 
 
NO 
 
NO 
 
NO 
Vorsanger, 2008 
Tramadol ER 200mg vs 
placebo 
VAS (0-100) 
 
SD from 
randomisation 
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Week: 
1 
 
8 
 
12 
 
39 (26·0) 
 
35 (26·0) 
 
38 (26·0) 
 
129 
 
129 
 
129 
 
45 (25·9) 
 
40 (25·9) 
 
39 (25·9) 
 
126 
 
126 
 
126 
 
-6 (-12·4 to 
0.4) 
-5 (-11·4 to 
1.4) 
-1 (-7·4 to 
5.4) 
 
NO 
 
NO 
 
NO 
Schnitzer, 2000 
Tramadol vs placebo  
VAS  
Day 49 (final 
visit) 
35 (27.9) 127 51 (29.8) 127 -16 (-23.1 
to -8.9) 
YES 
Schnitzer, 2000 
Tramadol vs placebo  
RMDQ 
Day 49 (final 
visit) 
36.7 (25.8) 127 42.5 (25.8) 127 -5.8 (-12.1 
to 0.5) 
NO 
Uberall, 2012 
Tramadol vs placebo 
Week 4 mean 
change NRS 
-21 (20) 107 -20 (18) 110 -1·0 (-6·1 to 
4·1) 
NO 
Peloso ,2004 
Tramadol/paracetamol 
vs placebo 
Final visit Day 
91 
 
47·4 (15·0) 167 62·9 (15·53) 169 -15·5 (-18·8 
to -12·2) 
YES 
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Note: SD for placebo 
and treatment groups 
taken from baseline 
data 
Ruoff, 2003 
Tramadol/Paracetamol 
combination  
Note: SD for placebo 
and treatment groups 
taken from baseline 
data 
VAS (day 91) 44·4 (14·5) 
 
91 52·3 (14·9) 
 
74 -7·9 (-12·4 
to -3·4) 
NO 
Ruoff, 2003 
Tramadol/Paracetamol 
combination vs 
placebo 
RMDQ (day 
91) 
10·7 (6·3) 
 
44·6 (26·3) 
91 11·6 (6·3) 
 
48·3 (26·3) 
74 -3·7 (-11·8 
to 4·4) 
NO 
Perrot, 2006 
Tramadol+paracetamol 
vs tramadol 
monotherapy 
Note: SD for placebo 
and treatment group 
VAS end of 
study Day 10 
27·9 (13·0) 
 
51 24·8 (14·6)  48 3·1 (-1·9 to 
8·1) 
NO 
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taken from baseline 
data 
Hale, 2010 
Hydromorphone 
Note: values estimated 
from graph in Figure 4 
of study – clinic visits. 
SD from screening 
used for placebo and 
treatment groups   
NRS (0-10) 
 
1 week 
 
 
8 weeks 
 
 
12 weeks 
 
 
34 (19·4) 
 
 
31 (19·4) 
 
 
32 (19·4) 
 
 
133 
 
 
133 
 
 
133 
 
 
 
41 (18·8) 
 
 
41 (18·8) 
 
 
41 (18·8)  
 
 
133 
 
 
133 
 
 
133 
 
 
-7 (-11·6 to 
-2·4) 
 
-10 (-14·6 
to -5·4) 
 
-9 (-13·6 to 
-4·4) 
 
 
NO 
 
 
YES 
 
 
NO 
 
Gordon, 2010 
Transdermal 
buprenorphine vs 
placebo 
Pain intensity 
VAS 
Week 4  
 
40·9 (20·2) 
 
 
 
37 
 
 
 
48 (22·5) 
 
 
 
42 
 
 
 
-7·1 (-16·5 
to 2·3) 
 
 
NO 
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Steiner, 2011a 
Buprenorphine 
transdermal vs placebo 
SE converted to SD  
 
Average pain 
over past 24 
hours at week 
12 NRS 
 
 
 
38·1 (19·4) 
 
 
 
257 
 
 
 
43·9 (21·2) 
 
 
 
283 
 
 
 
-5·8 (-9·2 to 
-2·4) 
 
 
 
NO 
Steiner, 2011b 
Buprenorphine 
(transdermal) 5 µg/h  
vs Buprenorphine 
(transdermal) 20  µg/h 
SE converted to SD 
 
 
Week 8 
 
Week 12  
 
38·3 (19·0) 
 
40·2 (20·2) 
 
138 
 
127 
 
33·5 (17·9) 
 
33·5 (16·6) 
 
164 
 
142 
 
4·8 (0·6 to 
9·0) 
6·7 (2·3 to 
11·1) 
 
NO 
 
NO 
Steiner, 2011b 
Buprenorphine 
(transderamal) 5  µg/h  
vs  
oxycodone 40 mg 
 
Week 8 
 
Week 12  
 
38·3 (19·0) 
 
40·2 (20·2) 
 
138 
 
127 
 
32·4 (19·1) 
 
32·6 (18·9) 
 
173 
 
154 
 
5·0 (1·6  to 
1·0) 
7·6 (3·0 to 
12·2) 
 
NO 
 
NO 
186 
 
 
 
  
Steiner, 2011b 
Buprenorphine 20  
µg/h  vs oxycodone 40 
mg 
 
Week 8 
 
Week 12 
 
33·5 (17·9) 
 
33·5 (16·6) 
 
164 
 
142 
 
32·4 (19·1) 
 
32·6 (18·9) 
 
173 
 
154 
 
1·1 (-2·8 to 
5·0) 
9·0 (-3·1 to 
4·9) 
 
NO 
 
NO 
Hale, 2005 
Oxymorphone vs 
placebo 
Note: used SD from 
Table 1 of study 
Mean change 
from baseline 
in pain 
intensity 
(VAS) 
 
DAY 7 
 
 
Day 18 
 
 
 
+8 (23·9) 
 
+8·5 (23·9) 
 
 
 
71 
 
71 
 
 
 
+26 (23·8) 
 
+27·5 (23·8) 
 
 
 
67 
 
67 
 
 
 
-18 (-26 to -
10) 
-19 (-27 to -
11) 
 
 
 
YES 
 
YES 
Hale, 2007 
Oxymorphone (OPANA 
er) vs placebo 
 
Note: SD from 
VAS 
Day 10 
 
 
 
28 (16·8) 
 
 
 
70 
 
 
 
51 (15·4) 
 
 
 
72 
 
 
 
-23 (-28·3 
to -17.7) 
 
-24 (-32·5 
 
YES 
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screening used   < 3months 31 (16·8) 49 55 (15·4) 18 to -15.5) YES 
Katz, 2007 
Oxymorphone ER vs 
placebo 
Used SD from Table 2 
of study 
Week 1 
 
Week 8 
 
Final (90 days) 
32 (24·5) 
 
33 (24·5) 
 
31 (24·5) 
105 
 
105 
 
105 
45 (27·9) 
 
45 (27·9) 
 
47 (27·9) 
100 
 
100 
 
100 
-13 (-20·2 
to -5·8) 
-12 (-19·2 
to -4.8) 
-16 (-23·2 
to -8·8) 
YES 
 
YES 
 
YES 
 
Hale, 2005 
Oxycodone vs placebo 
SD from Table 1 of 
study 
Mean change 
from baseline 
in pain 
intensity 
(VAS) 
 
DAY 7 
 
Day 18 
 
 
 
+9 (23·8) 
 
+6·5 (23·8) 
 
 
 
75 
 
75 
 
 
 
+26 (23·8) 
 
+27·5 (23·8) 
 
 
 
67 
 
67 
 
 
 
-17 (-24·8 
to -9·2) 
-21·0 (-28·8 
to -13·2) 
 
 
 
YES 
 
YES 
Webster, 2006 
Oxycodone four times 
daily vs placebo 
Pain 0-10 
converted to 
0-100 
 
Week 1 
 
 
 
 
 
 
 
 
 
 
-15 (-21·6 
 
 
188 
 
 
 
 
 
 
Week 12 
39 (25·3) 
 
 
40 (25·3) 
206 
 
 
206 
54 (28·7) 
 
 
52 (30·5) 
101 
 
 
101 
to -8·4) 
 
-12 (-18·9 
to -5·1) 
YES 
 
 
YES 
Buynak, 2010 
Oxycodone vs placebo 
Pain 0-10 
converted to 
0-100 
 
1 week 
 
8 weeks 
 
12 weeks 
 
 
60·8 (18·7) 
 
46·2 (17·5) 
 
46·2 (16·4) 
 
 
322 
 
171 
 
145 
 
 
67·6 (17·0) 
 
53·8 (19·0) 
 
55·1 (18·3) 
 
 
313 
 
177 
 
166 
 
 
-6·8 (-9·6 to 
-4·0) 
-7·6 (-11·4 
to -3·8) 
-8·9 (-12·8 
to -5·0) 
 
 
NO 
 
NO 
 
NO 
Webster, 2006 
Oxycodone plus low 
dose naltrexone four 
times daily vs placebo 
Pain 0-10 
converted 0-
100 
 
Week 1 
 
 
 
41 (25·1) 
 
 
 
 
206 
 
 
 
 
54 (28·7) 
 
 
 
 
101 
 
 
 
 
-13 (-19·6 
to -6·4) 
 
 
 
YES 
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Week 12 
 
42 (25·6) 
 
206 
 
52 (30·5) 
 
101 
 
-10 (-16·9 
to -3·1) 
 
YES 
Webster, 2006  
Oxycodone plus low 
dose naltrexone twice 
daily vs placebo 
Pain 0-10 
Converted to 
0-100 
Week 1 
 
 
Week 12 
 
 
42 (25·5) 
 
 
43 (25·5) 
 
 
206 
 
 
206 
 
 
54 (28·7) 
 
 
52 (30·5) 
 
 
101 
 
 
101 
 
 
-12 (-18·6 
to -5·4) 
 
 
-9 (-15·9 to 
-2·1) 
 
 
YES 
 
 
YES 
Webster, 2006 
Oxycodone four times 
daily vs 
oxycodone/naltrexone  
four times daily  
Week 1 
 
 
Week 12  
39 (25·3) 
 
 
40 (25·3) 
206 
 
 
206 
41 (25·1) 
 
 
42 (25·6) 
206 
 
 
206 
-2 (-6·9 to 
2.9) 
 
-2 (-6·9 to 
2.9) 
NO 
 
 
NO 
Webster, 2006 Week 1  39 (25·3) 206 42 (25·5) 206 -3 (-7·9 to NO 
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Oxycodone four times 
daily vs 
oxycodone/naltrexone 
twice daily  
 
 
Week 12  
 
 
40 (25·3) 
 
 
206 
 
 
43 (25·5) 
 
 
206 
1.9) 
 
-3 (-7·9 to 
1.9) 
 
 
NO 
Webster, 2006 
Oxycodone/naltrexone 
four times daily vs 
oxycodone/naltrexone 
twice daily 
Week 1 
 
 
Week 12  
41 (25·1) 
 
 
42 (25·6) 
206 
 
 
206 
42 (25·5) 
 
 
43 (25·5) 
206 
 
 
206 
-1 (-5·9 to 
3·9) 
 
-1 (-5·9 to 
3·9) 
NO 
 
 
NO 
Cloutier, 2013 
Oxycodone/naloxone 
vs placebo 
VAS  
Week 8 
48·6 (23·1) 32 55·9 (25·4) 31 -7·3 (-19·3 
to 4·7) 
NO 
Allan, 2005 
Transdermal fentanyl 
vs morphine  
VAS (at rest) 
7 days  
58·5 (23·9) 338 59·9 (25·9) 342 -1·4 (-5·1 to 
2·3) 
NO 
Allan, 2005 
Transdermal fentanyl 
vs morphine 
VAS (at rest) 
 13 months  
56 (27·6) 338 55·8 (27·7) 342 0·2 (-4·0 to 
4·4) 
NO 
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Buynak, 2010  
Tapendatol vs placebo 
Pain 0-10 
converted to 
0-100 scale 
1 week 
 
8 weeks 
 
12 weeks 
 
 
65·6 (17·0) 
 
47·4 (20·6) 
 
46·4 (19·9) 
 
 
313 
 
201 
 
183 
 
 
67·6 (17·0) 
 
53·8 (19·0) 
 
55·1 (18·3) 
 
 
313 
 
177 
 
166 
 
 
-2 (-4·8 to 
0·6) 
-6·4 (-10·4 
to 2·4) 
-8·7 (-12·7 
to -4·7) 
 
 
NO 
 
NO 
 
NO 
Chu, 2012 
Morphine vs placebo 
VAS mean 
change from 
baseline  
 
1 month 
-21·1 (15·9) 48 -12·5 (19·2) 55 -8·6 (-15·4 
to -1·8) 
NO 
Chu, 2012 
Morphine vs placebo 
Mean change 
RMDQ 
1 month 
-8·4 (12·8) 
 
Original score: 
2·0 (3·1) 
 
48 -2·1 (17·3) 
 
Original 
Score: 0·5 
(4·1) 
55 -6·3 (0·5 to 
12·1) 
NO 
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Khoromi, 2007  
Morphine vs placebo  
NRS at end of 
study  
34 (25) 9 38 (25) 7 -4 (-28·7 to 
20·7) 
NO 
Muscle relaxant trials  
Ralph, 2008 
Carisporodol vs 
placebo  
Note: SD for placebo 
and treatment group 
borrowed from 
baseline 
Day 7 RMDQ 17·1 (20·4) 
 
269 25·8 (20·8)  278 -8·7 (-12·2 
to -5·2) 
NO 
Hindle, 1972 
Carisprodol vs placebo 
Note: SD borrowed 
from nearest study 
(Ralph, 2008) 
0-100 pain 
intensity scale 
Day 4 mean 
change  
-14 (20·4) 14 0 (20·8) 14 -14 (-29·3 
to 1·3 to) 
YES but 
not 
statistically 
significant  
Rollings, 1983 
Carisoprodol vs 
VAS day 7 41 (20·4) 28 46 (20·4) 28 -5·0 (-15·7 
to 5·7) 
NO 
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cyclobenzaprine 
Serfer, 2010  
Carisoprodol 250mg vs 
placebo  
DAY 7  
RMDQ  
 
-22·5 (21·7) 
Original score: 
-5·4 (0·32) SD 
5·2 
 
 
264 
 
-18·3  (21·9) 
Original score: 
-4·4 (0·32) SD 
5·2 
 
 
269 
 
-4·2 (-7·0 to 
-0·5) 
 
NO 
Serfer, 2010  
Carisoprodol 350mg vs 
placebo  
DAY 7  
 
RMDQ 
 
-23·8 (21·3) 
-5·7 (SE: 0·3 
SD 5·1) 
 
 
273 
 
-18·3  (21·9) 
 
269 
 
-5·5 (-9·1 to 
-1·9) 
 
NO 
Serfer, 2010  
Carisoprodol 250mg vs 
carisoprodol 350mg  
DAY 7  
 
RMDQ 
 
-22·5 (21·7) 
 
264 
 
-23·8  (21·3) 
 
273 
 
1·3 (-2·3 to 
4·9) 
 
NO 
Chandanwale, 2011 
Eperisone HCl vs 
Lumbar pain 
VAS Day 7 
36·2 (13·4) 112 52·2 (18·5) 113 -16 (-20·2 
to -11·8) 
YES 
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placebo 
Chandanwale, 2011 
Eperisone HCl vs 
placebo 
Lumbar pain 
VAS day 14  
20·7 (15·1) 112 44·9 (23·0) 113 -24·2 (-29·3 
to -19·1) 
YES 
Rossi, 2012 
Eperisone vs tizanidine  
Eperisone+tramadol vs 
Tizanidine + tramadol 
Note: SD estimated 
from figure 1 of the 
study 
VAS at rest  
Day 5 
 
Day 30 
 
 
63 (12) 
 
22 (11) 
 
30 
 
30 
 
69 (11) 
 
23 (11) 
 
30 
 
30 
 
-6 (-11·8 to 
-0·2) 
-1 (-6·6 to 
4·6) 
 
NO 
 
NO 
Cabitza, 2008 
Thiocolchicoside vs 
eperisone (SD’s 
borrowed from 
Ketenci, 2005 and 
Chandanwale, 2011 
respectively) 
VAS Day 7 41 (11·7)  
 
80 38 (15·1) 
 
80 3 (-1·2 to 
7·2) 
NO 
Pareek, 2009 
Aceclofenac tizanidine 
Day 7 -58·8 (21·4) 94 (duo) -43·5 (20·6) 91 (ace 
alone) 
-15·3 (-21·4 
to -9·2) 
YES 
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vs aceclofenac alone  
Mean change in pain 
intensity (at rest) from 
baseline  
Uberall, 2012 
Flupirtine vs placebo 
Week 4 mean 
change NRS  
-24 (17)  109 -20 (18) 110 -4·0 (-8·6 to 
0·6) 
NO 
Tuzun, 2003 
Thiocolchocoside vs 
placebo 
Day 5 VAS 25·1 (20·9) 73 47·4 (19·8) 68 22·3 (-29·0 
to -15·6) 
YES 
Aksoy, 2002  
Thiocolchicoside + 
standard treatment 
(NSAID) vs standard 
treatment (NSAID) 
alone  
Note: values derived  
from figure 1 of the 
study and borrowed 
from baseline   
VAS  
 
Day 7 
 
Day 31  
 
 
33  
 
17  
 
 
174 
 
174 
 
 
40·5  
 
22  
 
 
155 
 
155 
 
 
-7·5 
p<0·005 
 
-5 p<0·005 
 
 
NO 
 
NO 
Aksoy, 2002  RMDQ       
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Thiocolchicoside + 
standard treatment vs 
standard treatment 
alone 
 
Day 7 
 
 
 
Day 31  
 
7 - original  
29·2 - 
transformed 
 
3 - original 
12·5 - 
transformed 
 
174 
 
 
174 
 
12 -original 
50 - 
transformed 
 
7·5 -original 
31·3 - 
transformed 
 
155 
 
 
155 
 
-20·8 
p<0.001 
 
 
-18·8 
p<0.001 
 
YES 
 
 
YES 
Ketenci, 2005  
Thiocolchicoside vs 
placebo 
DAY 7 VAS  6·3 (11·7) 38 43·7 (27·9) 27 -37·4 (-48·6 
to -26·2) 
YES  
Ketenci, 2005  
Thiocolchicoside vs 
tizanidine  
DAY 7 VAS 6·3 (11·7) 38 18·6 (16·6) 32 -12·3 (-19·1 
to -5·5) 
YES  
Ketenci, 2005  
Tizanidine vs placebo 
DAY 7 VAS 18·6 (16·6) 32 43·7 (27·9) 27 -25 (-37·1 
to -13·1) 
YES 
Berry, 1988   Day 7 VAS 29 (43·3) 51 33 (32·9) 54 -4 (-18·8 to NO 
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Note: We used methods endorsed in the Cochrane Handbook for missing data. We adopted median scores for missing means and used standard deviation (SD) values from baseline (or the most 
similar eligible study) as a substitute for missing SDs. Most studies reported average pain (on the VAS or NRS) at present or within the past 24-hours. We extracted outcomes for average pain (not 
worst or least pain) and where specified, this was pain at rest (not with activity). Two studies which were included reported average pain over the preceding 2 weeks or average pain over the past 
week respectively. We used this same approach for data extraction for disability outcomes for consistency. 
Steiner 2011a: SE from baseline used and converted to SD 
Steiner 2011b: SE converted to SD  
Allan 2005: SD calculated from SE 
Perrot 2006: SD used from baseline 
Cabitza 2008: SD’s for thiocolchicoside and eperisone borrowed from nearest study 
Note with Hale 2005 mean change represented by a positive (+) score as this represents worsening pain in both groups (oxymorphone, oxycodone and placebo). Favourable mean change from 
baseline is represented by a negative (-) outcome value. 
VAS: Visual Analogue Scale; NRS: Numeric rating scale; RMDQ: Roland Morris Disability Questionnaire.
Tizanidine/ibuprofen 
vs placebo/ibuprofen  
 10·8) 
Pipino, 1991 
Pridinol vs 
thiocolchicoside  
VAS 
Day 7 
30 (13·9) 60 30·1 (15·5) 60  -0·1 (-5·4 to 
5·2) 
NO 
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Study Total 
No. 
eligibl
e for 
entry* 
Pre-randomisation Post-randomisation: n (or Trial Proper phase)  Cumulative 
total who 
dropped out N 
(%)  
Total 
No. 
droppe
d out 
(%) 
Reasons for withdrawal: n Total No. 
dropped out 
Reasons for withdrawal: 
Oxymorphone 
Katz, 2007 326 121 
(37·1) 
AE: 59 
LOE: 4 
Loss to follow up: 8 
Other: 50 
87 Placebo: 53/100 
AE: 8 
LOE: 35 
Loss to follow up: 1 
Other: 9 
Oxymorphone: 34/105 
AE: 9 
LOE: 12 
Other: 13 
208 (63·8) 
Table 4. Drop-out rates for opioid trials. Reasons for withdrawal.  
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Hale, 
2005 
330 95 
(28·8) 
 
Oxymorphone 
53/166 
AE: 25 
LOE: 7 
Lost to follow 
up: 1 
Other: 20 
Oxycodone 
42/164 
AE: 26 
LOE: 4 
Lost to 
follow up: 
2 
Other: 10 
96 Placebo: 53/75 
AE: 5 
LOE: 44 
Lost to follow up: 1 
Other: 3 
 
Oxycodone: 21/80 
AE: 4 
LOE: 13 
Other: 4 
Oxymorphone: 
22/80 
AE: 2 
LOE: 16 
Lost to follow up: 1 
Other: 3 
191 (57·9) 
Hale, 
2007 
251 108 
(41·9) 
AE: 47 
LOE: 10 
Lost to follow up: 6 
Other: 45 
76 Placebo: 55/73 
AE: 8 
LOE: 39 
Lost to follow up: 1 
Other : 7 
Oxymorphone: 21/70 
AE: 7 
LOE: 8 
Lost to follow up: 1 
Other : 5 
184 (73·3) 
Tramadol/paracetamol combination 
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Peloso, 
2004 
 
338 N/A N/A 193 Placebo: 112/171 
AE: 13 
LOE: 82 
Other: 17 
Treatment: 81/167 
AE: 47 
LOE: 30 
Other: 4 
193 (57·1) 
Ruoff, 
2003 
322 N/A N/A 157 Placebo: 86/160 
AE: 9 
LOE: 59 
Other: 18 
Treatment: 71/162 
AE: 30 
LOE: 31 
Other: 10 
157 (48·8) 
Oxycodone 
Buynak, 
2010 
981 N/A N/A 530 Placebo: 174/326 
AE: 15 
LOE: 50 
Lost to follow up: 12 
Other: 97 
Oxycodone: 
201/334 
AE: 107 
LOE: 7 
Lost to follow up: 
8 
Other: 79 
Tapentadol: 
155/321 
AE:51 
LOE: 13 
Lost to follow up: 
13 
Other: 78 
530 (54·0) 
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Webster, 
2006 
719 N/A N/A 391 Placebo 59/101 
AE: 5 
LOE: 40 
Other: 14 
Oxycodone qid 
105/206 
AE: 49 
LOE: 15 
Other: 41 
Oxytrex 
qid 
119/206 
AE: 45 
LOE: 22 
Other: 
52 
Oxytrex 
bd 
108/206 
AE: 63 
LOE: 19 
Other: 
26 
391 (54·4) 
Hale, 
2005 (see 
above) 
      
Hydromorphone 
Hale, 
2010 
459 191 
(41·6) 
AE: 60 
LOE: 56 
Loss to follow up: 8 
Other: 67 
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Control: 90/134 
AE: 4 
LOE: 40 
Loss to follow up: 2 
Other: 44 
 
Treatment: 68/134 
AE: 9 
LOE: 16 
Loss to follow up: 3 
Other: 40 
 
349 (76·0) 
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Tramadol 
Schnitzer, 
2000 
380 126 
(33·2) 
AE:78 
LOE: 23 
Other: 25 
108 Control: 72/127 
AE: 6 
LOE: 61 
Other: 5 
Treatment: 36/127 
AE: 5 
LOE: 25 
Other: 6  
234 (61.6) 
Vorsanger
, 2008  
619 233 
(37·6) 
AE: 128 
LOE: 41 
Other: 64 
145 Tramadol 300 mg 
42/128 
AE: 13 
LOE: 13 
Other: 16 
Tramadol 200 mg 
42/129 
AE: 13 
LOE: 11 
Other: 18 
Placebo 61/129 
AE: 18 
LOE: 21 
Other: 22 
378 (61·1) 
BTDS 
Gordon, 
2010 
78 NA NA 29 BTDS 19/39 
AE: 16 
LOE: 1 
Lost to follow up: 1 
Placebo 10/39 
AE: 3 
LOE: 3 
Lost to follow up: 1 
29 (37·2) 
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Other: 1 Other: 3 
Steiner, 
2011b 
1160 498 
(42·9) 
AE: 144 
LOE: 239 
Other: 115 
227 BTDS 5 µg/h: 93/222 
AE: 14 
LOE: 52 
Other: 27 
BTDS 20 5µg/h: 
73/219 
AE: 29 
LOE: 25 
Other: 19 
Oxycodone: 61/221 
AE: 16 
LOE: 16 
Other: 29 
725 (63·0) 
Steiner, 
2011a 
1024 483 
(47·2) 
AE: 239 
LOE: 143 
Other: 101 
170 BTDS: 86/256 
AE: 40 
LOE: 22 
Other: 24 
Placebo: 84/283 
AE: 20 
LOE: 36 
Other:28 
653 (63·8) 
Allan, 
2005 
680 
 
NA NA 339 SRM 177/338 
AE: 125 
Other: 52 
 
TDF 162/342 
AE: 106 
Other: 56 
339 (49·8) 
Perrot, 
2006 
119 NA NA 20 PARA/tramadol: 
8/59 
Tramadol Only: 12/60 20 (16·8) 
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AE: 3 
LOE: 5 
Other: 1 
AE: 8 
Other: 4 
Cloutier, 
2013  
83 NA NA 20 Oxycodone/naloxone
: 9/39 
AE: 6 
Other: 3 
Placebo: 11/44 
AE: 5 
Lost to follow up: 2 
Other: 4 
20 (24·1) 
Uberall, 
2012 
363 NA NA 87 Placebo: 26/122 
AE: 4 
LOE: 2 
Other: 20 
Flupirtine: 28/133 
AE: 4 
LOE: 2 
Other: 22 
Tramadol: 33/118 
AE: 14 
LOE: 1 
Other: 18 
87 (24·0) 
Opioid vs 
placebo 
comparison 
59 (24.6) 
Khoromi, 
2007 
55 NA NA 15 MS Contin 
Other: 6/15 
Nortriptylin
e 
Other: 1/13 
Combination 
Other: 6/13 
Placebo 
Other: 2/14 
15 (27·3) 
Chu, 2012 139 Unclear  36 Morphine: 
21/69 
Placebo: 15/70 36 (25·9) 
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Other: 
21/69 
 
Other: 15/70 
 
*Post screening, reflects the study population who were eligible for entering the run in (pre- randomisation) and/or subsequently the randomisation (or Trial Proper) phase. AE: adverse events; LOE: lack of Efficacy; 
SRM: sustained release morphine; BTDS; buprenorphine transdermal system; PARA: paracetamol; bd: twice a day; qid: four times a day. 
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Study Number randomised 
Number completed 
Reasons for withdrawal (%) completed  
Ralph, 2008 Carisoprodol n=277 
246/277 completed 
 
Placebo   
n=285 
242/246 
completed 
Carisoprodol  
LOE: 8/277 
Other: unclear* 
Placebo 
LOE: 19/285 
Other: Unclear 
87% 
Chandanwale, 2011 
 
 
 
Eperisone 
n=120 
112/120 completed 
 
 
Placebo 
n=120 
113/120 
completed  
 
Eperisone 
Lost to follow up: 2/120 
Other: 6/120 
Placebo 
AE: 1/120 
Lost to follow up: 
3/120 
Other: 3/120 
94% 
Cabitza, 2008 
 
Eperisone 
N=80 
Thiocolchicoside  
N=80 
Eperisone 
Though not withdrawn 
4/80 patients reported 
Thiocolchicoside  
Though not 
withdrawn 17/80 
100% 
Table 5. Drop-out rates for muscle relaxant trials.  
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All completed  All completed  gastrointestinal adverse 
events (nausea, abdominal 
discomfort, vomiting) 
patients reported 
gastrointestinal 
adverse events 
e.g. nausea 
Hindle, 1972 
No adverse effects for 
these groups reported  
Carisoprodol  
N=16 
14/16 completed  
Placebo 
N=16 
14/16 completed  
Carisoprodol 
Lost to follow up: 1/16 
Condition worsened: 1/16  
Carisoprodol 
Lost to follow up: 
1/16 
Condition 
worsened: 1/16 
88% 
Rollings, 1983 Carisoprodol 
n=39 
28/39 completed 
Cyclobenzaprine 
n=39 
30/39 completed  
 
 
Carisoprodol 
AE: 5/39 
Other: 6/39 
Note: 20/39 patients 
reported CNS effects: 16/39 
drowsy, 10/39 dizziness, 
3/39 headache, 1/39 
irritable. 
3/39 patients reported GI 
effects (1 nausea/vomiting, 
1 constipation and 1     
Cyclobenzaprine  
AE: 3/39 
Other: 7/39 
Note: 21 patients 
reported CNS 
effects: 15 
drowsy, 2 tired, 3 
dizziness, 1 
headache, 1 
blackout, 1 
apprehensive, 1 
74% 
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diarrhoea) and 10/39 
patients reported 
autonomic adverse events 
3 paraesthesia, 4 dry 
mouth, 1 urinary frequency 
and 2 sweating) 
insomnia, 2 
nervousness. 
15 patients 
experienced 
autonomic SE: 14 
dry mouth and 1 
hot/cold flushes 
and 5 cases of GI 
SE: 2 nausea, 3 
constipation 
Tuzun, 2003 Thiocolchicoside 
n=77  
73/77 completed  
Placebo 
n=72 
64/72 completed  
Thiocolchicoside 
Protocol violation: 3/77 
LOE: 1/77 
 
Placebo 
Protocol violation: 
3/72 
LOE: 5/72 
92% 
Rossi, 2012 Group E (eperisone + 
tramadol) 
N=30 
All completed  
Group T 
(tizanidine + 
tramadol) 
N=30 
All completed  
N=30 
Note: treatment was 
stopped in 5 patients. No 
mention these patients 
were withdrawn. 
N=30 
Note: treatment 
was stopped in 9 
patients. No 
mention these 
patients were 
100% 
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AE: 
Tremor: 1/25 
Somnolence: 2/25 
Nausea, vomiting and 
dizziness: 2/25 
withdrawn. 
AE: 
Somnolence: 7/21 
Dizziness: 2/21 
Pareek, 2009  
Note: 24 patients 
reported 4 adverse 
events  
 
 
Vomiting 
Dizziness 
Dyspepsia 
Drowsiness 
Aceclofenac/tizanidine  
N=101 
94/101 completed  
 
 
5/101 
5/101 
0/101 
2/101 
Aceclofenac alone 
N=96 
 
91/96 completed 
 
7/98 
4/96 
1/96 
0/96 
Aceclofenac/tizanidine 
Lost to follow up: 4/101 
Other: 3/101 
 
Aceclofenac alone 
Lost to follow up: 
4/96 
Other: 1/96 
94% 
Aksoy, 2002 Standard treatment Standard 
treatment + 
Standard treatment Standard 100% 
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N=155 
All completed  
 
  
Thiocolchicoside 
N=174 
All completed  
 
AE: (not withdrawn) 
Gastrointestinal: 5/155 
Irritability: 1/155 
treatment + TCC 
AE: (not 
withdrawn) 
Gastrointestinal: 
10/174 
Irritability: 1/174 
Serfer, 2010 
 
 
 
Carisoprodol 
350mg  
N=281 
239/281 
completed  
 
Carisoprodol 
250mg 
N=271  
245/271 
completed  
 
 
Placebo  
N=276 
228/276 
completed  
Carisoprodol 
350mg  
AE: 15/281 
LOE: 7/281 
Lost to 
follow up: 
11/281 
Other: 
9/281 
Carisoprodol 
250mg 
AE: 3/271 
LOE: 2/271 
Lost to 
follow up: 
10/271 
Other: 
11/271 
 
Placebo  
AE: 10/276 
LOE: 20/276 
Lost to follow up: 
12/276 
Other: 6/276 
86% 
Berry, 1988 Tizanidine/ibuprofen Placebo/ibuprofen Tizanidine/ibuprofen Placebo/ibuprofen 89.5% 
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N=51 
46/51 completed  
N=54  
53/54 completed  
N=46 
AE: 5/51  
 
N=53 
AE: 1/54 
 
*Rossi, 2012: mentions that treatment was stopped due to adverse events in five patients from Group E and nine patients form Group T but does not mention these patients were withdrawn from the study. 
**Ralph, 2008: Between placebo and carisoprodol groups 13 withdrew due to adverse events, 13 withdrew consent, 11 were lost to follow up, three had protocol violations and seven discontinued due to other 
reasons. 
Berry, 1988: Reports that five patients were cured before the end of treatment, two in tizanidine/ibuprofen group and three in placebo/ibuprofen group however these patients were not withdrawn from the study. 
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Table 6. Morphine equivalent dose conversion for opioid analgesic medicines evaluated in this review. 
Study Drug (comparison group in main text) 
Morphine equivalent dose 
mg/day (Boudreau, 2009) 
Vorsanger, 2008 
tramadol 200mg/d (a) 
tramadol 300mg/d (b) 
40 
60 
Ruoff, 2003 tramadol 157·5mg/d  31·5 
Hale, 2010 hydromorphone 12-64 mg/d 48-256 (median dose 152 mg) 
Steiner, 2011a 
buprenorphine (transdermal administration) 10 or 20 ug/h 
over 7 days  36  
Gordon, 2010 
buprenorphine (transdermal administration) 29.8ug/h (7 
days) 60  
Hale, 2005 
oxymorphone 79·4 mg/day (b) 
oxycodone CR 155mg/day (a) 
238·2 
232·5 
Webster, 2006 
oxycodone/naltrexone (oxycodone) four times daily dosing  
34.5 mg/day (b) 51·75 
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Oxycodone/naltrexone (oxycodone) twice daily dosing  
34·7 mg/day (a) 
Oxycodone 39 mg/day (c) 
52·05 
58·5 
Allan, 2005 
SRM (sustained release morphine) 60-80 mg/day 
TDF (transdermal fentanyl) 25-50 ug/h 
60-80 
60-120 
Perrot, 2006 
Paracetamol + 
tramadol 172·5 mg/d 
tramadol 227·3 mg/d 
9·32 
11·94 
Hale, 2007 oxymorphone 80·9 mg/d 242·7 
Buynak, 2010 
tapentadol 313·2 mg/d (b) 
oxycodone 53 mg/d (a) 
114·94 
79·5 
Chu, 2012 morphine 78·3 mg/d 78·3 
Cloutier, 2013 
oxycodone 36·5 mg/d 
18.2 mg/d naloxone (opioid antagonist NA) 
54·75 
NA 
Steiner, 2011b oxycodone 40 mg/day 60 
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*Buprenorhpine 5 ug/h 
 
 
*Buprenorhpine 20 ug/h 
 Peloso, 2004  tramadol 158 mg/day + paracetamol 1369 mg/day 31·6 
Uberall, 2012  tramadol 200 mg/d 40 
Khoromi, 2007 morphine 62 mg/d 62 
Katz, 2007 oxymorphone 39·2 mg/d  117·6 
Note: The dose equivalence of transdermal buprenorphine and oral morphine is unclear. Dose conversions for buprenorphine listed here are based on those suggested by the manufacturer i.e. dose range covered 
by the three patch strengths may be equivalent to oral morphine up to 90 mg/day. Other literature suggests higher strength patches i.e. Buprenorphine 20 ug per hour patch might be equivalent to oral morphine up 
to 36mg/day or 53 mg/day (NPS: Rational Assessment of Drugs and Research, 2005; Munidphara, Norspan: pre-subcommittee response 2005; Sittl et al., 2005; Opiate Conversion Doses, 2010. 
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Table 7. Adverse event rates. Opioid analgesic vs placebo and muscle relaxant vs placebo trials. 
Study  
 
Length of  
treatment  
Treatment and  
dose* 
 
Morphine 
equivalent 
dose 
(mg/d) 
TER: Treatment Event Rate; PER: Placebo Event Rate   
Risk Ratio (p-value)  
Constipation Nausea Dizziness Headache Vomiting Pruritus Somnolence Dry mouth 
Buynak, 2010 12 weeks Tapentadol 
313·2 mg daily 
 
114·9 TER: 0·14 
(44/318) 
PER: 0·12 
(16/319) 
2·8 (<0·01) 
TER: 0·20 
(64/319) 
PER: 0·09 
(29/319) 
2·2 (<0·01) 
TER: 0·12 
(38/318) 
PER: 0·06 
(18/319) 
2·1 (<0·01) 
TER: 0·20 
(63/318) 
PER: 0·14 
(44/319) 
1·4 (0·04) 
TER: 0·09 
(29/328) 
PER: 0·02 
(5/319) 
5·8 (<0·01) 
TER: 0·07 
(23/318) 
PER: 0·02 
(6/319) 
3·8 (<0·01) 
TER: 0·13 
(42/318) 
PER: 0·03 
(8/319) 
5·3 (<0·01) 
TER: 0·04 
(12/328) 
PER: 0·02 
(7/319) 
3·7 (<0·01) 
Buynak, 2010  12 weeks Oxycodone 53·0 
mg daily 
 
79·5 TER: 0·27 
(88/328) 
PER: 0·12 
(16/319) 
5·4 (<0.01) 
TER: 0·34 
(113/328) 
PER: 0·09 
(29/319) 
3·8 (<0.01) 
TER: 0·17 
(56/328) 
PER: 0·06 
(18/319) 
3·0 (<0.01) 
TER: 0·17 
(55/328) 
PER: 0·14 
(44/319) 
1·2 (0·3) 
TER: 0·20 
(63/328) 
PER: 0·02 
(5/319) 
12·2 (<0·01) 
TER: 0·17 
(55/328)  
PER: 0·02 
(6/319) 
8·9 (<0·01) 
TER: 0·16 
(53/328) 
PER: 0·03 
(8/319) 
6·4 (<0·01) 
TER: 0·04 
(12/328) 
PER: 0·02 
(7/319) 
1·7 (0·3) 
Chu, 2012  4 weeks Morphine 78·3 
mg daily 
78·3 TER: 0·10 
(5/48) 
PER: 0·02 
TER: 0·08 
(4/48) 
PER: 0 
NA NA NA TER: 0·02 
(1/48) 
PER: 0 
NA TER: 0 (0/48) 
PER: 0·02 (1/55) 
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 (1/55) 
5·8 (0·07) 
(0/55) 
10·3 (0·05) 
(0/55) 
3·4 (0·45) 
0·34 (0·48) 
Cloutier, 2013 8 weeks Oxycodone 36·5 
mg daily 
(+naloxone) 
54·8 TER: 0·08 
(6/74) 
PER: 0·03 
(2/77) 
3·12 (0·13) 
TER: 0·12 
(9/74) 
PER: 0·12 
(9/77) 
1·04 (0·93) 
TER: 0·04 
(3/74) 
PER: 0·03 
(2/77) 
1·6 (0·62) 
NA TER: 0·05 
(4/74) 
PER: 0·04 
(3/77) 
1·4 (0·66) 
NA TER: 0·05 
(4/74) 
PER: 0 (0/77) 
9·4 (0·06) 
TER: 0·04 (3/74) 
PER: 0·05 (4/77) 
0·8 (0.70) 
Gordon, 2010 8 weeks Transdermal 
Buprenorphine 
29.8 ug/h once 
weekly 
60·0 TER: 0·16 
(12/73)  
PER: 0·06 
(4/68) 
2·8 (0·04) 
TER: 0·53 
(39/73) 
PER: 0·18 
(12/68) 
3·03 
(<0.01) 
 
TER: 0·33 
(24/73) 
PER: 0·04 
(3/68) 
7·5 (<0.01) 
TER: 0·12 
(9/73) 
PER: 0·04 
(3/68) 
2·8 (0·08) 
TER: 0·22 
(16/73) 
PER: 0·04 
(3/68) 
5·0 (<0·01) 
 
TER: 0·23 
(17/73) 
PER: 0·21 
(14/66) 
1·13 (0·70) 
TER: 0·22 
(16/73) 
PER: 0·07 
(5/68) 
3·0 (0·01) 
TER: 0·18 
(13/73) 
PER: 0 (0/68) 
25·2 (<0·01) 
Hale, 2010  
 
12 weeks Hydromorphone 
12·0-64·0 mg 
daily 
152·0 
(median 
dose) 
TER: 0·07 
(10/134) 
PER: 0·04 
(5/134) 
TER: 0·09 
(12/134) 
PER: 0·07 
(10/134) 
NA TER: 0·05 
(7/134) 
PER: 0·07 
(10/134) 
TER: 0·06 
(8/134) 
PER: 0·04 
(6/134) 
NA TER: 0·0075 
(1/134) 
PER: 0 
(0/134) 
NA 
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2 (0·20) 1·2 (0·70) 0·7 (0·50) 1·3 (0·60) 3·0 (0·50) 
Hale, 2005  18 days Oxymorphone 
79·4 mg daily 
 
238·2 TER: 0·35 
(39/110) 
PER: 0·11 
(12/108) 
3·2 (<0·01) 
NA NA NA NA NA NA NA 
Hale, 2007 18 days Oxycodone 
155·0  mg daily 
 
232·5 TER: 0·29 
(32/111) 
PER: 0·11 
(12/108) 
2·6 (0·01) 
NA NA NA NA NA NA NA 
Hale, 2007  12 weeks Oxymorphone 
80·9 mg daily 
 
242·7 TER: 0·06 
(4/70) 
PER: 0·01 
(1/72) 
4·1 (0·16) 
TER: 0·03 
(2/70) 
PER: 0·01 
(1/72) 
2·1 (0·50) 
NA TER: 0·03 
(2/70) 
PER: 0 
(0/72) 
5·1 (0·23) 
TER: 0 
(0/70) 
PER: 0.01 
(1/72) 
0·34 (0.50) 
TER: 0·01 
(1/70) 
PER: 0 
(0/72) 
3·1 (0.50) 
TER: 0·03 
(2/70) 
PER: 0 (0/72) 
5·1 (0.20) 
NA 
Katz, 2007  12 weeks Oxymorphone  
39·2 mg daily  
117·6 TER: 0·07 
(7/105) 
TER: 0·11 
(12/105) 
TER: 0·05 
(5/105) 
TER: 0·04 
(4/105) 
TER: 0·08 
(8/105) 
TER: 0·03 
(3/105) 
TER: 0·02 
(2/105) 
NA 
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 PER: 0·01 
(1/100) 
6·7 (0·03) 
PER: 0·09 
(9/100) 
1·3 (0·60) 
PER: 0·03 
(3/100) 
1·6 (0·50) 
PER: 0·02 
(2/100) 
1·9 (0·40) 
PER: 0·01 
(1/100) 
7·6 (0·02) 
PER: 0·01 
(1/100) 
2·9 (0·30) 
PER: 0 
(0/100) 
4·8 (0·20) 
Peloso, 2004 91 days Tramadol 158·0 
mg daily 
(+paracetamol)  
15·8 TER: 0·10 
(17/167) 
PER: 0·01 
(2/169) 
8·6 (<0.01) 
TER: 0·12 
(20/167) 
PER: 0·02 
(3/169) 
6·7 (<0·01) 
TER: 0·11 
(18/167) 
PER: 0·006 
(1/169) 
18·2 
(<0·01) 
TER: 0·07 
(11/167) 
PER: 0·04 
(7/169) 
1·6 (0·30) 
TER: 0·06 
(10/167) 
PER: 0 
(0/169) 
21·3 (0·01) 
NA TER: 0·09 
(15/167) 
PER: 0·02 
(3/169) 
5·1 (<0·01) 
TER: 0.07 
(11/167) 
PER: 0 (0/169) 
23·3 (<0·01) 
Ruoff, 2003 91 days Tramadol 157·5 
mg daily 
(+paracetamol) 
31·5 TER: 0·11 
(18/161) 
PER: 0·05 
(8/157) 
2·2 (0.10) 
TER: 0·13 
(21/161) 
PER: 0·03 
(5/157) 
4·1 (<0·01) 
TER: 0·07 
(12/161) 
PER: 0·02 
(3/157) 
3·9 (0.02) 
TER: 0·09 
(14/161) 
PER: 0·04 
(6/157) 
2·3 (0.07) 
NA TER: 0·07 
(11/161) 
PER: 0·01 
(2/157) 
5·4 (0.01) 
TER: 0·08 
(13/161) 
PER: 0·006 
(1/157) 
12·7 (<0·01) 
NA 
Schnitzer, 
2000  
4 weeks Tramadol 242·0 
mg daily 
48·5 NA TER: 
11/127 
PER: 3/127 
3·67 (0·04) 
NA TER: 6/127 
PER: 4/127 
1·50 (0·52) 
NA NA NA NA 
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Steiner, 
2011a  
12 weeks Transdermal 
Buprenorphine 
10-20 ug/h once 
weekly 
36·0 TER: 0·04 
(9/256) 
PER: 0·01 
(3/283) 
3·3 (0·06) 
TER: 0·13 
(32/256) 
PER: 0·11 
(31/283) 
1·14 (0·60) 
TER: 0·04 
(10/256) 
PER: 0·01 
(3/283) 
3·7 (0·04) 
TER: 0·05 
(14/256) 
PER: 0·05 
(14/283) 
1·1 (0·80) 
TER: 0·04 
(11/256) 
PER: 0·02 
(5/283) 
2·4 (0·09) 
TER: 0·04 
(11/256) 
PER: 0·07 
(19/283) 
0·64 (0·20) 
TER: 0·02 
(4/256) 
PER: 0·02 
(6/283) 
0·7 (0·60) 
NA 
Uberall, 2012  6 weeks Tramadol 200·0 
mg daily 
 
20·0 TER: 0.04 
(5/116) 
PER: 0·03 
(3/120) 
2·6 (0·23) 
TER: 0·19 
(22/116) 
PER: 0·03 
(3/120) 
7·6 (<0·01) 
TER: 0·13 
(15/116) 
PER: 0·03 
(4/120) 
3·9 (<0.01) 
TER: 0·03 
(4/116) 
PER: 0·02 
(2/120) 
2·1 (0.40) 
TER: 0·11 
(13/116) 
PER: 0·008 
(1/120) 
13·4 (<0.01) 
NA 
 
NA TER: 0·02 
(2/116) 
PER: 0·02 
(2/120) 
1·03 (1·0) 
Vorsanger, 
2008 
 
12 weeks Tramadol 200·0 
mg daily 
 
20·0 TER: 0.05 
(7/129) 
PER: 0·008 
(1/129) 
7 (0·03) 
TER: 0·08 
(10/129) 
PER: 0·07 
(9/129) 
1·1 (0·81) 
TER: 0·10 
(13/129) 
PER: 0·09 
(12/129) 
1·08 (0·83) 
TER: 0·12  
(15/129) 
PER: 0·11 
(14/129) 
1·07 (0·84) 
NA NA NA NA 
Vorsanger, 
2008  
 
12 weeks Tramadol 300·0 
mg daily 
 
30·0 TER: 0·15 
(19/128) 
PER: 0·008 
TER: 0·19 
(25/128) 
PER: 0·07 
TER: 0·14 
(18/128) 
PER: 0·09 
TER: 0·14 
(19/128) 
PER: 0·11 
NA NA NA NA 
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(1/129) 
19·15 (<0·01) 
(9/129) 
2·80 
(<0·01) 
(12/129) 
1·51 (0·23) 
(15/129) 
1·28 (0·45) 
Muscle Relaxant vs Placebo Trials  Drowsiness Nausea Dizziness Headache Abdominal 
Pain 
Malaise Heartburn Diarrhoea 
Chandanwale, 
2011 
2 weeks Eperisone 50·0 
mg three time 
daily 
N/A NA TER: 0·02 
(2/112) 
PER: 0·03 
(3/113) 
0·67 (0.66) 
TER: 0·009 
(1/112) 
PER: 0 
(0/113) 
3·03 (0.47) 
TER: 0·009 
(1/112) 
PER: 0 
(0/113)  
3·03 (0.47) 
TER: 0 
(0/112) 
PER: 0·03 
(3/113) 
0·14 (0.13) 
TER: 0·009 
(1/112) 
PER: 0·009 
(1/113) 
1·01 (1.0) 
 
NA 
 
NA 
Ralph, 2008 1 week Carisoprodol 
250·0 mg once 
daily 
N/A TER: 0·14 
(37/277) 
PER: 0·05 
(13/285) 
2·93 (<0·01) 
 
NA 
TER: 0·10 
(27/277) 
PER: 0·03 
(9/285) 
3·09 (0·01) 
TER: 0·04 
(10/277) 
PER: 0·01 
(4/285) 
2·57 (0.09) 
 
NA 
 
NA 
 
NA 
 
NA 
Serfer, 2010 1 week Carisoprodol 
250·0 mg four 
times daily 
N/A TER: 0·12 
(33/279) 
PER: 0.07 
TER: 0·01 
(4/279) 
PER: 0·03 
TER: 0·06 
(16/279) 
PER: 0·007 
TER: 0·06 
(16/279) 
PER: 0·03 
 
NA 
 
NA 
 
NA 
 
NA 
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(18/276) 
1·81 (0.03) 
(7/276) 
0·57 (0.35) 
(2/276) 
7·91 
(<0·01) 
(7/276) 
2·26 (0·57) 
Serfer, 2010 1 week Carisoprodol 
350·0 mg four 
times daily  
N/A TER: 0·16 
(45/279) 
PER: 0·07 
(18/276) 
0·22 (<0.01) 
TER: 0·04 
(12/279) 
PER: 0·03 
(7/276) 
1·70 (0.25) 
TER: 0·07 
(19/279) 
PER: 0·007 
(2/276) 
9·40 
(<0.01) 
TER: 0·03 
(9/279) 
PER: 0·03 
(7/276) 
1·27 (0.63) 
 
NA 
 
NA 
 
NA 
 
NA 
Tuzun, 2003 5 days Thiocolchicoside  
IM 4·0 mg twice 
daily 
N/A NA TER: 0·01 
(1/73) 
PER: 0·02 
(1/64) 
0·88 (0·93) 
TER: 0 
(0/73) 
PER: 0·02 
(1/64) 
0·29 (0·46) 
 
NA 
 
NA 
 
NA 
TER: 0·01 
(1/73) 
PER: 0·02 
(1/64) 
0·88 (0·93) 
TER: 0·03 (2/73) 
PER: 0 (0/64) 
4·4 (0·25) 
Uberall, 2012 6 weeks Flupirtine 400·0 
mg once daily  
 
N/A NA TER: 0·017 
(2/119) 
PER: 0·03 
(3/120) 
TER: 0·06 
(7/119) 
PER: 0·03 
(4/120) 
TER: 0·008 
(1/119) 
PER:0·017 
(2/120) 
TER: 0·017 
(2/119) 
PER: 0·05 
(6/120) 
 
NA 
 
NA 
 
NA 
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*Mean dose during treatment phase. Note: Adverse events reported by > one third of studies investigating placebo vs opioid analgesic studies are presented. IM – intramuscular administration.  
Note: Univariate analysis showed no significant effect of morphine equivalent dose or study duration on treatment event rate (TER) across studies (p>0.05 for all comparisons).  
Morphine equivalent doses derived from Boudreau et al., 2009 in citation list. Also see Online Appendix Table five for complete list of morphine equivalents. 
 
 
 
 
 
 
 
 
 
 
 
 
0·67 (0·66) 1·76 (0·35) 0.50 (0·57) 0·34 (0·15) 
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Table 8. Adverse event rates. Number (%) of participants with adverse events in placebo controlled studies of opioid analgesics and muscle 
relaxants. 
Study Run-in phase-active drug RCT phase-placebo (%) RCT Phase-active drug 
Opioid analgesic trials 
Buynak, 2010  190/319 (59·6%) Tapentadol: 
240/318 (75·5%) 
Oxycodone: 
278/328 (84.5%) 
Cloutier, 2013  Unclear Unclear  
Gordon, 2010  Unclear Unclear  
Note: This crossover study report that 58/65 
(89.2%) in placebo group and 72/73 (98.6%) 
in treatment (buprenorphine) group 
experienced at least one adverse event. 
 
Hale, 2010  73/134 (54·5%) Hydromorphone: 64/134 (47·8%)  
Hale, 2005  Unclear Unclear 
“During the treatment phase, approximately 
half the patients reported opioid-associated 
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side effects, including those assigned to 
placebo group.” 
Hale, 2007 “During the open-label titration period, 174 
(70·0%) patients reported adverse events.” 
Unclear Unclear 
Katz, 2007 224/325 (68·9%) patients experienced at least 
on adverse event  
44/100 (44·0%) Oxymorphone: 61/105 (58·1%) 
Ruoff, 2003  73/157 (46·5%) Tramadol/paracetamol: 111/161 (68·9%) 
Steiner, 2011a   146/283 (51·6%)  Buprenorphine: 140/256 (54·7%) 
Uberall, 2012  44/120 (36·7%) Tramadol: 98/116 (84·5%) 
Vorsanger, 2008 499/619 (80·6%) had adverse events during 
the run in period 
Unclear Unclear 
Muscle Relaxant trials    
Chandanwale, 2011 51/225 (22·7%) 29/113 (25·7%) Eperisone: 22/112 (19·6%) 
Ralph, 2008 100/561 (17·8%) reported drowsiness +/- 
dizziness +/- headache 
Unclear 
26/284 (9·2%) cases of drowsiness 
+/- dizziness +/- headache 
Unclear 
Carisoprodol: 74/277 (26·7%) cases of 
drowsiness +/- dizziness +/- headache 
Tuzun, 2003 8/137 (5·8%) 4/64 (6·3%) Thiocolchicoside: 4/73 (5·5%) 
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Uberall, 2012 89/239 (37·2%) 44/120 (36·7%) Flupirtine: 45/119 (37·8%) 
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Table 9. Main effect sizes and grading of evidence. 
Outcome Condition Drug Class  Time period  MD [95% CI] GRADE Level 
of evidence  
Comments 
Pain Chronic 
LBP 
Opioid analgesics Short term  -10·6 [-13·5, -
7·7] 
Moderate  Downgraded for publication bias  
Pain Chronic 
LBP 
Opioid analgesics Intermediate 
term 
-9·2 [-11·7, -
6·7]. 
High NA 
Pain Acute 
LBP 
Muscle relaxants Short term  -21·3, [-29·0, -
13·5]; 
High NA 
Pain Chronic 
LBP 
Muscle relaxants Short term -4 [-8.6, 0.6]. Very Low Single study of flupirtine (Uberall, 2012) 
downgraded for imprecision, 
inconsistency and publication bias. 
Disability  Acute 
LBP 
Muscle relaxants Short term  -18·8 p<0·001 Very Low 
quality 
Single study of thiocolchicoside (Aksoy, 
2002) downgraded for inconsistency, low 
Pedro rating and publication bias.  
Disability Acute 
LBP 
Muscle relaxants Short term  -6·5 [-10·9, -
2·1] and -7·2 [-
10·3, -4·0] 
Moderate  Downgraded for publication bias (2 
studies: Ralph, 2008 and Serfer, 2010) 
Disability  Chronic Combination opioid analgesic Intermediate  MD -3·7 [-11·8, Very Low Single study (Ruoff, 2003) of 
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LBP medicines containing a simple 
analgesic 
4·4], Tramadol/paracetamol downgraded for 
imprecision, inconsistency and 
publication bias  
Disability Chronic 
LBP 
Opioid analgesic  Short -6·3 [0·5, 12·1], Very Low Single study of morphine (Chu, 2012) 
downgraded for imprecision, 
inconsistency and publication bias  
Sensitivity 
analysis  
      
Pain Chronic 
LBP 
Combination opioid analgesic 
medicines containing an opioid 
antagonist (agonist/antagonist) 
Short term MD -11·1 [-
17·3, -4·9] 
Moderate Two studies ( Webster, 2006 and 
Cloutier, 2013) downgraded for 
publication bias  
Pain Chronic 
LBP 
Combination opioid analgesic 
medicines containing an opioid 
antagonist (agonist/antagonist) 
Intermediate 
term 
-9·5 [-17·2, -
1·8].   
Low Single study (Webster, 2006) 
downgraded for inconsistency and 
publication bias 
Pain Chronic 
LBP 
Combination opioid analgesic 
medicines containing a simple 
analgesic 
Intermediate 
term  
-11·9 [-19·3, -
4·4], 
Moderate Two studies (Ruoff, 2003 and Peloso, 
2004) Downgraded for publication bias  
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Table 10. Over The Counter (OTC) availability of NSAIDs included in this review in selected countries. 
NSAID Argentina Australia Belgium Canada Chile China Japan Korea Mexico NZ Philippines  Singapore  UK USA 
Diclofenac 
(oral) 
✔ ✔1 __ __ __ ✔ __ ✔ ✔ ✔ __ __ __ __ 
Diclofenac 
(topical) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ __ ✔ ✔ __ 
Ibuprofen 
(oral)2 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Ibuprofen 
(topical)  
✔ ✔ Not 
registered 
✔ ✔ ✔ ✔ ✔ __ ✔ ✔ ✔ ✔ __ 
Indomethacin 
(topical) 
__ __3 __ __ __ ✔ ✔ ✔ Not 
registered 
✔ __ Not 
registered 
Not 
registered 
__ 
Mefenamic 
Acid  
Not 
registered 
✔ __ __ __ __ __ ✔ __ ✔ ✔ __ __ __ 
Naproxen 
(oral) 
✔ ✔ __ ✔ ✔ ✔ __ ✔ ✔ ✔ __ ✔ ✔ ✔ 
Piroxicam 
(topical) 
✔ ✔ ✔ __ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ __ 
In Australia, Pharmacy Only medicine in dose units 12.5 mg or less, Pharmacist Only Medicine in dose units 25 mg or less. Available in dose units 12.5 mg or less in all other countries. 
In most countries, ibuprofen in dose units 200 mg or less (restricted pack sizes) available OTC. In Australia, ibuprofen in 400 mg as a single dose unit was made available transiently as a Pharmacist Only/ S3 Medicine 
(2011-early 2013).  
Indomethacin 1% or less in a spray form not widely available. 
Note: this information has been derived from World Self Medication Industry: Tables of OTC ingredients: accessed from: http://www.wsmi.org/otc.htm 
This information was current at the time it was accessed (August 2011 - March 2012) however is subject to change.
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Table 11. Search Strategy ONE (OVID resources: MEDLINE, AMED, CENTRAL, 
PsycINFO, Cochrane database of Systematic Reviews). 
Terms 
 
Searches MEDLINE Results 
Study types 1.         REVIEW, ACADEMIC.pt. OR REVIEW, TUTORIAL.pt. OR     META–
ANALYSIS.pt. OR META–ANALYSIS.sh. OR systematic$ adj25 review$ OR 
systematic$ adj25 overview$ OR meta-analy$ or metaanaly$ or (meta analy$) 
OR Randomized controlled trial.pt OR controlled clinical trial.pt or randomized 
controlled trials.mp OR controlled clinical trials.mp OR random allocation.sh OR 
double-blind method.sh OR single-blind method.sh OR clinical trial.pt OR exp 
clinical trial/ OR clin$ adj25 trial$.tw OR (singl$ or doubl$) adj25 (blind$ or 
mas$).tw OR placebos.sh OR placebo$.tw OR random$.tw OR research 
design.sh OR comparative study.sh OR exp evaluation studies/ OR follow-up 
studies.sh OR prospective studies.sh OR cross-over studies.sh OR (control$ or 
prospective$ or volunteer$).tw 
 
4763383 
 2. 
ANIMAL/ not HUMAN/ 
 
 3. 
1 NOT 2 
3767346 
Low back pain  4. 
Low back pain.sh OR low back ach$.tw OR lumbago.mp OR (low$ adj25 back 
pain).tw OR (low$ adj25 back ach$).tw OR low back strain.tw OR low$ back 
pain$.tw OR (simpl$ adj25 low$ back pain).mp. OR (mechanic$ adj25 low$ back 
pain).mp OR (non-specific adj25 low$ back pain).mp. backache.mp OR back 
pain.sh OR back pain.mp OR  exp "sprains and strains"/ and exp SPINE/ OR exp 
Intervertebral Disk Displacement/ OR Intervertebral Disk Displacement.mp OR 
back pain.tw OR  simple back pain.tw OR  low back syndrome.tw OR low back 
dysfunction.tw OR non-specific back pain.tw OR lumbar pain.tw 
 
 
48054 
 5. 
3 and 4  
16795 
Paracetamol 6. 
Acetaminophen.sh OR paracetamol.mp OR paracetamol$.tw 
14818 
 
NSAID’s 
 
Aspirin 
 
Ibuprofen 
 
Diclofenac 
 
Mefenamic acid 
 
7.          
Anti-Inflammatory Agents, Non-Steroidal.sh OR NSAID.mp  
 
Aspirin.sh OR acetylsalicylic acid.tw  
 
Ibuprofen.sh  
 
Diclofenac.sh OR voltaren.mp  
 
Mefenamic acid.sh OR ponstan.mp  
 
90002 
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Naproxen 
 
Piroxicam 
 
Ketoprofen  
Naproxen.sh OR methoxypropiocin.mp  
 
Piroxicam.sh OR feldene.mp  
 
Ketoprofen.sh OR orudis.mp OR benzoylhydratropic acid.mp  
 
Topically applied dose 
forms 
 
 
 
 
 
 
 
Methyl salicylate  
 
Menthol 
 
Tea tree oil  
 
Eucalyptus oil 
 
Olive oil  
 
Peppermint oil 
 
Arnica 
 
Camphor  
 
 
Lignocaine  
9.  
            Administration, Topical.sh OR (topical$ adj25 drug admin$).mp. 
            OR (topical$ adj25 application$).mp OR top$ drug admin$.tw. 
OR topical$ admin$.tw OR topical$ cream$.tw. OR topical$      gel$.tw OR 
topical$ rub$.tw OR topical$ oint$.tw OR ointments.sh OR liniments.sh OR 
rub$.mp OR gels.sh OR patch$.mp OR top$ salicylate$.mp OR topical 
NSAID$.tw. OR irritants.sh OR rubefacient$.mp OR counter-irritant$.tw OR 
counterirritant$.tw 
 
Methyl salicylate$.tw OR salicylates.sh OR oil of wintergreen.mp  
 
Menthol.sh 
 
“Tea tree oil”.sh OR melaleuca alternifolia oil.mp 
 
Eucalyptus.sh OR Eucalyptus oil.mp 
 
Olive oil.mp 
 
Peppermint oil.mp 
 
Arnica.sh  
 
Camphor.sh OR  Cinnamomum camphora.tw OR vicks.mp OR vicks*.tw OR vicks 
vaporub*.tw 
 
Lidocaine.sh OR lignocaine.tw OR lignocaine patch$.tw OR lidoderm.mp 
258439 
 
Complementary 
Alternative medicines  
 
 
 
Glucosamine  
 
Chondroitin  
 
Omega 3 fatty acids  
 
Fish Oil 
 
Flaxseed Oil 
10. 
            Complementary Therapies.sh OR (complement$ adj5   medicine$).tw. 
OR (alternative$ medicine$).tw OR CAM OR (complement$ alternative$ 
medicine$).tw OR (complement$ adj5 drug$).tw OR (alternative$ adj5 
medicine$).tw OR (alternative$ adj5 drug$).tw. 
 
Glucosamine.sh OR (glucosamine sul?ate).tw  
 
Chondroitin.sh 
 
Fatty acids, omega-3.sh  
 
Fish oils.sh OR Fish oil$.tw 
 
linseed oil.sh OR flaxseed oil.mp 
47062 
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Lyprinol  
 
Methylsulfonylmethane 
 
(Green lip$ mussel extract).tw OR  lyprinol.tw 
 
Methylsulfonylmethane.tw OR MSM.tw 
 
Herbal medicines  
 
Devil’s claw 
 
Willow bark 
 
Capsaicin 
 
Turmeric 
 
Valerian  
 
Horse Chestnut 
 
 
Dong Quai 
 
 
Fever-few 
 
Ginger  
 
Garlic  
 
St John’s Wort  
11. 
Herbal medicine.sh OR (herb$ adj5 medicine$).tw  
 
(Devil$ adj5 claw$).tw OR harpagophytum.sh  
 
            Willow$ bark.tw. OR Salix alba.tw 
 
Capsaicin.sh OR Capsicum frutescen$.tw OR zostrix.tw  
 
Curcuma.sh OR turmeric.sh  
 
Valerian.sh OR valerian$ officinal$.tw 
 
Aesculus.sh OR Horse chestnut.tw OR Aesculus hippocast$.tw  OR Aesculus 
hippocastanum*.tw 
 
Dong Quai.tw OR angel$ polymorph$.tw. OR Angelica sinensis*.tw OR 
angelica.sh 
 
Fever few OR Tanacetum parthenium.sh OR  
 
Ginger OR Zingiber officinale OR Zingiber officinale*.tw 
 
Garlic.sh OR Allium sativum.tw  
 
(St$ John$) adj5 (wort).tw OR hypericum.sh OR Hypericum perforatum.tw OR 
Hypericum ascyron.tw 
22405 
 
Minerals  
 
 
Vitamins 
12. 
Magnesium.sh OR magnesium tablet$.tw OR magnesium powder*.tw OR OR 
magnesium sul?ate  OR epsom  
salt$.tw  
Vitamin B complex.sh OR B adj5 vitamin$.tw  
73993 
 
Combination low dose 
opioid analgesics 
 
13.  
Nurofen Plus.tw OR (ibuprofen and codeine).mp OR (paracetamol and 
codeine).mp OR (aspirin and codeine).mp OR  
OR panadeine*.tw OR ibuprofen combination.tw OR paracetamol 
combination.tw or aspirin combination.tw  
926 
Over the Counter 
Combination 
antihistamine drugs   
14. 
(Doxylamine AND paracetamol AND codeine).tw OR mersyndol*.tw 
6 
 
Educational interventions  
15. 
Health education.sh OR community health education.tw OR health 
promotion.sh OR (education$ adj5 session$).tw OR (education$ 
intervention$).tw OR compact dis$.tw OR leaflet$.tw OR brochure$.tw OR 
 
173780 
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pamphlet$.tw OR (patient education$).tw OR (drug information$).tw OR 
written information.tw OR video$.tw OR video-audio media.sh OR online 
video$.tw OR web-based.tw. 
Advice provided by 
health care professionals  
16. 
Counseling.sh OR advice.tw OR recommendation$.tw OR (evidence-base$) adj5 
advice.tw OR evidence-base$ adj5 recommend$  
169390 
Support aids  17. 
Walking adj5 aid$.tw OR lumbar adj5 belt$.tw OR lumbar adj5 support$.tw OR 
lumbar adj5 body support$.tw OR orthotic devices.sh OR magnetic belts OR 
magnetic adj5 belt$.tw OR  back belt$.tw OR back adj5 support$.tw OR back 
adj5 aid$.tw  
6203 
Artificial heat therapy  18. 
Heat adj5 pack$.tw OR  heat adj5 pad$.tw OR  heat adj5 wrap$.tw OR heat adj5 
wrap$.tw OR hot adj5 towel$.tw OR hot adj5 bath$.tw OR hot adj5 water 
bottle$.tw OR electric adj5 heat pad$.tw OR heat adj5 therapy.tw 
684 
Ice packs  
 
 
19. 
Ice-pack$.tw OR ice adj5 pack$.tw OR ice adj5 application$.tw OR cold-
pack$.tw OR cold adj5 pack$.tw 
867 
TENS machine  20. 
Transcutaneous Electric Nerve Stimulation/ OR TENS.tw OR analgesic 
cutaneous electrostimulation.tw 
8092 
 21. 
6 or 7 OR 7 or 8 OR 8 or 9 OR 9 or 10 OR 10 or 11 OR 11 or 12 OR 12 or 13 OR 
13 or 14 OR 14 or 15 OR 15 or 16 OR 16 or 17 OR 17 or 18 OR 18 or 19 OR 19 or 
20 
 
 22.  
5 and 21 
1944 
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Table 12. Selection Criteria for inclusion of over-the-counter interventions in this 
systematic review. 
The drug or herbal remedy must meet at least three of the following criteria: 
Available as either a single preparation or combination preparation product in the 
community and is easily accessible to consumers; 
Is marketed, promoted or indicated for use in back pain / backache by the manufacturer; 
 
Has any of the following claims; 
anti-inflammatory OR 
anti-spasmodic/muscle relaxant OR 
calmative OR 
analgesic  
 
Has at least one significant published and peer-reviewed study investigating its use or 
potential use in the management of low back pain; 
 
Can be safely self-administered by the consumer (oral, injectable or rectal administration). 
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Table 13. Data Extraction for Pain. 
 
 Intervention  Control  Mean Difference 
95%CI 
Intervention Mean SD Total Mean SD Total  
Advice short term 
(Pengel, 2007) 
27.0 20.0 55 35.0 20.0 59 
-8.0 [-15.4, -0.7] 
‡‡ 
Advice intermediate 
(Pengel, 2007) 
32.0 26.0 58 36.0 24.0 61 
-4.0 [-13.0, 5.0] 
‡‡ 
Advice long term 
(Pengel, 2007) 
30.0 29.0 59 31.0 26.0 56 
-1.0 [-11.1, 9.1] 
‡‡ 
Advice immediate 
(Storheim 2003) 
-20.9 25.1 34 -10.0 19.9 29 
-10.9 [-22.0, 0.2] 
† 
Advice short term 
(Jellema 2005) 
20.0 15.0 141 20.0 30.0 162 0.0 [-5.2, 5.2] 
Advice intermed 
(Jellema 2005) 
0.0 22.0 135 0.0 15.0 163 0.0 [-4.4, 4.4] 
Advice long term 
(Jellema 2005) 
0.0 22.0 132 0.0 15.0 155 0.0 [-4.4, 4.4] 
Bed rest immediate 
(Gilbert, 1985) 
24.2 20.4 47 22.9 20.1 48 1.3 [-6.9, 9.5] ‡ 
Bed rest immediate 
(Rozenberg, 2002) 
28.1 20.4 137 24.0 20.1 140 4.1 [-0.7, 8.9] 
Bed rest short term 
(Malmivaara 1995) 
24.0 19.8 62 19.0 19.8 61 5.0 [-2.0, 12.0] 
Bed rest short term 
(Rozenberg 2002) 
13.7 18.2 136 10.2 17.8 139 3.5 [-0.8, 7.8] 
Bed rest intermediate 
(Malmivaara 1995) 
21.0 18.8 59 13.0 18.8 62 8.0 [1.3, 14.7] 
Bed rest intermediate 
(Rozenberg 2002) 
9.8 17.4 135 6.5 17.0 137 3.3 [-0.8, 7.4] 
Heat wrap immediate 
(Nadler 2003b) 
34.4 16.2 31 47.9 15.3 32 
-13.5 [-21.3, -
5.7]  
Diclofenac 12.5 mg prn 
immediate (Dreiser 
2003) 
-48.4 26.1 122 -37.5 26.9 121 
-10.9 [-17.6, -
4.2] 
Ibuprofen 200 mg prn 
immediate (Dreiser 
2003) 
-48.8 24.0 119 -37.5 26.9 121 
-11.3 [-17.8, -
4.9] 
 
†Converted SE to SD 
‡ Borrowed SD from Rozenberg study 
‡‡Used median score (as mean), and SD = 1.35xIQR.  
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Table 14. Data Extraction for Disability. 
 Intervention  Control  Mean 
Difference 
95%CI 
Intervention Mean SD Total Mean SD Total  
Advice short term (Pengel, 2007) 18.3 19.2 55 22.1 20.0 59 -3.8 [-11.0, 3.4] 
Advice intermediate (Pengel, 2007) 17.1 19.6 58 19.6 19.2 61 -2.5 [-9.5, 4.5] 
Advice long term (Pengel, 2007) 15.8 20.0 59 17.5 25.0 56 -1.7 [-10.0, 6.6] 
Advice intermed (Storheim 2003) -14.6 17.0 34 -6.7 15.7 29 -7.9 [-16.0, 0.2] 
Advice short term (Jellema 2005) 33.3 24.6 142 33.3 24.6 163 0.0 [-5.5, 5.5] ‡‡ 
Advice intermed (Jellema 2005) 16.7 12.5 134 12.5 9.2 163 4.2 [1.7, 6.7] ‡‡ 
Advice long term (Jellema 2005) 16.7 12.5 132 16.7 12.5 154 0.0 [-2.9, 2.9] ‡‡ 
Bed rest immediate (Rozenberg, 2002) 30.7 20.0 137 26.4 4.9 140 4.3 [0.9, 7.8] 
Bed rest immediate (Wilkinson 1995) 36.0 19.9 15 26.4 21.1 18 9.6 [-4.4, 23.6] 
Bed rest short term (Malmivaara 1995) 16.0 11.6 62 10.0 11.6 61 6.0 [1.9, 10.1] 
Bed rest short term (Wilkinson 1995) 22.9 21.6 14 19.2 15.0 20 3.7 [-9.4, 16.8] 
Bed rest short term (Rozenberg 2002) 13.8 16.5 136 10.3 16.7 139 3.5 [-0.4, 7.4] 
Bed rest intermediate (Malmivaara 1995) 11.8 10.4 59 7.4 10.4 62 4.4 [0.7, 8.1] 
Bed rest intermediate (Rozenberg 2002) 9.7 14.0 135 7.4 14.1 137 2.3 [-1.0, 5.6] 
Heat wrap immediate (Nadler 2003a) 19.2 20.5 92 27.9 21.0 88 -8.7 [-14.8, -2.6] 
†† 
Heat wrap immediate (Nadler 2003b) 15.0 16.3 31 24.2 16.5 32 -9.2 [-17.3, -1.1] 
† 
Diclofenac 12.5 mg prn immediate 
(Dreiser 2003) 
-35.8 23.8 119 -23.8 22.1 116 -12.0 [-17.9, -
6.1] 
Ibuprofen 200 mg prn immediate (Dreiser 
2003) 
-33.8 21.7 118 -23.8 22.1 116 -10.0 [-15.6, -
4.4] 
 
†Converted SE to SD 
††Borrowed SD from baseline 
‡‡Used median score (as mean), and SD = 1.35xIQR.  
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Table 15. Effects of Interventions on Recovery and Sickness Leave.  
Study Outcome  Time  Treatment RR (95% CI) Treatment Control  
Milgrom 1993 No recovery* Variable time to 
outcome  
 
 
 
 
 
 
Paracetamol  
1000 mg three times a 
day for 7-days  
 
Ibuprofen 
800 mg three times a 
day for 7-days  
2.52 (0.96, 6.77) 
 
 
 
1.38 (0.67, 2.81) 
 
 
 
 
 
11/24 
 
 
 
11/24 
4/22 
 
 
 
8/24 
Indahl 1995 
 
Sickness leave  200 days >6 
months 
 
400 days > 1 year 
Face-to-face education 
and examination in 
spine clinic vs usual 
care 
0.5 (0.4, 0.6) p=0.0 
 
 
0.4 (0.3, 0.5) p=0.0 
139/463 
 
 
69/463 
 
307/512 
 
 
200/512 
Jellema 2005 No recovery* 
 
 
 
 
 
 
 
 
 
 
Six weeks 
26 weeks 
52 weeks  
 
 
 
 
 
 
 
 
GP consultation with 
emphasis on 
psychosocial 
prognostic factors (at 
least one consultation 
of 20 min) plus 
educational booklet vs 
usual care 
 
 
1.07 (0.8, 1.43) 
1.05 (0.75, 1.47) 
1.15 (0.81, 1.65) 
 
 
 
 
 
 
 
 
56/142  
44/136  
42/132  
 
 
 
 
 
 
 
 
60/163  
50/163  
43/156  
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Sickness Leave    
Six weeks 
26 weeks 
52 weeks 
 
0.8 (0.5, 1.4) p=0.5 
0.3 (0.1, 1.2) p=0.1 
1.1 (0.4, 2.7) p=0.9 
 
 
19/116 
3/110 
8/107 
 
26/132 
11/134 
9/128 
Rozenberg 2002   Sickness leave 
 
 
Day five Bed rest vs normal 
activity 
1.7 (1.3, 2.1) p<0.01 76/88 43/83 
Wilkinson 1995 Sickness leave  Four weeks  1.3 (0.9, 1.9) p=0.14 10/10 9/12 
Malmivaara 
1995 
Sickness leave One week 
 
Three weeks 
 
 
 
 2.0 (1.1, 3.7) p=0.02 
 
3.0 (0.3, 27.6) p=0.34 
 
 
25/62 
 
3/62 
 
 
 
12/61 
 
1/61 
 
 
*Data on no recovery is reported. 
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Table 16. Case Scenarios for Simulated patient Study. 
Case  Case scenario Rationale 
Scenario One: 
Acute non-specific 
low back pain 
 
A 48 year old office worker (male) has an 
episode of low back pain. He is usually very 
active, playing lots of sport and doing regular 
exercise (e.g. jogging, gym). He rates his low 
back pain as a 5 out of 10. The pain started a 
week ago and is located in the low-back region, 
right sided and the pain is not radiating to other 
parts of his back, arms or legs. The pain is 
relieved by stretching his low-back and using a 
heated wheat bag. The pain is worse after 
playing sport, to the point where in the last 
week he had to stop mid-game during 
basketball. He has no previous history of low-
back pain. The patient thinks that an x-ray is 
required to “find out what is wrong”, and he is 
fearful that movement and activity might make 
the pain worse. 
 
This is a case of acute non-specific 
LBP [pain of duration less than 6 
weeks with no identifiable structural 
cause (van Tulder et al., 2006) 
(although in this case ergonomic 
factors such as incorrect positioning 
or sitting down for extended periods 
of time at work are possible risk 
factors]. Acute non-specific Low back 
pain affects men and women equally 
and is prevalent in persons aged 
between 30 and 50 years of age 
(Chou et al., 2008). In this case, the 
patient is a 48 y.o. male and 
therefore meets this criteria. Acute 
LBP is usually a self-limiting 
condition and up to 70% of cases 
resolve completely within 6 weeks of 
pain onset (90% of cases are 
completed resolved within 3 months 
of pain onset) (van Tulder et al., 
2006). The patient reports that local 
application of heat pack relieves the 
pain to some degree however this is 
not enough. Local application of heat 
in the form of heat wrap or heat 
pack has benefits in acute LBP 
(French et al., 2011) as does 
maintaining normal activity and 
avoiding prolonged periods of bed 
rest in line with current evidence-
based guidelines (Australian Acute 
Musculoskeletal Pain Guidelines 
Group (2004), Chan et al., 2002).  
X rays are only recommended in 
acute LBP where a bone fracture is 
suspected (Australian Acute 
Musculoskeletal Pain Guidelines 
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Group (2004), Chan et al., 2002). In 
this case the patient has no risk 
factors for vertebral fracture (elderly 
age, vitamin D or calcium deficiency, 
previous history of bone fracture or 
currently on a bisphosphonate, 
taking an antiepileptic, oral or 
inhaled corticosteroids). However, 
the patient should be advised to see 
their GP if the pain worsens, or is not 
relieved by these simple first line 
measures.  
Scenario Two: 
CLINICAL RED FLAG 
(SUSPECTED 
VERTEBRAL 
COMPRESSION 
FRACTURE) 
 
A 67-year-old woman has low-back pain that 
started immediately after she fell off a chair at 
home 4 days ago while reaching for her glasses. 
The pain has been constant since then, 
although she gets some slight relief from 
paracetamol (two tablets four times a day). The 
patients’ medication history is as follows:  
Fosamax Once weekly (since 1994) (had a bone 
fracture of the wrist a long time ago) 
Ostelin (Vitamin D) 1000IU 1 capsule daily 
(vitamin D deficiency) 
Calcium tablet (600mg elemental calcium) 1 d 
(Calcium deficiency) 
She does not drink or smoke, has a generally 
balanced diet and prefers drinking water to 
caffeinated beverages. 
This is a case of a clinical red flag 
(suspected bone fracture) warranting 
immediate referral to the GP for 
closer investigation. The patient is an 
elderly women with obvious risk 
factors for bone fracture (Henschke 
et al., 2009) (being treated for 
osteoporosis with a bisphosphonate 
for 18 years, has vitamin D and 
calcium deficiency for which she is 
taking vitamin D and calcium). The 
patient reports limitation of 
movement and has had plenty of bed 
rest in the past few days since the 
fall.  
She reports that paracetamol 
provides some pain relief but that 
the pain is constant and does not go 
away completely.  
In this case an X-ray referral is 
warranted given her medical and 
medication history. The patient is 
advised to see their GP immediately 
for a proper assessment.  
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Table 17. Training material including questions likely to be asked and scripted responses.  
Clinical Case Scenarios Questions likely to be asked Answers 
 
Scenario One:  
ACUTE NON-SPECIFIC LOW BACK PAIN 
 
Simulated patient enters the pharmacy. 
Walks up to dispensary and enquires: 
 
“Hi I’d like something for low back pain 
please”  
(symptom based request) 
 
OR 
 
“Hi I’d like some diclofenac please. Is this 
the best thing for low back pain?” 
(direct product based request) 
In all visits, simulated patient instructed to 
ask if it is necessary for the patient to see 
the doctor for an x-ray 
Who is this product for?  
How old are they? 
Is the pain bad? 
 
 
What are the symptoms? 
Is it getting worse? 
Does it radiate up the back or to 
his arms/legs? 
How long has he had the pain 
for? 
Does he have a sore back often? 
Does he know how it might have 
happened? 
 
Does he keep active? 
 
Does he take any other 
medication 
 
Does he have any other health 
conditions? 
 
Has he tried anything for the 
pain yet? 
 
Is that helping? 
 
Has he tried any pain killers? 
 
Seen Dr or other health care 
provider about it? 
 
Any known allergies? 
 
Does he smoke/drink 
alcohol/have a sedentary 
lifestyle? 
 
Male relative (husband, dad etc) 
48 years old 
He is not saying it is really bad (5/10) but he 
did have to stop playing basketball the other 
night because of the pain. 
Low back pain, right sided, does not radiate. 
No, he just wants to get rid of it. 
No. 
 
A week now. 
 
No, never before 
He isn’t sure, but he does have an office job 
and he sits down all day. That may have 
something to do with it. 
Yes he goes jogging and goes to the gym and 
plays sport like basketball 
No 
 
 
No 
 
 
He has been trying to stretch it and he has 
been using a wheat bag. 
 
A little bit 
 
No, he has just been putting up with it 
 
No – not yet. 
 
 
No. 
 
No. Generally healthy and active. 
 
 
 
 
Scenario Two: Who has the pain? Female relative (elderly – so grandmother, 
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Note: Quality Care Pharmacy Program (QCPP) accredited pharmacies are assessed against Australian Standard AS85000:2011 every two 
years. In addition, accredited pharmacies are assessed annually against prescribed requirements for the supply of ‘Pharmacy Only’ (S2) 
and ‘Pharmacist Only’ (S3) medicines referred to in Element 2 of the Standard. The assessment program trains actors to purchase an over-
the-counter (OTC) medicine for a pseudo-patient who may or may not be the mystery shopper. 
 
 
 
CLINICAL RED FLAG (SUSPECTED 
VERTEBRAL COMPRESSION FRACTURE) 
Simulated patient enters pharmacy. Walks 
up to the dispensary and enquires: 
“Hi, my mum/ grandmother had a fall and 
hurt her lower back. She has been taking 
regular paracetamol but it doesn’t seem to 
be enough. What else can you 
recommend?” 
In all visits, simulated patient instructed to 
ask if it is necessary for the patient to see 
the doctor for an x-ray 
 
How long has the pain been 
present?  
Where is the pain located? 
Do you know what might have 
caused it? 
 
How bad is the pain? 
Can she move around OK? 
 
 
Is the pain getting 
better/worse?  
Has she tried any medications to 
relieve the pain? 
 
How is she taking the 
paracetamol 
Is she taking any other 
medications? 
 
 
 
Does she have any medical 
conditions? 
 
 
Does she have any known 
allergies? 
Does she have any 
considerations with regards to 
any medication (e.g. sensitivity 
to a particular medication)? 
Does she drink alcohol or 
smoke? 
(A possible consideration when 
recommending paracetamol). 
mother, mother in law) 
Pain started 4 days ago.  
 
In the lower back 
It started immediately after falling from her 
chair while reaching for her reading glasses.  
 
Moderate 
She is not moving around as well, she has had 
to rest in bed and is not able to carry out some 
of her usual tasks such as gardening.  
The pain has been constant  
 
She finds some relief from paracetamol, 
however the pain does not completely go 
away  
2 tablets four times a day. 
Yes.  
Produce the medication list: 
Fosamax once weekly 
Vitamin D 1000 IU – 1 capsule daily 
Calcium tablet (600mg elemental calcium) 1 
tablet daily 
Osteoporosis – she had a fracture of the wrist 
a few years ago (however you cannot 
remember all the details)  
She also has vitamin D and calcium deficiency.   
None 
 
No 
 
 
 
No 
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Table 18. Characteristics of Pharmacies according to location: Pharmacy Access/Remoteness 
Index of Australia (PHARIA). 
 
Scenario PHARIA Category N visits Total Number of 
visits per state 
Number of 
simulated 
patients per state 
Fracture 
Scenario 
n=198 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
181/198  
 
2/198  
 
11/198  
 
3/198  
 
1/198  
 
0/198 
NSW: 99 
 
VIC: 62 
 
QLD: 37 
 
NSW: 2 
 
VIC: 2 
 
QLD: 1 
 
Non-
specific 
LBP 
n=336 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
275/336 
 
12/336 
 
26/336 
 
7/336 
 
13/336 
 
3/336 
NSW: 79 
 
VIC: 92 
 
QLD: 99 
 
SA: 32 
 
WA: 27 
 
NT: 7 
NSW: 3 
 
VIC: 4 
 
QLD: 4 
 
SA: 2 
 
WA: 2 
 
NT: 1 
PHARIA categories; refer to: http://www.adelaide.edu.au/apmrc/research/projects/pharia/pharia-info.html 
Highly accessible locations across Australia 
Accessible (Group A) locations across Australia 
Accessible (Group B) locations across Australia 
Moderately Accessible locations across Australia 
Remote locations in Australia  
Very remote areas across Australia 
NSW: New South Wales; VIC: Victoria; QLD: Queensland; SA: South Australia; WA: Western Australia; NT: Northern Territory 
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Table 19: Symptom Based Versus Product based request. Results on primary outcome 
measures.  
 
Item SBR n=164   
 
PBR n=172    P value* 
Imaging suggested** 23/90 23/113 0.38 
Reassurance of favourable prognosis  11/164 15/172 0.49 
Advice to stay active  8/164 7/172 0.72 
Advice to rest  1/164 9/172 0.04 
Advice to avoid prolonged period of bed rest 0 (0) 0 (0) - 
Urgent referral to a HCP 0/164 6/172 0.08 
Supply of simple analgesic*** 127/163 169/171 <0.01 
Supply of complex pain medicine*** 25/163 2/171 <0.01 
*test of proportions 
** as a proportion of visits where the question on imaging was asked 
*** as a proportion of visits where a medicine was supplied. 
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Table 20. Symptom based versus Product based request. Information gathering and 
medicines information provision (safe and appropriate practice). 
Information Gathering and Medicines Information Provision 
 SBR n=164  
N=addressed 
(%)  
PBR n=172   
N=addressed 
(%)  
P-value* 
Information Gathered 
The actual symptoms that prompted the request 163/164 170/172 0.59 
Duration of symptoms 80/164 72/172 0.20 
Severity of symptoms 36/164 30/172 0.30 
If the patient has previous history of LBP  21/164 11/172 0.051 
If the patient takes any other medication 140/164 124/172 <0.01 
If the patient has any other medical conditions 129/164 129/172 0.43 
If the patient has tried any other treatment for these symptoms  123/164 88/172 <0.01 
Medicines Information Provision** 
Appropriate dose directions (and spacing intervals specified) 104/163 106/171 0.73 
Maximum dose per day 41/163 68/171 <0.01 
Side effects 45/163 52/171 0.57 
Screening  
Screened for precautions or contraindications to medications 105 103 0.43 
*test of proportions 
** as a proportion of visits where a medicine was supplied 
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Table 21. Symptom based versus product based request. Number of referrals, nature of 
pharmacological and non-pharmacological management. 
Referral  
 SBR n=164  
 
PBR n=172    P value*  
GP  87/164 88/172 0.73 
No referral to a HCP 61/164 76/172 0.19 
Non-pharmacological recommendation 
Heat application 47/164 34/172 0.06 
Ice application 5/164 4/172 0.68 
Increase water and or fibre  2/164 3/172 0.69 
Pharmacological recommendation** 
Diclofenac 25 mg tablets 74/163 147/171 <0.01 
Diclofenac 12.5 mg  tablets 6/163 19/171 0.015 
Ibuprofen 200 mg tablets/capsules 38/163 2/171 <0.01 
Ibuprofen 200mg + codeine 12.8 mg tablets 20/163 2/171 <0.01 
Paracetamol 500 mg + codeine (10 mg to 15 mg) tablets 5/163 0/171 0.10 
Paracetamol (500 mg to 665 mg) tablets 9/163 1/171 0.03 
Topical NSAID 9/163 0/171 0.04 
None 1/164 1/172 0.97 
Paracetamol recommended (in addition to product supplied or action recommended) 
Yes 
No 
40/164 
124/164 
 
25/172 
147/172 
 
0.02 
0.02 
*test of proportions  
** As a proportion of visits where a medicine was supplied 
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Figure 1: Summary of search. 
 
Trials excluded 
 
Ineligible outcome 
measure (n=32)  
 
32 studies included  
articles identified for 
abstract review 
1667 study titles 
screened for eligibility  
16 articles 
identified 
through hand 
search of 
reference lists 
 
2149 Articles identified 
from databases: 
Medline: 838 
Embase: 656 
CENTRAL: 351 
CINAHL: 204 
PsycINFO: 100 
 
measure (n=47) 
 
(n=44) 
comparison or control 
(n=17) 
(n=15) 
64 articles identified for 
full review  
Studies excluded  
Not relevant to topic 
n=1480 
 
498 duplicates  
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Figure 2. Funnel analysis and Egger’s test (two-tailed p-value 0·03) for the primary time 
point and outcome: short term pain relief. Circles represent one opioid analgesic vs 
placebo comparison. 
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Figure 3. Regression of log dose (morphine equivalents) on difference in means; short term pain relief. p-value = 0·003. Note size of circles 
represent inididual sudy weight.  
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Figure 4. Funnel plot of standard error by difference in means; opioid analgesic studies: intermediate pain relief. Egger’s p=0·50. 
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Figure 5. Intermediate and short term effects on pain from head-to-head opioid analgesic trials. Note each comparison is individually 
presented. 
Oxycodone vs oxycodone/naltrexone 
Webster, 2006 Oxycodone qid vs oxycodone/NTX bd 
Webster, 2006 Oxycodone qid vs oxycodone/NTX qid 
 
Oxycodone/naltrexone 
Webster, 2006 Oxycodone/NTX qid vs bd  
 
Buprenorphine vs other  
Steiner, 2011b BTDS 20 µg/h vs oxycodone 40 mg 
Steiner, 2011b BTDS 5 µg/h vs BTDS 20 µg/h 
Steiner, 2011b BTDS 5 µg/h vs oxycodone 40 mg  
 
Morphine vs tramadol
19
 
 
Short term effects  
Steiner, 2011b BTDS 20 µg/h vs oxycodone 40 mg 
Steiner, 2011b BTDS 5 µg/h vs BTDS 20 µg/h 
Steiner, 2011b BTDS 5 µg/h vs oxycodone 40 mg  
 
 
Morphine vs tramadol
19
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Figure 6. Head-to-head comparison of muscle relaxants on pain in acute LBP; short term. Negative outcome values represent mean change 
from baseline.  
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Figure 7. Effects of carisoprodol on disability; short term.  
 
 
 
Ralph, 2008 carisoprodol 250 mg/d 
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9 trials excluded 
 
Ineligible control 
(n=5)  
Symptom duration 
not specified (n=1) 
Insufficient data 
(n=2) 
Not relevant to 
context n=1 
13 studies included  
Other e.g ineligible 
outcome measures (n=24) 
181 articles identified 
for abstract review187 
3374 study titles 
screened for eligibility 
5 articles 
identified 
through hand 
search of 
reference lists 
4336 Articles identified 
from databases: 
Medline: 1944 
Embase: 1078 
CENTRAL: 756 
AMED: 384 
PsycINFO: 174 
Language Criteria 
(n=4)Ineligible outcome 
Intervention not eligible 
(n=29)Not specific for LBP 
Preventive trials (n=7) 
Non-randomised (n=24) 
 
Not specific for acute LBP 
(n=20) 
 
Did not compare 
intervention to eligible 
control (n=25)Ineligible 
Reported on chronic LBP 
sufferers (n=26)Other 
159 trials excluded 
123 Trials excluded  
22 articles identified 
for full review  
3193 studies excluded 
Not relevant to topic 
n=2081 
Reviews n=1112 
967 duplicates  
Figure 8. Summary of search. 
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Figure 9. Adverse effects of drugs included in counselling.  
 
NS-SBR: Scenario One (non-specific LBP) symptoms based request 
NS-PBR: Scenario one: (non-specific LBP) product based request 
RFC: SBR: Scenario two red flag Condition: symptom based request. 
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Figure 10. Screening for precautions. Medical conditions enquired about when supplying a 
medicine. 
NS-SBR: Scenario One (non-specific LBP) symptoms based request 
NS-PBR: Scenario one: (non-specific LBP) product based request 
RFC: SBR: Scenario two red flag Condition: symptom based request. 
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